

## Author Index for 1993

- Abbruzzese, M. 48:191  
Ackenheil, M. 48:201  
Adami, H. 46:47  
Adés, J. 46:203  
Adler, L.E. 49:29  
Alam, M.Y. 46:139  
Alpert, M. 48:181  
Altemus, M. 49:1  
Amsterdam, J.D. 48:37  
Anderson, G. 47:267  
Apovian, M. 47:291  
Apter, S. 46:151  
Aronowitz, B. 48:257  
Aronson, M. 47:175  
Arora, R.C. 47:111  
Ashleigh, E.A. 46:1  
Axelson, D.A. 47:163  
Baghai, T. 47:215  
Bailly, D. 47:57  
Ball, S. 48:145  
Balon, R. 46:89  
Barbato, G. 47:79  
Barthélémy, C. 46:261  
Bauer, L.O. 46:229, 47:69  
Baumgartner, A. 48:153  
Beals, J. 47:255  
Bergeman, C.S. 48:229  
Berger, M. 49:109  
Berger, R. 46:89  
Bernstein, D. 47:291  
Beuscart, R. 47:57  
Bierer, L.M. 49:211  
Biggs, M.M. 46:269  
Bissette, G. 46:1  
Blackson, T. 46:9  
Bliwise, D.L. 48:277  
Boehnlein, J. 47:255  
Bosmans, E. 49:11, 49:151  
Botsis, A.J. 47:281  
Boutros, N. 47:243  
Bouvard, M. 49:63  
Boyko, O.B. 47:163  
Bräunig, P. 47:187  
Bradshaw, S.L. 46:295  
Breier, A. 47:47  
Brewerton, T.D. 46:201  
Brown, J. 46:29  
Brown, S.-L. 47:281  
Bruder, G. 49:167  
Bruton, C.J. 48:145  
Büchler, M. 46:261  
Buchanan, A. 46:29  
Buchanan, R.W. 47:47, 47:205  
Buhari, A. 49:121  
Bulbena, A. 46:59  
Calabrese, J. 47:229, 49:11, 49:151  
Campos-Barros, A. 48:153  
Carosella, N.W. 49:41  
Carpenter, W.T., Jr. 47:47  
Carroll, B.T. 46:119  
Carroll, J.S. 48:277  
Carter, C.S. 48:17  
Carter, J.L. 46:119  
Cartwright, R.D. 46:165  
Casanova, M.F. 49:41  
Cassady, S. 46:47  
Castillo, S. 46:1  
Castle, D.J. 49:199  
Chaderjian, M.C. 48:17  
Chambers, M.J. 46:207  
Chappell, P.B. 47:267  
Charney, D.S. 48:119  
Chase, G.A. 49:219  
Cherpi, C. 46:261  
Chudzik, J. 47:121  
Cichon, S. 46:253  
Clausnitzer, L. 47:297  
Coccaro, E.F. 47:291, 48:219, 48:229  
Cohen, D.J. 47:267  
Cohen, J. 48:181  
Cohen, L. 48:257  
Cooper, T. 49:219  
Cooreman, W. 47:229  
Copolov, D.L. 48:79  
Cosyns, P. 47:229, 49:11, 49:151  
Cottraux, J. 49:63  
Coursey, R.D. 47:87  
Cowley, D.S. 47:151  
Cromwell, R.L. 46:295  
Crow, T. 48:27  
d'Elia, G. 47:7, 47:23  
Daffner-Bujia, C. 47:215  
Danilenko, K.V. 47:99  
Dannals, R.F. 49:219  
Datiles, M. 47:87  
Daveloose, D. 46:203  
Davidson, M. 46:151  
Davis, J.M. 48:57  
Davis, K.L. 46:151, 49:211  
Dawson-Hughes, B. 49:77  
de Loof, C. 47:1  
De Meester, I. 49:151  
DeCaria, C. 48:257, 49:167  
DeLisi, L.E. 48:27  
Dement, W.C. 48:277  
Demitrack, M.A. 49:1  
Dietzel, M. 48:153  
Dippold, C. 49:89  
Docktor, B. 46:207  
Doraiswamy, P.M. 47:163  
Doran, A.R. 47:141  
Duró, J.C. 46:59  
Early, T.S. 49:183  
Eckstein, R. 48:201  
Ehlers, C.L. 49:121  
El-Mallakh, R.S. 47:297  
Ellinwood, E.H., Jr. 47:163  
Endicott, J. 46:79  
Faedda, G.L. 48:1  
Faraone, S.V. 48:243  
Farmer, A.E. 49:199  
Fasiczka, A.L. 49:139  
Fimmers, R. 46:253  
Finkelstein, G. 47:281  
Forsyth, C.S. 48:145  
Frank, E. 49:121, 49:139  
Freedman, R. 49:29  
Frenkel, M. 48:257  
Friedman, D. 49:167  
Fritze, J. 46:253  
Fung, K.P. 49:97  
Gambini, O. 48:191  
Ganguli, R. 48:69  
Garamoni, G.L. 49:139  
Garver, D.L. 48:93  
Garvey, M.J. 47:129  
Gehris, T.L. 46:119  
Genhart, M.J. 47:87  
George, M.S. 46:201, 49:257  
Gietzen, D.W. 47:141  
Giles, D.E. 46:269  
Given, B.A. 49:239  
Given, C.W. 49:239  
Glitz, D. 46:89  
Glod, C.A. 46:29  
Goddard, A.W. 48:119  
Gold, J.M. 49:41  
Gold, P.W. 49:1  
Golombok, S. 48:135  
Goodman, W.K. 48:119

- Goodwin, D.C. 48:1  
 Gorman, J. 46:79  
 Gräf, K.-J. 48:153  
 Graw, P. 46:107  
 Green, A.I. 46:139  
 Greenblatt, D.J. 47:151  
 Griez, E. 47:1, 47:295  
 Griffith, J.M. 49:29  
 Grochocinski, V.J. 49:121  
 Gross, G. 47:187  
 Gruzelier, J.H. 46:127  
 Gullion, C.M. 48:9  
 Gyulai, L. 48:37  
 Haag, C. 47:215  
 Halaris, A. 47:187  
 Hale, J. 47:205  
 Haller, J.W. 49:183  
 Handelsman, L. 47:175  
 Harden, R.N. 46:201  
 Hardin, M.T. 47:267  
 Hardy, B.W. 48:9  
 Haroutunian, V. 49:211  
 Harris, S. 49:77  
 Harrison, W. 46:79  
 Hassett, A. 48:79  
 Hérault, J. 46:261  
 Helgason, T. 46:69  
 Heninger, G.R. 48:119  
 Hill, C. 48:79  
 Hinz, A. 47:215  
 Hirschowitz, J. 46:151  
 Hirt, J. 48:79  
 Hofschuster, E. 48:201  
 Hollander, E. 48:257, 49:167  
 Hommer, D.W. 47:151  
 Horton, K. 48:145  
 Horvath, T.B. 47:291  
 Huber, G. 47:187  
 Ivarsson, O. 46:69  
 Jacobson, J. 47:175  
 Jain, S.K. 46:295  
 Janicak, P.G. 48:57  
 Jarrett, R.B. 46:269  
 Jennings, J.R. 49:139  
 Joffe, R.T. 46:29  
 Kågedal, B. 47:7  
 Kahn, R.S. 46:151  
 Kalaian, H.A. 49:239  
 Kathol, R.G. 46:119  
 Kavoussi, R.J. 48:219  
 Keks, N.A. 48:79  
 Kellner, R. 46:285  
 Kelly, K.A. 47:87  
 Kersteen-Tucker, Z. 46:175  
 Keshavan, M.S. 49:89  
 Ketter, T.A. 49:257  
 Kinney, D.K. 48:47  
 Kinzie, J.D. 47:255  
 Kirkpatrick, B. 47:47  
 Kirtland, A. 48:37  
 Kjellman, B.F. 47:7, 47:23  
 Kleinman, J.E. 49:41  
 Knight, R.T. 46:175  
 Knott, P. 46:151, 47:291  
 Knott, P.J. 49:211  
 Körner, J. 46:253  
 Kotler, M. 47:281  
 Kräuchi, K. 46:107  
 Krah, D.D. 49:1  
 Krishnan, K.R.R. 47:163  
 Kristbjarnarson, H. 46:69  
 Kroft, C.D.L. 49:251  
 Kürten, I. 48:153  
 Kulkarni, J. 48:79  
 Kupfer, D.J. 49:121, 49:139  
 Laakmann, G. 47:215  
 Lader, M. 48:135  
 Lajonchere, C.M. 48:47  
 Lam, R.W. 46:29  
 Lanczik, M. 46:253  
 Langohr, J.I. 46:1  
 Lannfelt, L. 46:69, 46:253  
 Lasko, N.B. 48:107  
 Lauer, C.J. 49:109  
 Lawrence, T. 47:291  
 Lebegue, B. 46:29  
 Leboyer, M. 46:261  
 Leckman, J.F. 47:267  
 Lee, J. 49:97  
 Lee, K.A. 46:209, 48:277  
 Leibenluft, E. 46:213  
 Leite, P. 49:167  
 Lejoyeux, M. 46:203  
 Lelord, G. 46:261  
 Leung, P. 47:255  
 Levin, A. 48:257  
 Levitt, A.J. 46:29  
 Levy, D.L. 48:47  
 Lewis, N. 46:1  
 Liddle, P.F. 46:127  
 Liebowitz, M.R. 48:257  
 Lish, J.D. 48:37  
 Loneragan, C. 47:37  
 Losonczy, M. 47:175  
 Lousberg, H. 47:295  
 Lyons, M.J. 48:243  
 Mackie, B. 48:79  
 Maclin, E.L. 47:141  
 Madden, P.A. 46:213  
 Maes, M. 47:229, 49:11, 49:151  
 Magliozzi, J.R. 47:141  
 Mallet, J. 46:261  
 Mallinger, A.G. 49:89  
 Mannsmann, U. 48:153  
 Manson, S.M. 47:255  
 Marangell, L.B. 49:257  
 Marin, D.B. 49:211  
 Marks, I. 49:63  
 Marks, R.C. 48:57  
 Marler, M. 47:187  
 Martín-Santos, R. 46:59  
 Mateo, A. 46:59  
 Mathalon, D.H. 46:175  
 Matheson, B. 48:79  
 Mathew, V.M. 46:127  
 Mazière, J.-C. 46:203  
 McClearn, G.E. 46:239, 48:229  
 McCorkle, R. 49:239  
 McDonald, W.M. 47:163  
 McEachran, A.B. 49:121  
 McGuffin, P. 49:199  
 McKenzie, D.P. 48:79  
 McLaughlin, M. 48:79  
 Medoff, D. 48:47  
 Meller, W.H. 46:119  
 Meltzer, H.Y. 47:111, 47:229, 49:11, 49:151  
 Mempel, W. 48:201  
 Merril, C.R. 48:27  
 Mezzich, A.C. 46:9  
 Möller, H.-J. 46:253  
 Moeller, F.G. 48:93  
 Mohs, R.C. 49:211  
 Moises, H.W. 46:69  
 Molcho, A. 47:281  
 Molina, L. 46:59  
 Mollard, E. 49:63  
 Moodley, P. 48:135  
 Moran, M. 46:47  
 Moss, H.B. 46:9, 46:29, 46:213, 47:79, 49:99  
 Müh, J.-P. 46:261



- Müller, N. 48:201  
 Murburg, M.M. 46:1  
 Murdock, M.V. 48:9  
 Murray, M.G. 46:29  
 Nee, J. 46:79  
 Nekich, J.C. 48:277  
 Nelson, E. 49:183  
 Nemeroff, C.B. 46:1, 47:163  
 Neumann, C.S. 46:295  
 Nöthen, M.M. 46:253  
 Noel, M. 47:129  
 Nofzinger, E.A. 49:139  
 Nordahl, T.E. 48:17  
 O'Shara-Celaya, L.J. 48:17  
 Olson, A.M. 47:141  
 Orelan, L. 46:239  
 Oren, D.A. 46:29, 47:79, 49:99  
 Orhagen, T. 47:7  
 Orr, S.P. 48:107  
 Orsulak, P.J. 48:93  
 Ozaki, N. 49:99  
 Pandey, G.N. 48:57  
 Pandey, S.C. 48:57  
 Pappalardo, K.M. 46:139  
 Park, S. 47:175  
 Parquet, P.J. 47:57  
 Pascualy, M. 46:1  
 Pathak, D. 46:285  
 Patterson, L.J. 47:163  
 Pazzaglia, P.J. 49:257  
 Peabody, C. 47:243  
 Pearlson, G. 49:219  
 Pedersen, N.L. 46:239  
 Perl, D.P. 49:211  
 Perrot, A. 46:261  
 Peskind, E.R. 46:1  
 Pettegrew, J.W. 49:89  
 Petty, F. 48:9  
 Pfefferbaum, A. 46:175  
 Pigott, T.A. 49:1  
 Pitman, R.K. 48:107  
 Pitts, A.F. 46:119  
 Plail, J.A. 46:9  
 Plutchik, R. 47:281  
 Pohl, R. 46:89  
 Pols, H. 47:1, 47:295  
 Polymeropoulos, M.H. 48:27  
 Porta, M. 46:59  
 Post, R.M. 49:257  
 Pouget, E.R. 48:181  
 Powers, R.E. 49:41  
 Price, R.A. 48:37  
 Propping, P. 46:253  
 Purohit, D.P. 49:211  
 Putilov, A.A. 47:99  
 Putnam, F.W. 49:1  
 Rabin, B.S. 48:69  
 Racadot, N. 47:57  
 Radford-Paregol, M. 48:47  
 Raese, J.D. 48:93  
 Ramesh, C. 46:89  
 Rao, M.L. 47:187  
 Raskind, M.A. 46:1  
 Raus, J. 47:229  
 Ravert, H.T. 49:219  
 Reich, J. 48:267  
 Reimann, D. 49:109  
 Resnick, S.M. 48:37  
 Reynolds, C. 46:239  
 Reynolds, C.F., III 49:139  
 Rietschel, M. 46:253  
 Roberts, G.W. 48:145  
 Roberts, L.A. 46:229  
 Robertson, L.C. 48:17  
 Roffwarg, H.P. 46:269  
 Rosenthal, N.E. 46:19, 47:79, 47:87, 49:99  
 Roudier, M. 46:203  
 Roy-Byrne, P.P. 47:151  
 Royston, M.C. 48:145  
 Rubinow, D.R. 49:1  
 Rudorfer, M.V. 46:19  
 Rush, A.J. 46:269, 48:9  
 Rustin, T. 47:243  
 Ryan, T.M. 49:211  
 Sachdev, P. 47:37  
 Saletu, B. 48:153  
 Salzman, C. 46:139  
 Samuelson, S.D. 46:119  
 Sandberg, D. 46:79  
 Saoud, J.B. 48:257  
 Sapp, J. 49:219  
 Sauvage, D. 46:261  
 Scahill, L.D. 47:267  
 Scarone, S. 48:191  
 Scharpé, S. 47:229, 49:11, 49:151  
 Schatzberg, A.F. 46:139  
 Schildkraut, J.J. 46:139  
 Schmeidler, J.M. 49:211  
 Schmidt, G.G. 46:41  
 Schulz, R. 49:239  
 Schwartz, J.-C. 46:69, 46:253  
 Schwartz, P.J. 46:29, 46:213, 47:79, 49:99  
 Schwartz, R.M. 49:139  
 Senkova, N.I. 37:99  
 Servant, D. 47:57  
 Sharma, R.P. 48:57  
 Shaya, E.K. 49:219  
 Shine, P. 48:135  
 Sholomskas, D.E. 48:119  
 Sibtain, N. 48:145  
 Siever, L.J. 47:291  
 Singh, B. 48:79  
 Skwerer, R.G. 46:19  
 Sobieraj, J.T. 46:139  
 Sokoloff, P. 46:69, 46:253  
 Somervell, P.D. 47:255  
 Song, I.S. 47:175  
 Srinivasan, K. 46:89  
 Starcevic, V. 46:285  
 Stein, D.J. 48:257  
 Stein, M.B. 49:251  
 Steinberg, J.L. 48:93  
 Stern, R.G. 46:151  
 Stoll, A.L. 48:1  
 Stommel, M. 49:239  
 Strakowski, S.M. 48:1  
 Strauss, M. 49:219  
 Strauss, M.E. 47:205  
 Strebel, B. 47:187  
 Strijewski, A. 47:121  
 Sullivan, E.V. 46:175  
 Suy, E. 47:229, 49:11, 49:151  
 Tang, S.W. 47:121  
 Tarter, R.E. 46:9  
 Teicher, M.H. 46:29  
 Tenke, C. 49:167  
 Thaker, G. 46:47  
 Thase, M.E. 49:139  
 Thorell, L.-H. 47:7, 47:23  
 Tohen, M. 48:1  
 Torrey, E.F. 48:27  
 Towey, J. 49:167  
 Trestman, R.L. 47:291  
 Tsuang, M.T. 48:243  
 Tuason, V.B. 47:141  
 Tune, L.E. 49:219  
 Tupler, L.A. 47:163  
 Uhlenhuth, E.H. 46:285  
 Uyttenbroeck, W. 47:229

- Vallejo, J. 46:59  
Vallescar, R. 46:59  
van Aalst, V. 47:1  
van Praag, H.M. 47:281  
Vandervorst, C. 47:229  
Vanyukov, M.M. 46:9  
Veith, R.C. 46:1  
Vignau, J. 47:57  
Viret, J. 46:203  
Voderholzer, U. 47:205  
Volf, N.V. 47:99  
Wagner, H.N., Jr. 49:219  
Waldo, M. 49:29  
Walker, J.R. 49:251  
Waller, D.A. 48:9  
Warner, D. 47:243  
Waternaux, C. 46:139  
Waternaux, C.M. 48:243  
Wehr, T.A. 46:213  
Weinberg, P. 46:89  
Weinberger, D.R. 49:41  
Welkowitz, J. 48:181  
Wessely, S. 49:199  
Westbrook, F. 47:37  
Whybrow, P.C. 48:37  
Wiegand, M. 49:109  
Wiener, J. 47:175  
Wiese, C. 46:69  
Williams, J. 49:199  
Williams, R.J. 46:41  
Wilson, A.A. 49:219  
Wirz-Justice, A. 46:107  
Wittmann, R. 47:215  
Wolf, R. 48:153  
Wong, D.F. 49:219  
Wood, E. 46:165  
Woods, S.W. 48:119  
Xiao, H. 48:27  
Yang, L. 46:69  
Yeragani, V.K. 46:89  
Yeung, A.S. 48:243  
Young, T. 49:219  
Yurgelun-Todd, D.A. 48:47  
Zandbergen, J. 47:1, 47:295  
Zigun, J.R. 47:297  
Zipursky, R.B. 46:175  
Zoega, T. 46:69  
Zouridakis, G. 47:243

## Subject Index for 1993

### **Adrenocorticotrophic hormone**

- affective disorder, arginine vasopressin, 46:119
  - affective disorder, cortisol, 46:119
  - affective disorder, dexamethasone suppression test, 46:119
  - arginine vasopressin, affective disorder, 46:119
  - arginine vasopressin, cortisol, 46:119
  - arginine vasopressin, dexamethasone suppression test, 46:119
  - cortisol, affective disorder, 46:119
  - cortisol, arginine vasopressin, 46:119
  - cortisol, dexamethasone suppression test, 46:119
  - dexamethasone suppression test, affective disorder, 46:119
  - dexamethasone suppression test, arginine vasopressin, 46:119
  - dexamethasone suppression test, cortisol, 46:119
  - hypothalamic-pituitary-adrenal axis, affective disorder, 46:119
- ### **Affective disorder**
- adrenocorticotrophic hormone, arginine vasopressin, 46:119
  - adrenocorticotrophic hormone, cortisol, 46:119
  - adrenocorticotrophic hormone, dexamethasone suppression test, 46:119
  - aging, tryptophan, 49:151
  - amino acids, haptoglobin, 49:151
  - amino acids, immune function, 49:151
  - amino acids, interleukin, 49:151
  - amino acids, serotonin, 49:151
  - amino acids, transferrin, 49:151
  - amino acids, tryptophan, 49:151
  - antidepressant medication, attention, 46:295
  - antidepressant medication, cortisol, 46:213
  - antidepressant medication, memory, 46:295
  - antidepressant medication, prolactin, 46:213
  - antidepressant medication, thyroid hormones, 46:213
  - antidepressant medication, treatment duration, 46:295
  - antidepressant medication, visual pattern integration, 46:295
  - arginine vasopressin, adrenocorticotrophic hormone, 46:119
  - arginine vasopressin, cortisol, 46:119
  - arginine vasopressin, dexamethasone suppression test, 46:119

### **Affective disorder continued**

- attention, antidepressant medication, 46:295
- attention, memory, 46:295
- attention, treatment duration, 46:295
- attention, visual pattern integration, 46:295
- bipolar subtype, calcium channel blockers, 49:257
- bipolar subtype, depressive symptoms, 47:129
- bipolar subtype, dopamine D<sub>3</sub> receptor protein, 46:253
- bipolar subtype, family history, 48:37, 48:47
- bipolar subtype, first episode mania, 48:1
- bipolar subtype, genetics, 46:253, 48:37, 48:47
- bipolar subtype, *N*-acetyl-beta-glucosaminidase, 47:129
- bipolar subtype, nimodipine, 49:257
- bipolar subtype, obstetric complications, 48:47
- bipolar subtype, outcome prediction, 48:1
- bipolar subtype, rapid cycling, 48:37, 49:257
- bipolar subtype, serine to glycine substitution on dopamine D<sub>3</sub>, 46:253
- bipolar subtype, serotonin, 47:129
- bipolar subtype, substance abuse, 48:37
- bipolar subtype, therapeutic response, 49:257
- bipolar subtype, Tridimensional Personality Questionnaire, 48:1
- calcium channel blockers, bipolar subtype, rapid cycling, 49:257
- calcium channel blockers, nimodipine, 49:257
- calcium channel blockers, therapeutic response, 49:257
- carbohydrate craving, circadian rhythms, 46:107
- carbohydrate craving, diet, 46:107
- carbohydrate craving, eating sweets, 46:107
- carbohydrate craving, phototherapy, 46:107
- carbohydrate craving, seasonal depression, 46:107
- Center for Epidemiologic Studies Depression Scale, American Indians, 47:255
- Center for Epidemiologic Studies Depression Scale, cross-cultural diagnosis, 47:255
- circadian rhythms, carbohydrate craving, 46:107
- circadian rhythms, daytime affect, 49:139
- circadian rhythms, diet, 46:107
- circadian rhythms, eating sweets, 46:107



**Affective disorder continued**

circadian rhythms, endogenous subtype, 47:215  
 circadian rhythms, growth hormone, 47:215  
 circadian rhythms, growth hormone releasing hormone, 47:215  
 circadian rhythms, nocturnal penile tumescence, 49:139  
 circadian rhythms, phototherapy, 46:107  
 circadian rhythms, seasonal depression, 46:107  
 circadian rhythms, sexual function, 49:139  
 circadian rhythms, sleep, 47:215, 49:139  
 circannual rhythm, light visor treatment, 46:29  
 circannual rhythm, phototherapy, 46:29  
 circannual rhythm, seasonal depression, 46:29  
 circannual rhythms, eye blink rate, 47:79  
 circannual rhythms, gender differences, 47:79  
 circannual rhythms, phototherapy, 47:79  
 circannual rhythms, prevalence in northern Canada, 46:41  
 circannual rhythms, seasonal depression, 46:41, 47:79  
 cortisol, adrenocorticotrophic hormone, 46:119  
 cortisol, antidepressant medication, 46:213  
 cortisol, arginine vasopressin, 46:119  
 cortisol, dexamethasone suppression test, 46:119, 47:7, 47:23, 47:163, 49:11  
 cortisol, dysthymic disorder, 47:7  
 cortisol, electrodermal activity, 47:23  
 cortisol, haptoglobin, 49:11  
 cortisol, hippocampus, 47:163  
 cortisol, immune function, 49:11  
 cortisol, interleukins, 49:11  
 cortisol, magnetic resonance imaging, 47:163  
 cortisol, prolactin, 46:213  
 cortisol, sleep deprivation, 46:213  
 cortisol, thyroid stimulating hormone, 46:213, 47:7, 47:23  
 cortisol, thyroxine, 47:7, 47:23  
 cortisol, transferrin, 49:11  
 cortisol, triiodothyronine, 46:213, 47:7, 47:23  
 cross-cultural assessment, American Indians, 47:255  
 cross-cultural assessment, Center for Epidemiologic Studies Depression Scale, 47:255  
 cross-cultural assessment, diagnosis, 47:255  
 cross-cultural assessment, epidemiology, 47:255

**Affective disorder continued**

daytime affect, circadian rhythms, 49:139  
 daytime affect, nocturnal penile tumescence, 49:139  
 daytime affect, sexual function, 49:139  
 daytime affect, sleep, 49:139  
 depressed mood, naps, 49:109  
 depressed mood, sleep, 49:109  
 depressed mood, sleep deprivation, 49:109  
 depressive symptoms, bipolar subtype, 47:129  
 depressive symptoms, *N*-acetyl-beta-glucosaminidase, 47:129  
 depressive symptoms, serotonin, 47:129  
 dexamethasone suppression test, adrenocorticotrophic hormone, 46:119  
 dexamethasone suppression test, arginine vasopressin, 46:119  
 dexamethasone suppression test, cortisol, 46:119, 47:7, 47:23, 47:163, 49:11  
 dexamethasone suppression test, dysthymic disorder, 47:7  
 dexamethasone suppression test, electrodermal activity, 47:23  
 dexamethasone suppression test, haptoglobin, 49:11  
 dexamethasone suppression test, hippocampus, 47:163  
 dexamethasone suppression test, immune function, 49:11  
 dexamethasone suppression test, interleukins, 49:11  
 dexamethasone suppression test, magnetic resonance imaging, 47:163  
 dexamethasone suppression test, thyroid stimulating hormone, 47:7, 47:23  
 dexamethasone suppression test, thyroxine, 47:7, 47:23  
 dexamethasone suppression test, transferrin, 49:11  
 dexamethasone suppression test, triiodothyronine, 47:7, 47:23  
 diagnosis, cross-cultural assessment, American Indians, 47:255  
 diagnosis, epidemiology, 47:255  
 diet, carbohydrate craving, 46:107  
 diet, circadian rhythms, 46:107  
 diet, eating sweets, 46:107  
 diet, phototherapy, 46:107  
 diet, seasonal depression, 46:107  
 divorce, dream masochism, 46:165

- Affective disorder** continued
- divorce, gender differences, 46:165
  - divorce, personality, 46:165
  - divorce, sex role identification, 46:165
  - divorce, sleep, 46:165
  - dopamine D<sub>3</sub> receptor protein, bipolar subtype, 46:253
  - dopamine D<sub>3</sub> receptor protein, genetics, 46:253
  - dopamine, serine to glycine substitution on dopamine D<sub>3</sub>, 46:253
  - dream masochism, divorce, 46:165
  - dream masochism, gender differences, 46:165
  - dream masochism, personality, 46:165
  - dream masochism, sex role identification, 46:165
  - dream masochism, sleep, 46:165
  - dysthymic disorder, cortisol, 47:7
  - dysthymic disorder, dexamethasone suppression test, 47:7
  - dysthymic disorder, thyroid stimulating hormone, 47:7
  - dysthymic disorder, thyroxine, 47:7
  - dysthymic disorder, triiodothyronine, 47:7
  - electrodermal activity, cortisol, 47:23
  - electrodermal activity, dexamethasone suppression test, 47:23
  - electrodermal activity, thyroid stimulating hormone, 47:23
  - electrodermal activity, thyroxine, 47:23
  - electrodermal activity, triiodothyronine, 47:23
  - electrooculography, phototherapy, 49:99
  - electrooculography, seasonal depression, 49:99
  - endogenous subtype, circadian rhythms, 47:215
  - endogenous subtype, growth hormone, growth hormone releasing hormone, 47:215
  - endogenous subtype, sleep, 47:215
  - epidemiology, cross-cultural assessment, American Indians, 47:255
  - epidemiology, diagnosis, 47:255
  - eye blink rate, circannual rhythms, 47:79
  - eye blink rate, gender differences, 47:79
  - eye blink rate, phototherapy, 47:79
  - eye blink rate, seasonal depression, 47:79
  - family history, bipolar subtype, 48:37, 48:47
  - family history, human leukocyte antigen, 48:201
  - family history, immune function, 48:201
  - family history, lymphocytes, 48:201
  - family history, obstetric complications, 48:47
- Affective disorder** continued
- family history of personality disorder, genetics, 48:243
  - family history of personality disorder, schizophrenia, 48:243
  - family history, schizophrenia, 48:201
  - family history, substance abuse, 48:37
  - first episode mania, bipolar subtype, 48:1
  - first episode mania, outcome prediction, 48:1
  - first episode mania, Tridimensional Personality Questionnaire, 48:1
  - fluoxetine, sleep deprivation, 46:213
  - gender differences, circannual rhythms, 47:79
  - gender differences, divorce, 46:165
  - gender differences, dream masochism, 46:165
  - gender differences, eye blink rate, 47:79
  - gender differences, immune function, 49:151
  - gender differences, personality, 46:165
  - gender differences, phototherapy, 47:79
  - gender differences, seasonal depression, 47:79
  - gender differences, sex role identification, 46:165
  - gender differences, sleep, 46:165
  - genetics, bipolar subtype, 46:253, 48:37, 48:47
  - genetics, dopamine D<sub>3</sub> receptor protein, 46:253
  - genetics, family history of personality disorder, 48:243
  - genetics, human leukocyte antigen, 48:201
  - genetics, immune function, 48:201
  - genetics, lymphocytes, 48:201
  - genetics, obstetric complications, 48:47
  - genetics, schizophrenia, 48:201, 48:243
  - genetics, serine to glycine substitution on dopamine D<sub>3</sub>, 46:253
  - genetics, substance abuse, 48:37
  - growth hormone, circadian rhythms, 47:215
  - growth hormone, endogenous subtype, 47:215
  - growth hormone, sleep, 47:215
  - growth hormone releasing hormone, circadian rhythms, 47:215
  - growth hormone releasing hormone, endogenous subtype, 47:215
  - growth hormone releasing hormone, sleep, 47:215
  - haptoglobin, amino acids, 49:151
  - haptoglobin, cortisol, 49:11
  - haptoglobin, dexamethasone suppression test, 49:11
  - haptoglobin, immune function, 47:229, 49:11, 49:151

**Affective disorder** continued

haptoglobin, interleukin, 49:11, 49:151  
 haptoglobin, serotonin, 49:151  
 haptoglobin, sleep, 47:229  
 haptoglobin, somatic symptoms, 47:229  
 haptoglobin, transferrin, 49:11, 49:151  
 haptoglobin, tryptophan, 49:151  
 haptoglobin, weight and anorexia, 47:229  
 hippocampus, cortisol, 47:163  
 hippocampus, dexamethasone suppression test, 47:163  
 hippocampus, magnetic resonance imaging, 47:163  
 homovanillic acid, cerebrospinal fluid, 46:19  
 homovanillic acid, 5-hydroxyindoleacetic acid, 46:19  
 homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 homovanillic acid, norepinephrine, 46:19  
 homovanillic acid, orthostatic challenge, 46:19  
 homovanillic acid, phototherapy, 46:19  
 homovanillic acid, seasonal depression, 46:19  
 human leukocyte antigen, family history, 48:201  
 human leukocyte antigen, genetics, 48:201  
 human leukocyte antigen, immune function, 48:201  
 human leukocyte antigen, lymphocytes, 48:201  
 human leukocyte antigen, schizophrenia, 48:201  
 5-hydroxyindoleacetic acid, cerebrospinal fluid, 46:19  
 5-hydroxyindoleacetic acid, homovanillic acid, 46:19  
 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 5-hydroxyindoleacetic acid, norepinephrine, 46:19  
 5-hydroxyindoleacetic acid, orthostatic challenge, 46:19  
 5-hydroxyindoleacetic acid, phototherapy, 46:19  
 5-hydroxyindoleacetic acid, seasonal depression, 46:19  
 immune function, amino acids, 49:151  
 immune function, cortisol, 49:11  
 immune function, dexamethasone suppression test, 49:11  
 immune function, family history, 48:201  
 immune function, gender differences, 49:151

**Affective disorder** continued

immune function, genetics, 48:201  
 immune function, haptoglobin, 47:229, 49:11, 49:151  
 immune function, human leukocyte antigen, 48:201  
 immune function, hypothalamic-pituitary-adrenal axis, 49:11  
 immune function, interleukins, 49:11, 49:151  
 immune function, lymphocytes, 48:201  
 immune function, psychomotor retardation, 47:229  
 immune function, schizophrenia, 48:201  
 immune function, serotonin, 49:151  
 immune function, sleep, 47:229  
 immune function, somatic symptoms, 47:229  
 immune function, transferrin, 49:11, 49:151  
 immune function, tryptophan, 49:151  
 immune function, weight and anorexia, 47:229  
 interleukins, amino acids, 49:151  
 interleukins, cortisol, 49:11  
 interleukins, dexamethasone suppression test, 49:11  
 interleukins, haptoglobin, 49:11, 49:151  
 interleukins, immune function, 49:11, 49:151  
 interleukin, serotonin, 49:151  
 interleukins, transferrin, 49:11, 49:151  
 interleukin, tryptophan, 49:151  
 interpersonal psychotherapy, rapid eye movement latency, 49:121  
 interpersonal psychotherapy, recovery, 49:121  
 interpersonal psychotherapy, sleep, 49:121  
 joint hypermobility syndrome, mitral valve prolapse, 46:59  
 joint hypermobility syndrome, simple phobia, 46:59  
 language, laterality, 47:99  
 language, motor performance, 47:99  
 language, phototherapy, 47:99  
 language, seasonal depression, 47:99  
 laterality, language, 47:99  
 laterality, motor performance, 47:99  
 laterality, phototherapy, 47:99  
 laterality, seasonal depression, 47:99  
 light visor treatment, circannual rhythm, 46:29  
 light visor treatment, seasonal depression, 46:29  
 lymphocytes, family history, 48:201  
 lymphocytes, genetics, 48:201  
 lymphocytes, human leukocyte antigen, 48:201  
 lymphocytes, immune function, 48:201



**Affective disorder continued**

lymphocytes, schizophrenia, 48:201  
 magnetic resonance imaging, cortisol, 47:163  
 magnetic resonance imaging, dexamethasone suppression test, 47:163  
 magnetic resonance imaging, hippocampus, 47:163  
 memory, antidepressant medication, 46:295  
 memory, attention, 46:295  
 memory, treatment duration, 46:295  
 memory, visual pattern integration, 46:295  
 3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 46:19  
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:19  
 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, 46:19  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:19  
 3-methoxy-4-hydroxyphenylglycol, orthostatic challenge, 46:19  
 3-methoxy-4-hydroxyphenylglycol, phototherapy, 46:19  
 3-methoxy-4-hydroxyphenylglycol, seasonal depression, 46:19  
 mitral valve prolapse, joint hypermobility syndrome, 46:59  
 mitral valve prolapse, simple phobia, 46:59  
 motor performance, language, 47:99  
 motor performance, laterality, 47:99  
 motor performance, phototherapy, 47:99  
 motor performance, seasonal depression, 47:99  
 N-acetyl-beta-glucosaminidase, bipolar subtype, 47:129  
 N-acetyl-beta-glucosaminidase, depressive symptoms, 47:129  
 N-acetyl-beta-glucosaminidase, serotonin, 47:129  
 naps, depressed mood, 49:109  
 naps, sleep deprivation, 49:109  
 nimodipine, bipolar subtype, rapid cycling, 49:257  
 nimodipine, therapeutic response, 49:257  
 nocturnal penile tumescence, circadian rhythms, 49:139  
 nocturnal penile tumescence, daytime affect, 49:139  
 nocturnal penile tumescence, sexual function, 49:139  
 nocturnal penile tumescence, sleep, 49:139  
 norepinephrine, cerebrospinal fluid, 46:19

**Affective disorder continued**

norepinephrine, homovanillic acid, 46:19  
 norepinephrine, 5-hydroxyindoleacetic acid, 46:19  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 norepinephrine, orthostatic challenge, 46:19, 47:291  
 norepinephrine, phototherapy, 46:19  
 norepinephrine, seasonal depression, 46:19  
 obstetric complications, bipolar subtype, 48:47  
 obstetric complications, family history, 48:47  
 obstetric complications, genetics, 48:47  
 orthostatic challenge, homovanillic acid, 46:19  
 orthostatic challenge, 5-hydroxyindoleacetic acid, 46:19  
 orthostatic challenge, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 orthostatic challenge, norepinephrine, 46:19, 47:291  
 orthostatic challenge, phototherapy, 46:19  
 orthostatic challenge, seasonal depression, 46:19  
 outcome prediction, bipolar subtype, 48:1  
 outcome prediction, first episode mania, 48:1  
 outcome prediction, Tridimensional Personality Questionnaire, 48:1  
 personality, divorce, 46:165  
 personality, dream masochism, 46:165  
 personality, gender differences, 46:165  
 personality, sex role identification, 46:165  
 personality, sleep, 46:165  
 phototherapy, carbohydrate craving, 46:107  
 phototherapy, circadian rhythms, 46:107  
 phototherapy, circannual rhythms, 46:29, 47:79  
 phototherapy, diet, 46:107  
 phototherapy, eating sweets, 46:107  
 phototherapy, electrooculography, 49:99  
 phototherapy, eye blink rate, 47:79  
 phototherapy, gender differences, 47:79  
 phototherapy, homovanillic acid, 46:19  
 phototherapy, 5-hydroxyindoleacetic acid, 46:19  
 phototherapy, language, 47:99  
 phototherapy, laterality, 47:99  
 phototherapy, light visor treatment, 46:29  
 phototherapy, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 phototherapy, motor performance, 47:99  
 phototherapy, norepinephrine, 46:19

**Affective disorder continued**

phototherapy, orthostatic challenge, 46:19  
 phototherapy, seasonal depression, 46:19, 46:29, 46:107, 47:79, 47:99, 49:99  
 prevalence in northern Canada, circannual rhythms, 46:41  
 prevalence in northern Canada, seasonal depression, 46:41  
 prolactin, antidepressant medication, 46:213  
 prolactin, cortisol, 46:213  
 prolactin, sleep deprivation, 46:213  
 prolactin, thyroid stimulating hormone, 46:213  
 prolactin, triiodothyronine, 46:213  
 psychomotor retardation, immune function, 47:229  
 rapid cycling, bipolar subtype, 48:37, 49:257  
 rapid cycling, calcium channel blockers, 49:257  
 rapid cycling, family history, 48:37  
 rapid cycling, genetics, 48:37  
 rapid cycling, nimodipine, 49:257  
 rapid cycling, substance abuse, 48:37  
 rapid cycling, therapeutic response, 49:257  
 rapid eye movement latency, interpersonal psychotherapy, 49:121  
 rapid eye movement latency, recovery, 49:121  
 rapid eye movement latency, remission, 46:269  
 rapid eye movement latency, sleep, 46:269, 49:121  
 recovery, interpersonal psychotherapy, 49:121  
 recovery, rapid eye movement latency, 49:121  
 recovery, sleep, 49:121  
 remission, rapid eye movement latency, 46:269  
 remission, sleep, 46:269  
 schizophrenia, family history, 48:201  
 schizophrenia, family history of personality disorder, 48:243  
 schizophrenia, genetics, 48:201, 48:243  
 schizophrenia, human leukocyte antigen, 48:201  
 schizophrenia, immune function, 48:201  
 schizophrenia, lymphocytes, 48:201  
 seasonal depression, carbohydrate craving, 46:107  
 seasonal depression, circadian rhythms, 46:107  
 seasonal depression, circannual rhythms, 46:29, 46:41, 47:79  
 seasonal depression, diet, 46:107  
 seasonal depression, eating sweets, 46:107

**Affective disorder continued**

seasonal depression, electrooculography, 49:99  
 seasonal depression, eye blink rate, 47:79  
 seasonal depression, gender differences, 47:79  
 seasonal depression, homovanillic acid, 46:19  
 seasonal depression, 5-hydroxyindoleacetic acid, 46:19  
 seasonal depression, language, 47:99  
 seasonal depression, laterality, 47:99  
 seasonal depression, light visor treatment, 46:29  
 seasonal depression, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 seasonal depression, motor performance, 47:99  
 seasonal depression, norepinephrine, 46:19  
 seasonal depression, orthostatic challenge, 46:19  
 seasonal depression, phototherapy, 46:19, 46:29, 46:107, 47:79, 47:99, 49:99  
 seasonal depression, prevalence in northern Canada, 46:41  
 serine to glycine substitution on dopamine D<sub>3</sub>, bipolar subtype, 46:253  
 serine to glycine substitution on dopamine D<sub>3</sub>, genetics, 46:253  
 serotonin, amino acids, 49:151  
 serotonin, bipolar subtype, 47:129  
 serotonin, depressive symptoms, 47:129  
 serotonin, haptoglobin, 49:151  
 serotonin, immune function, 49:151  
 serotonin, interleukin, 49:151  
 serotonin, *N*-acetyl-beta-glucosaminidase, 47:129  
 serotonin, transferrin, 49:151  
 serotonin, tryptophan, 49:151  
 sex role identification, divorce, 46:165  
 sex role identification, dream masochism, 46:165  
 sex role identification, gender differences, 46:165  
 sex role identification, personality, 46:165  
 sex role identification, sleep, 46:165  
 sexual function, circadian rhythms, 49:139  
 sexual function, daytime affect, 49:139  
 sexual function, nocturnal penile tumescence, 49:139  
 sexual function, sleep, 49:139  
 simple phobia, joint hypermobility syndrome, 46:59

**Affective disorder continued**

simple phobia, mitral valve prolapse, 46:59  
 sleep, circadian rhythms, 47:215, 49:139  
 sleep, daytime affect, 49:139  
 sleep, depressed mood, 49:109  
 sleep, divorce, 46:165  
 sleep, dream masochism, 46:165  
 sleep, endogenous subtype, 47:215  
 sleep, gender differences, 46:165  
 sleep, growth hormone, growth hormone releasing hormone, 47:215  
 sleep, haptoglobin, 47:229  
 sleep, immune function, 47:229  
 sleep, interpersonal psychotherapy, 49:121  
 sleep, nocturnal penile tumescence, 49:139  
 sleep, personality, 46:165  
 sleep, rapid eye movement latency, 46:269, 49:121  
 sleep, recovery, 49:121  
 sleep, remission, 46:269  
 sleep, sex role identification, 46:165  
 sleep, sexual function, 49:139  
 sleep, somatic symptoms, 47:229  
 sleep, weight and anorexia, 47:229  
 sleep deprivation, antidepressant medication, 46:213  
 sleep deprivation, cortisol, 46:213  
 sleep deprivation, depressed mood, 49:109  
 sleep deprivation, fluoxetine, 46:213  
 sleep deprivation, naps, 49:109  
 sleep deprivation, prolactin, 46:213  
 sleep deprivation, sleep, 49:109  
 sleep deprivation, thyroid stimulating hormone, 46:213  
 sleep deprivation, triiodothyronine, 46:213  
 somatic symptoms, haptoglobin, 47:229  
 somatic symptoms, immune function, 47:229  
 somatic symptoms, sleep, 47:229  
 somatic symptoms, weight and anorexia, 47:229  
 substance abuse, bipolar subtype, 48:37  
 substance abuse, family history, 48:37  
 substance abuse, genetics, 48:37  
 substance abuse, rapid cycling, 48:37  
 therapeutic response, bipolar subtype, 49:257  
 therapeutic response, calcium channel blockers, 49:257  
 therapeutic response, nimodipine, 49:257  
 therapeutic response, rapid cycling, 49:257  
 thyroid stimulating hormone, antidepressant medication, 46:213  
 thyroid stimulating hormone, cortisol, 46:213, 47:7, 47:23

**Affective disorder continued**

thyroid stimulating hormone, dexamethasone suppression test, 47:7, 47:23  
 thyroid stimulating hormone, dysthymic disorder, 47:7  
 thyroid stimulating hormone, electrodermal activity, 47:23  
 thyroid stimulating hormone, prolactin, 46:213  
 thyroid stimulating hormone, sleep deprivation, 46:213  
 thyroid stimulating hormone, thyroxine, 47:7, 47:23  
 thyroid stimulating hormone, triiodothyronine, 46:213, 47:7, 47:23  
 thyroxine, cortisol, 47:7, 47:23  
 thyroxine, dexamethasone suppression test, 47:7, 47:23  
 thyroxine, dysthymic disorder, 47:7  
 thyroxine, electrodermal activity, 47:23  
 thyroxine, thyroid stimulating hormone, 47:7, 47:23  
 thyroxine, triiodothyronine, 47:7, 47:23  
 transferrin, amino acids, 49:151  
 transferrin, cortisol, 49:11  
 transferrin, dexamethasone suppression test, 49:11  
 transferrin, haptoglobin, 49:11, 49:151  
 transferrin, immune function, 49:11, 49:151  
 transferrin, interleukins, 49:11, 49:151  
 transferrin, serotonin, 49:151  
 transferrin, tryptophan, 49:151  
 treatment duration, antidepressant medication, 46:295  
 treatment duration, attention, 46:295  
 treatment duration, memory, 46:295  
 treatment duration, visual pattern integration, 46:295  
 Tridimensional Personality Questionnaire, bipolar subtype, 48:1  
 Tridimensional Personality Questionnaire, first episode mania, 48:1  
 Tridimensional Personality Questionnaire, outcome prediction, 48:1  
 triiodothyronine, antidepressant medication, 46:213  
 triiodothyronine, cortisol, 46:213, 47:7, 47:23  
 triiodothyronine, dexamethasone suppression test, 47:7, 47:23  
 triiodothyronine, dysthymic disorder, 47:7  
 triiodothyronine, electrodermal activity, 47:23  
 triiodothyronine, prolactin, 46:213



**Affective disorder continued**

- triiodothyronine, sleep deprivation, 46:213
- triiodothyronine, thyroid stimulating hormone, 46:213, 47:7, 47:23
- triiodothyronine, thyroxine, 47:7, 47:23
- tryptophan, aging, 49:151
- tryptophan, amino acids, 49:151
- tryptophan, haptoglobin, 49:151
- tryptophan, immune function, 49:151
- tryptophan, interleukin, 49:151
- tryptophan, serotonin, 49:151
- tryptophan, transferrin, 49:151
- visual pattern integration, antidepressant medication, 46:295
- visual pattern integration, attention, 46:295
- visual pattern integration, memory, 46:295
- visual pattern integration, treatment duration, 46:295
- weight and anorexia, haptoglobin, 47:229
- weight and anorexia, immune function, 47:229
- weight and anorexia, sleep, 47:229
- weight and anorexia, somatic symptoms, 47:229

**Aging**

- affective disorder, tryptophan, 49:151
- agitation, circadian rhythms, 48:277
- agitation, circannual rhythms, 48:277
- agitation, dementia, 48:277
- agitation, sleep, 48:277
- agitation, sundowning, 48:277
- circadian rhythms, agitation, 48:277
- circadian rhythms, circannual rhythms, 48:277
- circadian rhythms, dementia, 48:277
- circadian rhythms, sleep, 48:277
- circadian rhythms, sundowning, 48:277
- circannual rhythms, agitation, 48:277
- circannual rhythms, circadian rhythms, 48:277
- circannual rhythms, dementia, 48:277
- circannual rhythms, sleep, 48:277
- circannual rhythms, sundowning, 48:277
- dementia, agitation, 48:277
- dementia, circadian rhythms, 48:277
- dementia, circannual rhythms, 48:277
- dementia, sleep, 48:277
- dementia, sundowning, 48:277
- depressed mood in elderly women, phototherapy, 47:87
- depressed mood in elderly women, sleep, 47:87

**Aging continued**

- dopamine D<sub>2</sub> receptor density, 49:219
- dopamine D<sub>2</sub> receptor density, gender differences, 49:219
- dopamine D<sub>2</sub> receptor density, illness duration, 49:219
- dopamine D<sub>2</sub> receptor density, methylspiperone, 49:219
- dopamine D<sub>2</sub> receptor density, positron emission tomography, 49:219
- dopamine D<sub>2</sub> receptor density, schizophrenia, 49:219
- dopamine D<sub>2</sub> receptor density, striatum, 49:219
- gender differences, dopamine D<sub>2</sub> receptor density, 49:219
- gender differences, positron emission tomography, 49:219
- gender differences, schizophrenia, 49:219
- illness duration, dopamine D<sub>2</sub> receptor density, 49:219
- illness duration, schizophrenia, 49:219
- methylspiperone, dopamine D<sub>2</sub> receptor density, 49:219
- methylspiperone, positron emission tomography, 49:219
- methylspiperone, schizophrenia, 49:219
- methylspiperone, striatum, 49:219
- phototherapy, depressed mood in elderly women, 47:87
- phototherapy, sleep, 47:87
- positron emission tomography, dopamine D<sub>2</sub> receptor density, 49:219
- positron emission tomography, schizophrenia, 49:219
- schizophrenia, dopamine D<sub>2</sub> receptor density, 49:219
- schizophrenia, positron emission tomography, 49:219
- sleep, agitation, 48:277
- sleep, circadian rhythms, 48:277
- sleep, circannual rhythms, 48:277
- sleep, dementia, 48:277
- sleep, depressed mood in elderly women, 47:87
- sleep, phototherapy, 47:87
- sleep, sundowning, 48:277
- striatum, dopamine D<sub>2</sub> receptor density, 49:219
- sundowning, agitation, 48:277
- sundowning, circadian rhythms, 48:277
- sundowning, circannual rhythms, 48:277
- sundowning, dementia, 48:277

- Aging continued**  
 sundowning, sleep, 48:277  
 tryptophan, affective disorder, 49:151
- Akathisia**  
 animal models, neuroleptic-induced  
 defecation in rats, 47:37  
 neuroleptic-induced defecation in rats,  
 animal models, 47:37
- Alcohol abuse/dependence**  
 agoraphobia, anxiety disorder, 46:285  
 agoraphobia, panic disorder, 46:285  
 agoraphobia, substance abuse, 46:285  
 anxiety disorder, agoraphobia, 46:285  
 anxiety disorder, substance abuse, 46:285  
 attention, cocaine, 46:202  
 attention, reaction time, 46:202  
 attention, substance abuse, 46:202  
 attention, visual and auditory suppression  
 tasks, 46:202  
 attention, withdrawal, 46:202  
 cocaine, attention, 46:202  
 cocaine, motor performance, 47:69  
 cocaine, reaction time, 46:202  
 cocaine, substance abuse, 46:202  
 cocaine, substance abuse, 47:69  
 cocaine, tremor and body sway, 47:69  
 cocaine, visual and auditory suppression  
 tasks, 46:202  
 cocaine, withdrawal, 46:202  
 comorbidity, agoraphobia, 46:285  
 comorbidity, anxiety disorder, 46:285  
 comorbidity, panic disorder, 46:285  
 comorbidity, substance abuse, 46:285  
 depression, glutamyltransferase, 47:57  
 depression, impulse control disorder, 47:57  
 depression, serotonin, 47:57  
 frontal lobe, memory, 46:175  
 frontal lobe, neuropsychology, 46:175  
 frontal lobe, schizophrenia, 46:175  
 frontal lobe, Wisconsin Card Sorting Test,  
 46:175  
 glutamyltransferase, depression, 47:57  
 glutamyltransferase, impulse control disorder,  
 47:57  
 glutamyltransferase, serotonin, 47:57  
 impulse control disorder, depression, 47:57  
 impulse control disorder, glutamyltransferase,  
 47:57  
 impulse control disorder, serotonin, 47:57  
 memory, frontal lobe, 46:175  
 memory, neuropsychology, 46:175  
 memory, schizophrenia, 46:175
- Alcohol abuse/dependence continued**  
 memory, Wisconsin Card Sorting Test, 46:175  
 motor performance, cocaine, 47:69  
 motor performance, substance abuse, 47:69  
 motor performance, tremor and body sway,  
 47:69  
 neuropsychology, frontal lobe, 46:175  
 neuropsychology, memory, 46:175  
 neuropsychology, schizophrenia, 46:175  
 neuropsychology, Wisconsin Card Sorting  
 Test, 46:175  
 panic disorder, agoraphobia, 46:285  
 panic disorder, substance abuse, 46:285  
 platelets, serotonin, 47:57  
 reaction time, attention, 46:202  
 reaction time, cocaine, 46:202  
 reaction time, substance abuse, 46:202  
 reaction time, visual and auditory suppression  
 tasks, 46:202  
 schizophrenia, frontal lobe, 46:175  
 schizophrenia, memory, 46:175  
 schizophrenia, neuropsychology, 46:175  
 schizophrenia, Wisconsin Card Sorting Test,  
 46:175  
 serotonin, depression, 47:57  
 serotonin, glutamyltransferase, 47:57  
 serotonin, impulse control disorder, 47:57  
 serotonin, platelets, 47:57  
 substance abuse, agoraphobia, 46:285  
 substance abuse, anxiety disorder, 46:285  
 substance abuse, attention, 46:202  
 substance abuse, cocaine, 46:202, 47:69  
 substance abuse, motor performance, 47:69  
 substance abuse, panic disorder, 46:285  
 substance abuse, reaction time, 46:202  
 substance abuse, tremor and body sway,  
 47:69  
 substance abuse, visual and auditory  
 suppression tasks, 46:202  
 substance abuse, withdrawal, 46:202  
 tremor and body sway, cocaine, 47:69  
 tremor and body sway, motor performance,  
 47:69  
 tremor and body sway, substance abuse, 47:69  
 visual and auditory suppression tasks,  
 attention, 46:202  
 visual and auditory suppression tasks,  
 cocaine, 46:202  
 visual and auditory suppression tasks,  
 reaction time, 46:202  
 visual and auditory suppression tasks,  
 substance abuse, 46:202

**Alcohol abuse/dependence** continued  
visual and auditory suppression tasks,  
withdrawal, 46:202

Wisconsin Card Sorting Test, frontal lobe,  
46:175

Wisconsin Card Sorting Test, memory,  
46:175

Wisconsin Card Sorting Test,  
neuropsychology, 46:175

Wisconsin Card Sorting Test, schizophrenia,  
46:175

withdrawal, attention, 46:202

withdrawal, cocaine, 46:202

withdrawal, depression, 47:57

withdrawal, reaction time, 46:202

withdrawal, serotonin, 47:57

withdrawal, visual and auditory suppression  
tasks, 46:202

### **Alzheimer's disease**

cognitive impairment, dihydroxyphenylacetic  
acid, 49:211

cognitive impairment, dopamine, 49:211

cognitive impairment, homovanillic acid,  
49:211

cognitive impairment, psychiatric symptoms,  
49:211

dihydroxyphenylacetic acid, cognitive  
impairment, 49:211

dihydroxyphenylacetic acid, dopamine, 49:211

dihydroxyphenylacetic acid, homovanillic  
acid, 49:211

dihydroxyphenylacetic acid, post-mortem  
study, 49:211

dihydroxyphenylacetic acid, psychiatric  
symptoms, 49:211

dopamine, cognitive impairment, 49:211

dopamine, dihydroxyphenylacetic acid, 49:211

dopamine, homovanillic acid, 49:211

dopamine, post-mortem study, 49:211

dopamine, psychiatric symptoms, 49:211

erythrocyte membrane, lipids, 46:203

hippocampus, neurofibrillary tangles, 49:41

hippocampus, post-mortem study, 49:41

hippocampus, schizophrenia, 49:41

hippocampus, senile plaques, 49:41

homovanillic acid, cognitive impairment,  
49:211

homovanillic acid, dihydroxyphenylacetic  
acid, 49:211

homovanillic acid, dopamine, 49:211

homovanillic acid, post-mortem study,  
49:211

**Alcohol abuse/dependence** continued  
homovanillic acid, psychiatric symptoms,  
49:211

lipids, erythrocyte membrane, 46:203

neurofibrillary tangles, hippocampus, 49:41

neurofibrillary tangles, post-mortem study,  
49:41

neurofibrillary tangles, schizophrenia, 49:41

neurofibrillary tangles, senile plaques, 49:41

psychiatric symptoms, cognitive impairment,  
49:211

psychiatric symptoms, dihydroxyphenylacetic  
acid, 49:211

psychiatric symptoms, dopamine, 49:211

psychiatric symptoms, homovanillic acid,  
49:211

schizophrenia, hippocampus, 49:41

schizophrenia, neurofibrillary tangles, 49:41

schizophrenia, post-mortem, 49:41

schizophrenia, senile plaques, 49:41

senile plaques, hippocampus, 49:41

senile plaques, neurofibrillary tangles, 49:41

senile plaques, post-mortem, 49:41

senile plaques, schizophrenia, 49:41

### **Amino acids**

affective disorder, haptoglobin, 49:151

affective disorder, immune function, 49:151

affective disorder, interleukin, 49:151

affective disorder, serotonin, 49:151

affective disorder, transferrin, 49:151

affective disorder, tryptophan, 49:151

circadian rhythm, dopamine, 47:187

circadian rhythm, neuroleptics, 47:187

circadian rhythm, phenylalanine, 47:187

circadian rhythm, schizophrenia, 47:187

circadian rhythm, therapeutic response,  
47:187

dopamine, circadian rhythm, 47:187

dopamine, neuroleptics, 47:187

dopamine, phenylalanine, 47:187

dopamine, schizophrenia, 47:187

dopamine, therapeutic response, 47:187

haptoglobin, affective disorder, 49:151

haptoglobin, immune function, 49:151

haptoglobin, interleukin, 49:151

haptoglobin, serotonin, 49:151

haptoglobin, transferrin, 49:151

haptoglobin, tryptophan, 49:151

immune function, affective disorder, 49:151

immune function, haptoglobin, 49:151

immune function, interleukin, 49:151

immune function, serotonin, 49:151



**Amino acids continued**

immune function, transferrin, 49:151  
 immune function, tryptophan, 49:151  
 interleukin, affective disorder, 49:151  
 interleukin, haptoglobin, 49:151  
 interleukin, immune function, 49:151  
 interleukin, serotonin, 49:151  
 interleukin, transferrin, 49:151  
 interleukin, tryptophan, 49:151  
 neuroleptics, circadian rhythm, 47:187  
 neuroleptics, dopamine, 47:187  
 neuroleptics, phenylalanine, 47:187  
 neuroleptics, schizophrenia, 47:187  
 neuroleptics, therapeutic response, 47:187  
 phenylalanine, circadian rhythm, 47:187  
 phenylalanine, dopamine, 47:187  
 phenylalanine, neuroleptics, 47:187  
 phenylalanine, schizophrenia, 47:187  
 phenylalanine, therapeutic response, 47:187  
 schizophrenia, circadian rhythm, 47:187  
 schizophrenia, dopamine, 47:187  
 schizophrenia, neuroleptics, 47:187  
 schizophrenia, phenylalanine, 47:187  
 schizophrenia, therapeutic response, 47:187  
 serotonin, affective disorder, 49:151  
 serotonin, haptoglobin, 49:151  
 serotonin, immune function, 49:151  
 serotonin, interleukin, 49:151  
 serotonin, transferrin, 49:151  
 serotonin, tryptophan, 49:151  
 therapeutic response, circadian rhythm, 47:187  
 therapeutic response, dopamine, 47:187  
 therapeutic response, neuroleptics, 47:187  
 therapeutic response, phenylalanine, 47:187  
 therapeutic response, schizophrenia, 47:187  
 transferrin, affective disorder, 49:151  
 transferrin, haptoglobin, 49:151  
 transferrin, immune function, 49:151  
 transferrin, interleukin, 49:151  
 transferrin, serotonin, 49:151  
 transferrin, tryptophan, 49:151  
 tryptophan, affective disorder, 49:151  
 tryptophan, haptoglobin, 49:151  
 tryptophan, immune function, 49:151  
 tryptophan, interleukin, 49:151  
 tryptophan, serotonin, 49:151  
 tryptophan, transferrin, 49:151

**Amphetamine**

affective lability, anxiety, 48:219  
 affective lability, normal subjects, 48:219  
 anxiety, affective lability, 48:219

**Amphetamine continued**

anxiety, normal subjects, 48:219  
 normal subjects, affective lability, 48:219  
 normal subjects, anxiety, 48:219  
**Animal models**  
 domperidone, dysphoria, 47:37  
 domperidone, haloperidol, 47:37  
 domperidone, locomotor activity, 47:37  
 domperidone, neuroleptic-induced defecation in rats, 47:37  
 dysphoria, domperidone, 47:37  
 dysphoria, haloperidol, 47:37  
 dysphoria, locomotor activity, 47:37  
 dysphoria, neuroleptic-induced defecation in rats, 47:37  
 haloperidol, domperidone, 47:37  
 haloperidol, dysphoria, 47:37  
 haloperidol, locomotor activity, 47:37  
 haloperidol, neuroleptic-induced defecation in rats, 47:37  
 locomotor activity, domperidone, 47:37  
 locomotor activity, dysphoria, 47:37  
 locomotor activity, haloperidol, 47:37  
 locomotor activity, neuroleptic-induced defecation in rats, 47:37  
 neuroleptic-induced defecation in rats, domperidone, 47:37  
 neuroleptic-induced defecation in rats, dysphoria, 47:37  
 neuroleptic-induced defecation in rats, haloperidol, 47:37  
 neuroleptic-induced defecation in rats, locomotor activity, 47:37  
 neuroleptic-induced defecation in rats, neuroleptics, 47:37

**Anorexia nervosa. See Eating disorders****Antidepressants**

affective disorder, attention, 46:295  
 affective disorder, cortisol, 46:213  
 affective disorder, memory, 46:295  
 affective disorder, prolactin, 46:213  
 affective disorder, sleep deprivation, 46:213  
 affective disorder, thyroid stimulating hormone, 46:213  
 affective disorder, treatment duration, 46:295  
 affective disorder, triiodothyronine, 46:213  
 affective disorder, visual pattern integration, 46:295  
 attention, affective disorder, 46:295  
 attention, memory, 46:295  
 attention, treatment duration, 46:295  
 attention, visual pattern integration, 46:295

**Antidepressants continued**

cortisol, affective disorder, 46:213  
 cortisol, prolactin, 46:213  
 cortisol, sleep deprivation, 46:213  
 cortisol, thyroid stimulating hormone, 46:213  
 cortisol, triiodothyronine, 46:213  
 memory, affective disorder, 46:295  
 memory, attention, 46:295  
 memory, treatment duration, 46:295  
 memory, visual pattern integration, 46:295  
 prolactin, affective disorder, 46:213  
 prolactin, cortisol, 46:213  
 prolactin, sleep deprivation, 46:213  
 prolactin, thyroid stimulating hormone, 46:213  
 prolactin, triiodothyronine, 46:213  
 sleep deprivation, affective disorder, 46:213  
 sleep deprivation, cortisol, 46:213  
 sleep deprivation, prolactin, 46:213  
 sleep deprivation, thyroid stimulating hormone, 46:213  
 sleep deprivation, triiodothyronine, 46:213  
 thyroid stimulating hormone, affective disorder, 46:213  
 thyroid stimulating hormone, cortisol, 46:213  
 thyroid stimulating hormone, prolactin, 46:213  
 thyroid stimulating hormone, sleep deprivation, 46:213  
 thyroid stimulating hormone, triiodothyronine, 46:213  
 treatment duration, affective disorder, 46:295  
 treatment duration, attention, 46:295  
 treatment duration, memory, 46:295  
 treatment duration, visual pattern integration, 46:295  
 triiodothyronine, affective disorder, 46:213  
 triiodothyronine, cortisol, 46:213  
 triiodothyronine, prolactin, 46:213  
 triiodothyronine, sleep deprivation, 46:213  
 triiodothyronine, thyroid stimulating hormone, 46:213  
 visual pattern integration, affective disorder, 46:295  
 visual pattern integration, attention, 46:295  
 visual pattern integration, memory, 46:295  
 visual pattern integration, treatment duration, 46:295

**Antisocial personality**

children, conduct disorder, 46:9  
 children, cortisol in saliva, 46:9  
 children, genetics, 46:9

**Antisocial personality continued**

children, substance abuse, 46:9  
 conduct disorder, cortisol in saliva, 46:9  
 conduct disorder, genetics, 46:9  
 conduct disorder, substance abuse, 46:9  
 cortisol in saliva, children, 46:9  
 cortisol in saliva, conduct disorder, 46:9  
 cortisol in saliva, substance abuse, 46:9  
 genetics, conduct disorder, 46:9  
 genetics, substance abuse, 46:9  
 substance abuse, conduct disorder, 46:9  
 substance abuse, cortisol in saliva, 46:9  
 substance abuse, genetics, 46:9  
**Anxiety disorder**  
 agoraphobia, alcohol dependence, 46:285  
 agoraphobia, comorbidity, 46:285  
 agoraphobia, panic disorder, 46:285  
 agoraphobia, substance abuse, 46:285  
 alcohol intake, benzodiazepines, 48:135  
 alcohol intake, computed tomography, 48:135  
 alcohol intake, diazepam, 48:135  
 alcohol intake, lorazepam, 48:135  
 alcohol intake, ventricle-brain ratio, 48:135  
 alcohol dependence, agoraphobia, 46:285  
 alcohol dependence, comorbidity, 46:285  
 alcohol dependence, panic disorder, 46:285  
 alcohol dependence, substance abuse, 46:285  
 attention, obsessive-compulsive disorder, 49:183  
 attention, Posner task, 49:183  
 attention, reaction time, 49:183  
 attention, spatial-linguistic conflict task, 49:183  
 auditory N200, event related potentials, 49:167  
 auditory N200, laterality, 49:167  
 auditory N200, neurological soft signs, 49:167  
 auditory N200, obsessive-compulsive disorder, 49:167  
 auditory N200, P3 component, 49:167  
 autonomic nervous system, heart rate, 46:89  
 autonomic nervous system, orthostatic challenge, 46:89  
 autonomic nervous system, panic disorder, 46:89  
 autonomic nervous system, power spectral analysis of heart rate, 46:89  
 benzodiazepines, alcohol intake, 48:135  
 benzodiazepines, computed tomography, 48:135

- Anxiety disorder continued**  
 benzodiazepines, diazepam, 48:135  
 benzodiazepines, lorazepam, 48:135  
 benzodiazepines, ventricle-brain ratio, 48:135  
 carbon dioxide, clomipramine, 47:295  
 carbon dioxide, panic disorder, 47:295  
 carbon dioxide, ventilatory response, 47:295  
 carbon dioxide,  $\text{HCO}_3$ , 47:1  
 carbon dioxide, hyperventilation, 47:1  
 carbon dioxide, panic disorder, 47:1  
 carbon dioxide,  $p\text{CO}_2$ , 47:1  
 carbon dioxide,  $p\text{H}$ , 47:1  
 carbon dioxide,  $p\text{O}_2$ , 47:1  
 carbon dioxide, respiratory alkalosis, 47:1  
 clomipramine, carbon dioxide, 47:295  
 clomipramine, panic disorder, 47:295  
 clomipramine, ventilatory response, 47:295  
 comorbidity, agoraphobia, 46:285  
 comorbidity, alcohol dependence, 46:285  
 comorbidity, panic disorder, 46:285  
 comorbidity, substance abuse, 46:285  
 computed tomography, alcohol intake, 48:135  
 computed tomography, benzodiazepines, 48:135  
 computed tomography, diazepam, 48:135  
 computed tomography, lorazepam, 48:135  
 computed tomography, ventricle-brain ratio, 48:135  
 cortisol, fluvoxamine, 48:119  
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 cortisol, norepinephrine, 48:119  
 cortisol, panic disorder, 48:119  
 cortisol, reuptake inhibitor, 48:119  
 cortisol, serotonin, 48:119  
 cortisol, yohimbine, 48:119  
 depressive mood, insomnia, 49:251  
 depressive mood, phobia, 49:251  
 depressive mood, quality of sleep, 49:251  
 depressive mood, sleep, 49:251  
 diazepam, alcohol intake, 48:135  
 diazepam, benzodiazepines, 48:135  
 diazepam, computed tomography, 48:135  
 diazepam, lorazepam, 48:135  
 diazepam response, eye movements, 47:151  
 diazepam response, panic disorder, 47:151  
 diazepam response, personality, 47:151  
 diazepam response, saccadic eye movement velocity, 47:151  
 diazepam response, Tridimensional Personality Questionnaire, 47:151
- Anxiety disorder continued**  
 diazepam, ventricle-brain ratio, 48:135  
 event related potentials, auditory N200, 49:167  
 event related potentials, laterality, 49:167  
 event related potentials, neurological soft signs, 49:167  
 event related potentials, obsessive-compulsive disorder, 49:167  
 event related potentials, P3 component, 49:167  
 eye movements, diazepam response, 47:151  
 eye movements, panic disorder, 47:151  
 eye movements, personality, 47:151  
 eye movements, saccadic eye movement velocity, 47:151  
 eye movements, Tridimensional Personality Questionnaire, 47:151  
 fluvoxamine, cortisol, 48:119  
 fluvoxamine, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 fluvoxamine, norepinephrine, 48:119  
 fluvoxamine, panic disorder, 48:119  
 fluvoxamine, reuptake inhibitor, 48:119  
 fluvoxamine, serotonin, 48:119  
 fluvoxamine, yohimbine, 48:119  
 $\text{HCO}_3$ , carbon dioxide, 47:1  
 $\text{HCO}_3$ , hyperventilation, 47:1  
 $\text{HCO}_3$ , panic disorder, 47:1  
 $\text{HCO}_3$ ,  $p\text{CO}_2$ , 47:1  
 $\text{HCO}_3$ ,  $p\text{H}$ , 47:1  
 $\text{HCO}_3$ ,  $p\text{O}_2$ , 47:1  
 $\text{HCO}_3$ , respiratory alkalosis, 47:1  
 heart rate, autonomic nervous system, 46:89  
 heart rate, orthostatic challenge, 46:89  
 heart rate, panic disorder, 46:89  
 heart rate, power spectral analysis of heart rate, 46:89  
 hyperventilation, carbon dioxide, 47:1  
 hyperventilation,  $\text{HCO}_3$ , 47:1  
 hyperventilation, panic disorder, 47:1  
 hyperventilation,  $p\text{CO}_2$ , 47:1  
 hyperventilation,  $p\text{H}$ , 47:1  
 hyperventilation,  $p\text{O}_2$ , 47:1  
 hyperventilation, respiratory alkalosis, 47:1  
 insomnia, depressive mood, 49:251  
 insomnia, phobia, 49:251  
 insomnia, quality of sleep, 49:251  
 insomnia, sleep, 49:251  
 joint hypermobility syndrome, panic disorder, 46:59  
 laterality, auditory N200, 49:167



**Anxiety disorder continued**

laterality, event related potentials, 49:167  
 laterality, neurological soft signs, 49:167  
 laterality, obsessive-compulsive disorder, 49:167  
 laterality, P3 component, 49:167  
 lorazepam, alcohol intake, 48:135  
 lorazepam, benzodiazepines, 48:135  
 lorazepam, computed tomography, 48:135  
 lorazepam, diazepam, 48:135  
 lorazepam, ventricle-brain ratio, 48:135  
 3-methoxy-4-hydroxyphenylglycol, cortisol, 48:119  
 3-methoxy-4-hydroxyphenylglycol, fluvoxamine, 48:119  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119  
 3-methoxy-4-hydroxyphenylglycol, panic disorder, 48:119  
 3-methoxy-4-hydroxyphenylglycol, reuptake inhibitor, 48:119  
 3-methoxy-4-hydroxyphenylglycol, serotonin, 48:119  
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 48:119  
 neurological soft signs, auditory N200, 49:167  
 neurological soft signs, event related potentials, 49:167  
 neurological soft signs, laterality, 49:167  
 neurological soft signs, obsessive-compulsive disorder, 49:167  
 neurological soft signs, P3 component, 49:167  
 norepinephrine, cortisol, 48:119  
 norepinephrine, fluvoxamine, 48:119  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 norepinephrine, panic disorder, 48:119  
 norepinephrine, reuptake inhibitor, 48:119  
 norepinephrine, serotonin, 48:119  
 norepinephrine, yohimbine, 48:119  
 obsessive-compulsive disorder, attention, 49:183  
 obsessive-compulsive disorder, auditory N200, 49:167  
 obsessive-compulsive disorder, event related potentials, 49:167  
 obsessive-compulsive disorder, laterality, 49:167  
 obsessive-compulsive disorder, neurological soft signs, 49:167

**Anxiety disorder continued**

obsessive-compulsive disorder, P3 component, 49:167  
 obsessive-compulsive disorder, Posner task, 49:183  
 obsessive-compulsive disorder, reaction time, 49:183  
 obsessive-compulsive disorder, spatial-linguistic conflict task, 49:183  
 orthostatic challenge, autonomic nervous system, 46:89  
 orthostatic challenge, heart rate, 46:89  
 orthostatic challenge, panic disorder, 46:89  
 orthostatic challenge, power spectral analysis of heart rate, 46:89  
 P3 component, auditory N200, 49:167  
 P3 component, event related potentials, 49:167  
 P3 component, laterality, 49:167  
 P3 component, neurological soft signs, 49:167  
 P3 component, obsessive-compulsive disorder, 49:167  
 panic disorder, agoraphobia, 46:285  
 panic disorder, alcohol dependence, 46:285  
 panic disorder, autonomic nervous system, 46:89  
 panic disorder, carbon dioxide, 47:295  
 panic disorder, carbon dioxide, 47:1  
 panic disorder, clomipramine, 47:295  
 panic disorder, comorbidity, 46:285  
 panic disorder, cortisol, 48:119  
 panic disorder, diazepam response, 47:151  
 panic disorder, eye movements, 47:151  
 panic disorder, fluvoxamine, 48:119  
 panic disorder,  $\text{HCO}_3$ , 47:1  
 panic disorder, heart rate, 46:89  
 panic disorder, hyperventilation, 47:1  
 panic disorder, joint hypermobility syndrome, 46:59  
 panic disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 panic disorder, norepinephrine, 48:119  
 panic disorder, orthostatic challenge, 46:89  
 panic disorder,  $p\text{CO}_2$ , 47:1  
 panic disorder, personality, 47:151  
 panic disorder,  $p\text{H}$ , 47:1  
 panic disorder,  $p\text{O}_2$ , 47:1  
 panic disorder, power spectral analysis of heart rate, 46:89  
 panic disorder, respiratory alkalosis, 47:1  
 panic disorder, reuptake inhibitor, 48:119

**Anxiety disorder continued**

panic disorder, saccadic eye movement velocity, 47:151  
 panic disorder, serotonin, 48:119  
 panic disorder, substance abuse, 46:285  
 panic disorder, Tridimensional Personality Questionnaire, 47:151  
 panic disorder, ventilatory response, 47:295  
 panic disorder, yohimbine, 48:119  
 $p\text{CO}_2$ ,  $\text{HCO}_3$ , 47:1  
 $p\text{CO}_2$ , hyperventilation, 47:1  
 $p\text{CO}_2$ , panic disorder, 47:1  
 $p\text{CO}_2$ ,  $p\text{H}$ , 47:1  
 $p\text{CO}_2$ ,  $p\text{O}_2$ , 47:1  
 $p\text{CO}_2$ , respiratory alkalosis, 47:1  
 personality, diazepam response, 47:151  
 personality, eye movements, 47:151  
 personality, panic disorder, 47:151  
 personality, saccadic eye movement velocity, 47:151  
 personality, Tridimensional Personality Questionnaire, 47:151  
 $p\text{H}$ , carbon dioxide, 47:1  
 $p\text{H}$ ,  $\text{HCO}_3$ , 47:1  
 $p\text{H}$ , hyperventilation, 47:1  
 $p\text{H}$ , panic disorder, 47:1  
 $p\text{H}$ ,  $p\text{CO}_2$ , 47:1  
 $p\text{H}$ ,  $p\text{O}_2$ , 47:1  
 $p\text{H}$ , respiratory alkalosis, 47:1  
 phobia, depressive mood, 49:251  
 phobia, insomnia, 49:251  
 phobia, quality of sleep, 49:251  
 phobia, sleep, 49:251  
 $p\text{O}_2$ , carbon dioxide, 47:1  
 $p\text{O}_2$ ,  $\text{HCO}_3$ , 47:1  
 $p\text{O}_2$ , hyperventilation, 47:1  
 $p\text{O}_2$ , panic disorder, 47:1  
 $p\text{O}_2$ ,  $p\text{CO}_2$ , 47:1  
 $p\text{CO}_2$ ,  $p\text{H}$ , 47:1  
 $p\text{CO}_2$ , respiratory alkalosis, 47:1  
 Posner task, attention, 49:183  
 Posner task, obsessive-compulsive disorder, 49:183  
 Posner task, reaction time, 49:183  
 Posner task, spatial-linguistic conflict task, 49:183  
 power spectral analysis of heart rate, autonomic nervous system, 46:89  
 power spectral analysis of heart rate, heart rate, 46:89  
 power spectral analysis of heart rate, orthostatic challenge, 46:89

**Anxiety disorder continued**

power spectral analysis of heart rate, panic disorder, 46:89  
 quality of sleep, depressive mood, 49:251  
 quality of sleep, insomnia, 49:251  
 quality of sleep, phobia, 49:251  
 quality of sleep, sleep, 49:251  
 reaction time, attention, 49:183  
 reaction time, obsessive-compulsive disorder, 49:183  
 reaction time, Posner task, 49:183  
 reaction time, spatial-linguistic conflict task, 49:183  
 respiratory alkalosis, carbon dioxide, 47:1  
 respiratory alkalosis,  $\text{HCO}_3$ , 47:1  
 respiratory alkalosis, hyperventilation, 47:1  
 respiratory alkalosis, panic disorder, 47:1  
 respiratory alkalosis,  $p\text{CO}_2$ , 47:1  
 respiratory alkalosis,  $p\text{H}$ , 47:1  
 respiratory alkalosis,  $p\text{CO}_2$ , 47:1  
 reuptake inhibitor, cortisol, 48:119  
 reuptake inhibitor, fluvoxamine, 48:119  
 reuptake inhibitor, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 reuptake inhibitor, norepinephrine, 48:119  
 reuptake inhibitor, panic disorder, 48:119  
 reuptake inhibitor, serotonin, 48:119  
 reuptake inhibitor, yohimbine, 48:119  
 saccadic eye movement velocity, diazepam response, 47:151  
 saccadic eye movement velocity, eye movements, 47:151  
 saccadic eye movement velocity, panic disorder, 47:151  
 saccadic eye movement velocity, personality, 47:151  
 saccadic eye movement velocity, Tridimensional Personality Questionnaire, 47:151  
 serotonin, cortisol, 48:119  
 serotonin, fluvoxamine, 48:119  
 serotonin, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 serotonin, norepinephrine, 48:119  
 serotonin, panic disorder, 48:119  
 serotonin, reuptake inhibitor, 48:119  
 serotonin, yohimbine, 48:119  
 sleep, depressive mood, 49:251  
 sleep, insomnia, 49:251  
 sleep, phobia, 49:251  
 sleep, quality of sleep, 49:251  
 spatial-linguistic conflict task, attention, 49:183

**Anxiety disorder** continued

- spatial-linguistic conflict task, obsessive-compulsive disorder, 49:183
- spatial-linguistic conflict task, Posner task, 49:183
- spatial-linguistic conflict task, reaction time, 49:183
- substance abuse, agoraphobia, 46:285
- substance abuse, alcohol dependence, 46:285
- substance abuse, comorbidity, 46:285
- substance abuse, panic disorder, 46:285
- Tridimensional Personality Questionnaire, diazepam response, 47:151
- Tridimensional Personality Questionnaire, eye movements, 47:151
- Tridimensional Personality Questionnaire, panic disorder, 47:151
- Tridimensional Personality Questionnaire, personality, 47:151
- Tridimensional Personality Questionnaire, saccadic eye movement velocity, 47:151
- ventilatory response, carbon dioxide, 47:295
- ventilatory response, clomipramine, 47:295
- ventilatory response, panic disorder, 47:295
- ventricle-brain ratio, alcohol intake, 48:135
- ventricle-brain ratio, benzodiazepines, 48:135
- ventricle-brain ratio, computed tomography, 48:135
- ventricle-brain ratio, diazepam, 48:135
- ventricle-brain ratio, lorazepam, 48:135
- yohimbine, cortisol, 48:119
- yohimbine, fluvoxamine, 48:119
- yohimbine, 3-methoxy-4-hydroxyphenylglycol, 48:119
- yohimbine, norepinephrine, 48:119
- yohimbine, panic disorder, 48:119
- yohimbine, reuptake inhibitor, 48:119
- yohimbine, serotonin, 48:119

**Arginine vasopressin**

- adrenocorticotrophic hormone, affective disorder, 46:119
- adrenocorticotrophic hormone, cortisol, 46:119
- adrenocorticotrophic hormone, dexamethasone suppression test, 46:119
- adrenocorticotrophic hormone, hypothalamic-pituitary-adrenal axis, 46:119
- affective disorder, adrenocorticotrophic hormone, 46:119
- affective disorder, cortisol, 46:119
- affective disorder, dexamethasone suppression test, 46:119

**Arginine vasopressin** continued

- affective disorder, hypothalamic-pituitary-adrenal axis, 46:119
- cortisol, adrenocorticotrophic hormone, 46:119
- cortisol, affective disorder, 46:119
- cortisol, dexamethasone suppression test, 46:119
- cortisol, hypothalamic-pituitary-adrenal axis, 46:119
- dexamethasone suppression test, adrenocorticotrophic hormone, 46:119
- dexamethasone suppression test, affective disorder, 46:119
- dexamethasone suppression test, cortisol, 46:119
- dexamethasone suppression test, hypothalamic-pituitary-adrenal axis, 46:119
- electrodermal response, electromyography, 48:107
- electrodermal response, heart rate response, 48:107
- electrodermal response, oxytocin, 48:107
- electrodermal response, personal combat imagery, 48:107
- electrodermal response, posttraumatic stress syndrome, 48:107
- electrodermal response, Vietnam veterans, 48:107
- electromyography, electrodermal response, 48:107
- electromyography, heart rate response, 48:107
- electromyography, oxytocin, 48:107
- electromyography, personal combat imagery, 48:107
- electromyography, posttraumatic stress syndrome, 48:107
- electromyography, Vietnam veterans, 48:107
- heart rate response, electrodermal response, 48:107
- heart rate response, electromyography, 48:107
- heart rate response, oxytocin, 48:107
- heart rate response, personal combat imagery, 48:107
- heart rate response, posttraumatic stress syndrome, 48:107
- heart rate response, Vietnam veterans, 48:107
- hypothalamic-pituitary-adrenal axis, adrenocorticotrophic hormone, 46:119
- hypothalamic-pituitary-adrenal axis, affective disorder, 46:119



**Arginine vasopressin continued**

hypothalamic-pituitary-adrenal axis, cortisol, 46:119

hypothalamic-pituitary-adrenal axis, dexamethasone suppression test, 46:119

oxytocin, electrodermal response, 48:107

oxytocin, electromyography, 48:107

oxytocin, heart rate response, 48:107

oxytocin, personal combat imagery, 48:107

oxytocin, posttraumatic stress syndrome, 48:107

oxytocin, Vietnam veterans, 48:107

personal combat imagery, electrodermal response, 48:107

personal combat imagery, electromyography, 48:107

personal combat imagery, heart rate response, 48:107

personal combat imagery, oxytocin, 48:107

personal combat imagery, posttraumatic stress syndrome, 48:107

personal combat imagery, Vietnam veterans, 48:107

posttraumatic stress syndrome, electrodermal response, 48:107

posttraumatic stress syndrome, electromyography, 48:107

posttraumatic stress syndrome, heart rate response, 48:107

posttraumatic stress syndrome, oxytocin, 48:107

posttraumatic stress syndrome, personal combat imagery, 48:107

posttraumatic stress syndrome, Vietnam veterans, 48:107

Vietnam veterans, electrodermal response, 48:107

Vietnam veterans, electromyography, 48:107

Vietnam veterans, heart rate response, 48:107

Vietnam veterans, oxytocin, 48:107

Vietnam veterans, personal combat imagery, 48:107

Vietnam veterans, posttraumatic stress syndrome, 48:107

**Attention**

affective disorder, antidepressant medication, 46:295

affective disorder, memory, 46:295

affective disorder, treatment duration, 46:295

affective disorder, visual pattern integration, 46:295

alcohol dependence, cocaine, 46:202

**Attention continued**

alcohol dependence, reaction time, 46:202

alcohol dependence, substance abuse, 46:202

alcohol dependence, visual and auditory suppression tasks, 46:202

alcohol dependence, withdrawal, 46:202

antidepressant medication, affective disorder, 46:295

antidepressant medication, memory, 46:295

antidepressant medication, treatment duration, 46:295

antidepressant medication, visual pattern integration, 46:295

anxiety disorder, obsessive-compulsive disorder, 49:183

anxiety disorder, Posner task, 49:183

anxiety disorder, reaction time, 49:183

anxiety disorder, spatial-linguistic conflict task, 49:183

cocaine, alcohol dependence, 46:202

cocaine, reaction time, 46:202

cocaine, substance abuse, 46:202

cocaine, visual and auditory suppression tasks, 46:202

cocaine, withdrawal, 46:202

continuous performance test, positive and negative symptoms, 47:205

continuous performance test, schizophrenia, 47:205

continuous performance test, span of apprehension, 47:205

continuous performance test, thought disorder, 47:205

memory, affective disorder, 46:295

memory, antidepressant medication, 46:295

memory, treatment duration, 46:295

memory, visual pattern integration, 46:295

obsessive-compulsive disorder, anxiety disorder, 49:183

obsessive-compulsive disorder, Posner task, 49:183

obsessive-compulsive disorder, reaction time, 49:183

obsessive-compulsive disorder, spatial-linguistic conflict task, 49:183

paranoid subtype, schizophrenia, 48:17

paranoid subtype, Stroop task, 48:17

paranoid subtype, undifferentiated subtype, 48:17

positive and negative symptoms, continuous performance test, 47:205

**Attention continued**

positive and negative symptoms, schizophrenia, 47:205

positive and negative symptoms, span of apprehension, 47:205

positive and negative symptoms, thought disorder, 47:205

Posner task, anxiety disorder, 49:183

Posner task, obsessive-compulsive disorder, 49:183

Posner task, reaction time, 49:183

Posner task, spatial-linguistic conflict task, 49:183

reaction time, alcohol dependence, 46:202

reaction time, anxiety disorder, 49:183

reaction time, cocaine, 46:202

reaction time, obsessive-compulsive disorder, 49:183

reaction time, Posner task, 49:183

reaction time, spatial-linguistic conflict task, 49:183

reaction time, substance abuse, 46:202

reaction time, visual and auditory suppression tasks, 46:202

reaction time, withdrawal, 46:202

schizophrenia, continuous performance test, 47:205

schizophrenia, paranoid subtype, 48:17

schizophrenia, positive and negative symptoms, 47:205

schizophrenia, span of apprehension, 47:205

schizophrenia, Stroop task, 48:17

schizophrenia, thought disorder, 47:205

schizophrenia, undifferentiated subtype, 48:17

span of apprehension, continuous performance test, 47:205

span of apprehension, positive and negative symptoms, 47:205

span of apprehension, schizophrenia, 47:205

span of apprehension, thought disorder, 47:205

spatial-linguistic conflict task, anxiety disorder, 49:183

spatial-linguistic conflict task, obsessive-compulsive disorder, 49:183

spatial-linguistic conflict task, Posner task, 49:183

spatial-linguistic conflict task, reaction time, 49:183

Stroop task, paranoid subtype, 48:17

**Attention continued**

Stroop task, schizophrenia, 48:17

Stroop task, undifferentiated subtype, 48:17

substance abuse, alcohol dependence, 46:202

substance abuse, cocaine, 46:202

substance abuse, reaction time, 46:202

substance abuse, visual and auditory suppression tasks, 46:202

substance abuse, withdrawal, 46:202

thought disorder, continuous performance test, 47:205

thought disorder, positive and negative symptoms, 47:205

thought disorder, schizophrenia, 47:205

thought disorder, span of apprehension, 47:205

treatment duration, affective disorder, 46:295

treatment duration, antidepressant medication, 46:295

treatment duration, memory, 46:295

treatment duration, visual pattern integration, 46:295

undifferentiated subtype, paranoid subtype, 48:17

undifferentiated subtype, schizophrenia, 48:17

undifferentiated subtype, Stroop task, 48:17

visual and auditory suppression tasks, alcohol dependence, 46:202

visual and auditory suppression tasks, cocaine, 46:202

visual and auditory suppression tasks, reaction time, 46:202

visual and auditory suppression tasks, substance abuse, 46:202

visual and auditory suppression tasks, withdrawal, 46:202

visual pattern integration, affective disorder, 46:295

visual pattern integration, antidepressant medication, 46:295

visual pattern integration, memory, 46:295

visual pattern integration, treatment duration, 46:295

withdrawal, alcohol dependence, 46:202

withdrawal, cocaine, 46:202

withdrawal, reaction time, 46:202

withdrawal, substance abuse, 46:202

withdrawal, visual and auditory suppression tasks, 46:202

**Auditory acuity**

asymmetry, schizophrenia, 46:127

schizophrenia, asymmetry, 46:127

**Autism**

c-Harvey-Ras-1 marker, dopamine-beta-hydroxylase, 46:261

c-Harvey-Ras-1 marker, genetics, 46:261

c-Harvey-Ras-1 marker, restriction fragment length polymorphism, 46:261

c-Harvey-Ras-1 marker, tryptophan hydroxylase, 46:261

c-Harvey-Ras-1 marker, tyrosine hydroxylase, 46:261

dopamine-beta-hydroxylase, c-Harvey-Ras-1 marker, 46:261

dopamine-beta-hydroxylase, genetics, 46:261

dopamine-beta-hydroxylase, restriction fragment length polymorphism, 46:261

dopamine-beta-hydroxylase, tryptophan hydroxylase, 46:261

dopamine-beta-hydroxylase, tyrosine hydroxylase, 46:261

genetics, c-Harvey-Ras-1 marker, 46:261

genetics, dopamine-beta-hydroxylase, 46:261

genetics, restriction fragment length polymorphism, 46:261

genetics, tryptophan hydroxylase, 46:261

genetics, tyrosine hydroxylase, 46:261

restriction fragment length polymorphism, c-Harvey-Ras-1 marker, 46:261

restriction fragment length polymorphism, dopamine-beta-hydroxylase, 46:261

restriction fragment length polymorphism, genetics, 46:261

restriction fragment length polymorphism, tryptophan hydroxylase, 46:261

restriction fragment length polymorphism, tyrosine hydroxylase, 46:261

tryptophan hydroxylase, c-Harvey-Ras-1 marker, 46:261

tryptophan hydroxylase, dopamine-beta-hydroxylase, 46:261

tryptophan hydroxylase, genetics, 46:261

tryptophan hydroxylase, restriction fragment length polymorphism, 46:261

tryptophan hydroxylase, tyrosine hydroxylase, 46:261

tyrosine hydroxylase, c-Harvey-Ras-1 marker, 46:261

tyrosine hydroxylase, dopamine-beta-hydroxylase, 46:261

tyrosine hydroxylase, genetics, 46:261

**Autism continued**

tyrosine hydroxylase, restriction fragment length polymorphism, 46:261

tyrosine hydroxylase, tryptophan hydroxylase, 46:261

**Autonomic nervous system**

anxiety disorder, heart rate, 46:89

anxiety disorder, orthostatic challenge, 46:89

anxiety disorder, panic disorder, 46:89

anxiety disorder, power spectral analysis of heart rate, 46:89

heart rate, anxiety disorder, 46:89

heart rate, orthostatic challenge, 46:89

heart rate, panic disorder, 46:89

heart rate, power spectral analysis of heart rate, 46:89

orthostatic challenge, anxiety disorder, 46:89

orthostatic challenge, heart rate, 46:89

orthostatic challenge, panic disorder, 46:89

orthostatic challenge, power spectral analysis of heart rate, 46:89

panic disorder, anxiety disorder, 46:89

panic disorder, heart rate, 46:89

panic disorder, orthostatic challenge, 46:89

panic disorder, power spectral analysis of heart rate, 46:89

power spectral analysis of heart rate, anxiety disorder, 46:89

power spectral analysis of heart rate, heart rate, 46:89

power spectral analysis of heart rate, orthostatic challenge, 46:89

power spectral analysis of heart rate, panic disorder, 46:89

**Behavior therapy**

fluvoxamine treatment, obsessive-compulsive disorder, 49:63

obsessive-compulsive disorder, fluvoxamine treatment, 49:63

**Benzodiazepines**

alcohol intake, anxiety disorder, 48:135

alcohol intake, computed tomography, 48:135

alcohol intake, diazepam, 48:135

alcohol intake, lorazepam, 48:135

alcohol intake, ventricle-brain ratio, 48:135

anxiety disorder, alcohol intake, 48:135

anxiety disorder, computed tomography, 48:135

anxiety disorder, diazepam, 48:135

anxiety disorder, lorazepam, 48:135

anxiety disorder, ventricle-brain ratio, 48:135



**Benzodiazepines continued**

- computed tomography, alcohol intake, 48:135
- computed tomography, anxiety disorder, 48:135
- computed tomography, diazepam, 48:135
- computed tomography, lorazepam, 48:135
- computed tomography, ventricle-brain ratio, 48:135
- diazepam, alcohol intake, 48:135
- diazepam, anxiety disorder, 48:135
- diazepam, computed tomography, 48:135
- diazepam, lorazepam, 48:135
- diazepam, ventricle-brain ratio, 48:135
- lorazepam, alcohol intake, 48:135
- lorazepam, anxiety disorder, 48:135
- lorazepam, computed tomography, 48:135
- lorazepam, diazepam, 48:135
- lorazepam, ventricle-brain ratio, 48:135
- ventricle-brain ratio, alcohol intake, 48:135
- ventricle-brain ratio, anxiety disorder, 48:135
- ventricle-brain ratio, computed tomography, 48:135
- ventricle-brain ratio, diazepam, 48:135
- ventricle-brain ratio, lorazepam, 48:135

**Blood pressure**

- desipramine, normal subjects, 46:1
- fluvoxamine, heart rate, 48:119
- fluvoxamine, panic disorder, 48:119
- fluvoxamine, yohimbine, 48:119
- heart rate, fluvoxamine, 48:119
- heart rate, panic disorder, 48:119
- heart rate, yohimbine, 48:119
- lactate infusion, menstrual cycle, 46:79
- lactate infusion, panic attacks, 46:79
- lactate infusion, premenstrual syndrome, 46:79
- menstrual cycle, lactate infusion, 46:79
- menstrual cycle, panic attacks, 46:79
- menstrual cycle, premenstrual syndrome, 46:79
- normal subjects, desipramine, 46:1
- panic disorder, fluvoxamine, 48:119
- panic disorder, heart rate, 48:119
- panic disorder, yohimbine, 48:119
- panic attacks, lactate infusion, 46:79
- panic attacks, menstrual cycle, 46:79
- panic attacks, premenstrual syndrome, 46:79
- premenstrual syndrome, lactate infusion, 46:79
- premenstrual syndrome, menstrual cycle, 46:79

**Blood pressure continued**

- premenstrual syndrome, panic attacks, 46:79
- yohimbine, fluvoxamine, 48:119
- yohimbine, heart rate, 48:119
- yohimbine, panic disorder, 48:119

**Bulima.** See Eating disorders

**Carbon dioxide**

- anxiety disorder,  $\text{HCO}_3$ , 47:1
- anxiety disorder, hyperventilation, 47:1
- anxiety disorder, panic disorder, 47:1
- anxiety disorder,  $p\text{CO}_2$ , 47:1
- anxiety disorder,  $p\text{H}$ , 47:1
- anxiety disorder,  $p\text{O}_2$ , 47:1
- anxiety disorder, respiratory alkalosis, 47:1
- $\text{HCO}_3$ , anxiety disorder, 47:1
- $\text{HCO}_3$ , hyperventilation, 47:1
- $\text{HCO}_3$ , panic disorder, 47:1
- $\text{HCO}_3$ ,  $p\text{CO}_2$ , 47:1
- $\text{HCO}_3$ ,  $p\text{H}$ , 47:1
- $\text{HCO}_3$ ,  $p\text{O}_2$ , 47:1
- $\text{HCO}_3$ , respiratory alkalosis, 47:1
- hyperventilation, anxiety disorder, 47:1
- hyperventilation,  $\text{HCO}_3$ , 47:1
- hyperventilation, panic disorder, 47:1
- hyperventilation,  $p\text{CO}_2$ , 47:1
- hyperventilation,  $p\text{H}$ , 47:1
- hyperventilation,  $p\text{O}_2$ , 47:1
- hyperventilation, respiratory alkalosis, 47:1
- panic disorder, anxiety disorder, 47:1
- panic disorder,  $\text{HCO}_3$ , 47:1
- panic disorder, hyperventilation, 47:1
- panic disorder,  $p\text{CO}_2$ , 47:1
- panic disorder,  $p\text{H}$ , 47:1
- panic disorder,  $p\text{O}_2$ , 47:1
- panic disorder, respiratory alkalosis, 47:1
- $p\text{CO}_2$ , anxiety disorder, 47:1
- $p\text{CO}_2$ ,  $\text{HCO}_3$ , 47:1
- $p\text{CO}_2$ , hyperventilation, 47:1
- $p\text{CO}_2$ , panic disorder, 47:1
- $p\text{CO}_2$ ,  $p\text{H}$ , 47:1
- $p\text{CO}_2$ ,  $p\text{O}_2$ , 47:1
- $p\text{CO}_2$ , respiratory alkalosis, 47:1
- $p\text{H}$ , anxiety disorder, 47:1
- $p\text{H}$ ,  $\text{HCO}_3$ , 47:1
- $p\text{H}$ , hyperventilation, 47:1
- $p\text{H}$ , panic disorder, 47:1
- $p\text{H}$ ,  $p\text{CO}_2$ , 47:1
- $p\text{H}$ ,  $p\text{O}_2$ , 47:1
- $p\text{H}$ , respiratory alkalosis, 47:1
- $p\text{O}_2$ , anxiety disorder, 47:1
- $p\text{O}_2$ ,  $\text{HCO}_3$ , 47:1
- $p\text{O}_2$ , hyperventilation, 47:1

**Carbon dioxide continued***pO<sub>2</sub>*, panic disorder, 47:1*pO<sub>2</sub>*, *pCO<sub>2</sub>*, 47:1*pO<sub>2</sub>*, *pH*, 47:1*pO<sub>2</sub>*, respiratory alkalosis, 47:1

respiratory alkalosis, anxiety disorder, 47:1

respiratory alkalosis, *HCO<sub>3</sub>*, 47:1

respiratory alkalosis, hyperventilation, 47:1

respiratory alkalosis, panic disorder, 47:1

respiratory alkalosis, *pCO<sub>2</sub>*, 47:1respiratory alkalosis, *pH*, 47:1respiratory alkalosis, *pO<sub>2</sub>*, 47:1**Center for Epidemiologic Studies Depression Scale**

cancer patients, caregivers of chronically ill, 49:239

cancer patients, depressed mood, 49:239

cancer patients, epidemiology, 49:239

cancer patients, gender differences, 49:239

caregivers of chronically ill, cancer patients, 49:239

caregivers of chronically ill, depressed mood, 49:239

caregivers of chronically ill, epidemiology, 49:239

caregivers of chronically ill, gender differences, 49:239

depressed mood, cancer patients, 49:239

depressed mood, caregivers of chronically ill, 49:239

depressed mood, epidemiology, 49:239

depressed mood, gender differences, 49:239

epidemiology, cancer patients, 49:239

epidemiology, caregivers of chronically ill, 49:239

epidemiology, depressed mood, 49:239

epidemiology, gender differences, 49:239

gender differences, cancer patients, 49:239

gender differences, caregivers of chronically ill, 49:239

gender differences, depressed mood, 49:239

gender differences, epidemiology, 49:239

**Cerebrospinal fluid**

affective disorder, homovanillic acid, 46:19

affective disorder, 5-hydroxyindoleacetic acid, 46:19

affective disorder, 3-methoxy-4-hydroxyphenylglycol, 46:19

affective disorder, norepinephrine, 46:19

affective disorder, orthostatic challenge, 46:19

affective disorder, phototherapy, 46:19

**Cerebrospinal fluid**

affective disorder, seasonal depression, 46:19

corticotropin releasing factor, cortisol, 46:1

corticotropin releasing factor, desipramine, 46:1

corticotropin releasing factor, norepinephrine, 46:1

cortisol, corticotropin releasing factor, 46:1

cortisol, desipramine, 46:1

cortisol, norepinephrine, 46:1

desipramine, corticotropin releasing factor, 46:1

desipramine, cortisol, 46:1

desipramine, norepinephrine, 46:1

dissociative phenomena, eating disorder, 49:1

dissociative phenomena, endorphins, 49:1

dissociative phenomena, homovanillic acid, 49:1

dissociative phenomena, 5-hydroxyindoleacetic acid, 49:1

dissociative phenomena, 3-methoxy-4-hydroxyphenylglycol, 49:1

eating disorder, dissociative phenomena, 49:1

eating disorder, endorphins, 49:1

eating disorder, homovanillic acid, 49:1

eating disorder, 5-hydroxyindoleacetic acid, 49:1

eating disorder, 3-methoxy-4-hydroxyphenylglycol, 49:1

endorphins, dissociative phenomena, 49:1

endorphins, eating disorder, 49:1

endorphins, homovanillic acid, 49:1

endorphins, 5-hydroxyindoleacetic acid, 49:1

endorphins, 3-methoxy-4-

hydroxyphenylglycol, 49:1

homovanillic acid, affective disorder, 46:19

homovanillic acid, dissociative phenomena, 49:1

homovanillic acid, eating disorder, 49:1

homovanillic acid, endorphins, 49:1

homovanillic acid, 5-hydroxyindoleacetic acid, 46:19, 49:1

homovanillic acid, 3-methoxy-4-

hydroxyphenylglycol, 46:19, 49:1

homovanillic acid, norepinephrine, 46:19

homovanillic acid, orthostatic challenge, 46:19

homovanillic acid, phototherapy, 46:19

homovanillic acid, seasonal depression, 46:19

5-hydroxyindoleacetic acid, affective disorder, 46:19

5-hydroxyindoleacetic acid, dissociative phenomena, 49:1

5-hydroxyindoleacetic acid, eating disorder, 49:1

**Cerebrospinal fluid continued**

5-hydroxyindoleacetic acid, endorphins, 49:1  
 5-hydroxyindoleacetic acid, homovanillic acid, 46:19, 49:1  
 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19, 49:1  
 5-hydroxyindoleacetic acid, norepinephrine, 46:19  
 5-hydroxyindoleacetic acid, orthostatic challenge, 46:19  
 5-hydroxyindoleacetic acid, phototherapy, 46:19  
 5-hydroxyindoleacetic acid, seasonal depression, 46:19  
 3-methoxy-4-hydroxyphenylglycol, affective disorder, 46:19  
 3-methoxy-4-hydroxyphenylglycol, dissociative phenomena, 49:1  
 3-methoxy-4-hydroxyphenylglycol, eating disorder, 49:1  
 3-methoxy-4-hydroxyphenylglycol, endorphins, 49:1  
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:19, 49:1  
 3-methoxy-4-hydroxyphenylglycol, hydroxyindoleacetic acid, 46:19, 49:1  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:19  
 3-methoxy-4-hydroxyphenylglycol, orthostatic challenge, 46:19  
 3-methoxy-4-hydroxyphenylglycol, phototherapy, 46:19  
 3-methoxy-4-hydroxyphenylglycol, seasonal depression, 46:19  
 norepinephrine, affective disorder, 46:19  
 norepinephrine, corticotropin releasing factor, 46:1  
 norepinephrine, cortisol, 46:1  
 norepinephrine, desipramine, 46:1  
 norepinephrine, homovanillic acid, 46:19  
 norepinephrine, 5-hydroxyindoleacetic acid, 46:19  
 norepinephrine, hypothalamic-pituitary-adrenal axis, 46:1  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 norepinephrine, orthostatic challenge, 46:19  
 norepinephrine, phototherapy, 46:19  
 norepinephrine, seasonal depression, 46:19  
 orthostatic challenge, affective disorder, 46:19  
 orthostatic challenge, homovanillic acid, 46:19

**Cerebrospinal fluid continued**

orthostatic challenge, 5-hydroxyindoleacetic acid, 46:19  
 orthostatic challenge, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 orthostatic challenge, norepinephrine, 46:19  
 orthostatic challenge, phototherapy, 46:19  
 orthostatic challenge, seasonal depression, 46:19  
 phototherapy, affective disorder, 46:19  
 phototherapy, homovanillic acid, 46:19  
 phototherapy, 5-hydroxyindoleacetic acid, 46:19  
 phototherapy, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 phototherapy, norepinephrine, 46:19  
 phototherapy, orthostatic challenge, 46:19  
 phototherapy, seasonal depression, 46:19  
 seasonal depression, homovanillic acid, 46:19  
 seasonal depression, 5-hydroxyindoleacetic acid, 46:19  
 seasonal depression, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 seasonal depression, norepinephrine, 46:19  
 seasonal depression, orthostatic challenge, 46:19  
 seasonal depression, phototherapy, 46:19  
**c-Harvey-Ras marker**  
 autism, dopamine-beta-hydroxylase, 46:261  
 autism, genetics, 46:261  
 autism, restriction fragment length polymorphism, 46:261  
 autism, tryptophan hydroxylase, 46:261  
 autism, tyrosine hydroxylase, 46:261  
 dopamine-beta-hydroxylase, autism, 46:261  
 dopamine-beta-hydroxylase, genetics, 46:261  
 dopamine-beta-hydroxylase, restriction fragment length polymorphism, 46:261  
 dopamine-beta-hydroxylase, tryptophan hydroxylase, 46:261  
 dopamine-beta-hydroxylase, tyrosine hydroxylase, 46:261  
 genetics, autism, 46:261  
 genetics, dopamine-beta-hydroxylase, 46:261  
 genetics, restriction fragment length polymorphism, 46:261  
 genetics, tryptophan hydroxylase, 46:261  
 genetics, tyrosine hydroxylase, 46:261  
 restriction fragment length polymorphism, autism, 46:261  
 restriction fragment length polymorphism, dopamine-beta-hydroxylase, 46:261



**c-Harvey Ras marker continued**

restriction fragment length polymorphism, genetics, 46:261  
 restriction fragment length polymorphism, tryptophan hydroxylase, 46:261  
 restriction fragment length polymorphism, tyrosine hydroxylase, 46:261  
 tryptophan hydroxylase, autism, 46:261  
 tryptophan hydroxylase, dopamine-beta-hydroxylase, 46:261  
 tryptophan hydroxylase, genetics, 46:261  
 tryptophan hydroxylase, restriction fragment length polymorphism, 46:261  
 tryptophan hydroxylase, tyrosine hydroxylase, 46:261  
 tyrosine hydroxylase, autism, 46:261  
 tyrosine hydroxylase, dopamine-beta-hydroxylase, 46:261  
 tyrosine hydroxylase, genetics, 46:261  
 tyrosine hydroxylase, restriction fragment length polymorphism, 46:261  
 tyrosine hydroxylase, tryptophan hydroxylase, 46:261

**Childhood disorders**

antisocial personality disorder, conduct disorder, 46:9  
 antisocial personality disorder, cortisol in saliva, 46:9  
 antisocial personality disorder, genetics, 46:9  
 antisocial personality disorder, substance abuse, 46:9  
 conduct disorder, antisocial personality disorder, 46:9  
 conduct disorder, cortisol in saliva, 46:9  
 conduct disorder, genetics, 46:9  
 conduct disorder, substance abuse, 46:9  
 cortisol in saliva, antisocial personality disorder, 46:9  
 cortisol in saliva, conduct disorder, 46:9  
 cortisol in saliva, genetics, 46:9  
 cortisol in saliva, substance abuse, 46:9  
 genetics, antisocial personality disorder, 46:9  
 genetics, conduct disorder, 46:9  
 genetics, cortisol in saliva, 46:9  
 genetics, substance abuse, 46:9  
 substance abuse, antisocial personality disorder, 46:9  
 substance abuse, conduct disorder, 46:9  
 substance abuse, cortisol in saliva, 46:9  
 substance abuse, genetics, 46:9

**Circadian rhythms**

affective disorder, carbohydrate craving, 46:107  
 affective disorder, daytime affect, 49:139  
 affective disorder, diet, 46:107  
 affective disorder, eating sweets, 46:107  
 affective disorder, endogenous subtype, 47:215  
 affective disorder, growth hormone, 47:215  
 affective disorder, growth hormone releasing hormone, 47:215  
 affective disorder, nocturnal penile tumescence, 49:139  
 affective disorder, phototherapy, 46:107  
 affective disorder, seasonal depression, 46:107  
 affective disorder, sexual function, 49:139  
 affective disorder, sleep, 47:215  
 affective disorder, sleep, 49:139  
 aging, agitation, 48:277  
 aging, circannual rhythms, 48:277  
 aging, dementia, 48:277  
 aging, sleep, 48:277  
 aging, sundowning, 48:277  
 agitation, aging, 48:277  
 agitation, circannual rhythms, 48:277  
 agitation, dementia, 48:277  
 agitation, sleep, 48:277  
 agitation, sundowning, 48:277  
 amino acids, dopamine, 47:187  
 amino acids, neuroleptics, 47:187  
 amino acids, neutral serum amino acids, 47:187  
 amino acids, phenylalanine, 47:187  
 amino acids, schizophrenia, 47:187  
 amino acids, therapeutic response, 47:187  
 carbohydrate craving, affective disorder, 46:107  
 carbohydrate craving, diet, 46:107  
 carbohydrate craving, eating sweets, 46:107  
 carbohydrate craving, phototherapy, 46:107  
 carbohydrate craving, seasonal depression, 46:107  
 circannual rhythms, aging, 48:277  
 circannual rhythms, agitation, 48:277  
 circannual rhythms, dementia, 48:277  
 circannual rhythms, sleep, 48:277  
 circannual rhythms, sundowning, 48:277  
 daytime affect, affective disorder, 49:139  
 daytime affect, nocturnal penile tumescence, 49:139  
 daytime affect, sexual function, 49:139

**Circadian rhythms continued**

daytime affect, sleep, 49:139  
 dementia, aging, 48:277  
 dementia, agitation, 48:277  
 dementia, circannual rhythms, 48:277  
 dementia, sleep, 48:277  
 dementia, sundowning, 48:277  
 diet, affective disorder, 46:107  
 diet, carbohydrate craving, 46:107  
 diet, eating sweets, 46:107  
 diet, phototherapy, 46:107  
 diet, seasonal depression, 46:107  
 dopamine, amino acids, 47:187  
 dopamine, haloperidol, 47:141  
 dopamine, homovanillic acid, 47:141  
 dopamine, neuroleptics, 47:187  
 dopamine, neutral serum amino acids, 47:187  
 dopamine, normal subjects, 47:141  
 dopamine, phenylalanine, 47:187  
 dopamine, schizophrenia, 47:187  
 dopamine, therapeutic response, 47:187  
 eating sweets, affective disorder, 46:107  
 eating sweets, carbohydrate craving, 46:107  
 eating sweets, diet, 46:107  
 eating sweets, phototherapy, 46:107  
 eating sweets, seasonal depression, 46:107  
 endogenous subtype, affective disorder, 47:215  
 endogenous subtype, growth hormone, 47:215  
 endogenous subtype, growth hormone releasing hormone, 47:215  
 endogenous subtype, sleep, 47:215  
 growth hormone, affective disorder, 47:215  
 growth hormone, endogenous subtype, 47:215  
 growth hormone, growth hormone releasing hormone, 47:215  
 growth hormone, sleep, 47:215  
 growth hormone releasing hormone, affective disorder, 47:215  
 growth hormone releasing hormone, endogenous subtype, 47:215  
 growth hormone releasing hormone, growth hormone, 47:215  
 growth hormone releasing hormone, sleep, 47:215  
 haloperidol, dopamine, 47:141  
 haloperidol, homovanillic acid, 47:141  
 haloperidol, normal subjects, 47:141  
 homovanillic acid, dopamine, 47:141  
 homovanillic acid, haloperidol, 47:141

**Circadian rhythms continued**

homovanillic acid, normal subjects, 47:141  
 neuroleptics, amino acids, 47:187  
 neuroleptics, dopamine, 47:187  
 neuroleptics, neutral serum amino acids, 47:187  
 neuroleptics, phenylalanine, 47:187  
 neuroleptics, schizophrenia, 47:187  
 neuroleptics, therapeutic response, 47:187  
 neutral serum amino acids, amino acids, 47:187  
 neutral serum amino acids, dopamine, 47:187  
 neutral serum amino acids, neuroleptics, 47:187  
 neutral serum amino acids, phenylalanine, 47:187  
 neutral serum amino acids, schizophrenia, 47:187  
 neutral serum amino acids, therapeutic response, 47:187  
 nocturnal penile tumescence, affective disorder, 49:139  
 nocturnal penile tumescence, daytime affect, 49:139  
 nocturnal penile tumescence, sexual function, 49:139  
 nocturnal penile tumescence, sleep, 49:139  
 normal subjects, dopamine, 47:141  
 normal subjects, haloperidol, 47:141  
 normal subjects, homovanillic acid, 47:141  
 phenylalanine, amino acids, 47:187  
 phenylalanine, dopamine, 47:187  
 phenylalanine, neuroleptics, 47:187  
 phenylalanine, neutral serum amino acids, 47:187  
 phenylalanine, schizophrenia, 47:187  
 phenylalanine, therapeutic response, 47:187  
 phototherapy, affective disorder, 46:107  
 phototherapy, carbohydrate craving, 46:107  
 phototherapy, diet, 46:107  
 phototherapy, eating sweets, 46:107  
 phototherapy, seasonal depression, 46:107  
 prolactin, schizophrenia, 47:187  
 prolactin, tyrosine, 47:187  
 schizophrenia, amino acids, 47:187  
 schizophrenia, dopamine, 47:187  
 schizophrenia, neuroleptics, 47:187  
 schizophrenia, neutral serum amino acids, 47:187  
 schizophrenia, phenylalanine, 47:187  
 schizophrenia, prolactin, 47:187  
 schizophrenia, therapeutic response, 47:187

**Circadian rhythms continued**

schizophrenia, tyrosine, 47:187  
 seasonal depression, affective disorder, 46:107  
 seasonal depression, carbohydrate craving, 46:107  
 seasonal depression, diet, 46:107  
 seasonal depression, eating sweets, 46:107  
 seasonal depression, phototherapy, 46:107  
 sexual function, affective disorder, 49:139  
 sexual function, daytime affect, 49:139  
 sexual function, nocturnal penile tumescence, 49:139  
 sexual function, sleep, 49:139  
 sleep, affective disorder, 47:215  
 sleep, affective disorder, 49:139  
 sleep, aging, 48:277  
 sleep, agitation, 48:277  
 sleep, circannual rhythms, 48:277  
 sleep, daytime affect, 49:139  
 sleep, dementia, 48:277  
 sleep, endogenous subtype, 47:215  
 sleep, growth hormone, 47:215  
 sleep, growth hormone releasing hormone, 47:215  
 sleep, nocturnal penile tumescence, 49:139  
 sleep, sexual function, 49:139  
 sleep, sundowning, 48:277  
 sundowning, aging, 48:277  
 sundowning, agitation, 48:277  
 sundowning, circannual rhythms, 48:277  
 sundowning, dementia, 48:277  
 sundowning, sleep, 48:277  
 therapeutic response, amino acids, 47:187  
 therapeutic response, dopamine, 47:187  
 therapeutic response, neuroleptics, 47:187  
 therapeutic response, neutral serum amino acids, 47:187  
 therapeutic response, phenylalanine, 47:187  
 therapeutic response, schizophrenia, 47:187  
 tyrosine, prolactin, 47:187  
 tyrosine, schizophrenia, 47:187

**Circannual rhythms**

affective disorder, eye blink rate, 47:79  
 affective disorder, gender differences, 47:79  
 affective disorder, light visor treatment, 46:29  
 affective disorder, phototherapy, 46:29, 47:79  
 affective disorder, prevalence in northern Canada, 46:41  
 aging, agitation, 48:277  
 aging, circadian rhythms, 48:277  
 aging, dementia, 48:277

**Circannual rhythms continued**

aging, sleep, 48:277  
 aging, sundowning, 48:277  
 agitation, aging, 48:277  
 agitation, circadian rhythms, 48:277  
 agitation, dementia, 48:277  
 agitation, sleep, 48:277  
 agitation, sundowning, 48:277  
 circadian rhythms, aging, 48:277  
 circadian rhythms, agitation, 48:277  
 circadian rhythms, dementia, 48:277  
 circadian rhythms, sleep, 48:277  
 circadian rhythms, sundowning, 48:277  
 dementia, aging, 48:277  
 dementia, agitation, 48:277  
 dementia, circadian rhythms, 48:277  
 dementia, sleep, 48:277  
 dementia, sundowning, 48:277  
 depressed mood, normal women, 49:77  
 depressed mood, Profile of Mood States, 49:77  
 depressed mood, thyroid stimulating hormone, 49:77  
 depressed mood, thyroxine, 49:77  
 depressed mood, triiodothyronine, 49:77  
 depressed mood, Vitamin D, 49:77  
 eye blink rate, affective disorder, 47:79  
 eye blink rate, gender differences, 47:79  
 eye blink rate, phototherapy, 47:79  
 eye blink rate, seasonal depression, 47:79  
 gender differences, affective disorder, 47:79  
 gender differences, eye blink rate, 47:79  
 gender differences, phototherapy, 47:79  
 gender differences, seasonal depression, 47:79  
 light visor treatment, affective disorder, 46:29  
 light visor treatment, phototherapy, 46:29  
 normal women, depressed mood, 49:77  
 normal women, Profile of Mood States, 49:77  
 normal women, thyroid stimulating hormone, 49:77  
 normal women, thyroxine, 49:77  
 normal women, triiodothyronine, 49:77  
 normal women, Vitamin D, 49:77  
 phototherapy, affective disorder, 46:29, 47:79  
 phototherapy, eye blink rate, 47:79  
 phototherapy, gender differences, 47:79  
 phototherapy, light visor treatment, 46:29  
 phototherapy, seasonal depression, 46:29, 47:79  
 prevalence in northern Canada, affective disorder, 46:41  
 prevalence in northern Canada, seasonal depression, 46:41



**Circannual rhythms continued**

Profile of Mood States, depressed mood, 49:77  
 Profile of Mood States, normal women, 49:77  
 Profile of Mood States, thyroid stimulating hormone, 49:77  
 Profile of Mood States, thyroxine, 49:77  
 Profile of Mood States, triiodothyronine, 49:77  
 Profile of Mood States, Vitamin D, 49:77  
 seasonal depression, eye blink rate, 47:79  
 seasonal depression, gender differences, 47:79  
 seasonal depression, light visor treatment, 46:29  
 seasonal depression, phototherapy, 46:29, 47:79  
 seasonal depression, prevalence in northern Canada, 46:41  
 sleep, aging, 48:277  
 sleep, agitation, 48:277  
 sleep, circadian rhythms, 48:277  
 sleep, dementia, 48:277  
 sleep, sundowning, 48:277  
 sundowning, aging, 48:277  
 sundowning, agitation, 48:277  
 sundowning, circadian rhythms, 48:277  
 sundowning, dementia, 48:277  
 sundowning, sleep, 48:277  
 thyroid stimulating hormone, depressed mood, 49:77  
 thyroid stimulating hormone, normal women, 49:77  
 thyroid stimulating hormone, Profile of Mood States, 49:77  
 thyroid stimulating hormone, thyroxine, 49:77  
 thyroid stimulating hormone, triiodothyronine, 49:77  
 thyroid stimulating hormone, Vitamin D, 49:77  
 thyroxine, depressed mood, 49:77  
 thyroxine, normal women, 49:77  
 thyroxine, Profile of Mood States, 49:77  
 thyroxine, thyroid stimulating hormone, 49:77  
 thyroxine, triiodothyronine, 49:77  
 thyroxine, Vitamin D, 49:77  
 treatment, seasonal depression, 46:29  
 triiodothyronine, depressed mood, 49:77  
 triiodothyronine, normal women, 49:77  
 triiodothyronine, Profile of Mood States, 49:77  
 triiodothyronine, thyroid stimulating hormone, 49:77  
 triiodothyronine, thyroxine, 49:77  
 triiodothyronine, Vitamin D, 49:77  
 Vitamin D, depressed mood, 49:77  
 Vitamin D, normal women, 49:77  
 Vitamin D, Profile of Mood States, 49:77

**Circannual rhythms continued**

Vitamin D, thyroid stimulating hormone, 49:77  
 Vitamin D, thyroxine, 49:77  
 Vitamin D, triiodothyronine, 49:77  
**Clomipramine**  
 anxiety disorder, carbon dioxide, 47:295  
 anxiety disorder, panic disorder, 47:295  
 anxiety disorder, ventilatory response, 47:295  
 carbon dioxide, anxiety disorder, 47:295  
 carbon dioxide, panic disorder, 47:295  
 carbon dioxide, ventilatory response, 47:295  
 panic disorder, anxiety disorder, 47:295  
 panic disorder, carbon dioxide, 47:295  
 panic disorder, ventilatory response, 47:295  
 ventilatory response, anxiety disorder, 47:295  
 ventilatory response, carbon dioxide, 47:295  
 ventilatory response, panic disorder, 47:295  
**Clonidine**  
 diagnostic systems, growth hormone, 48:79  
 diagnostic systems, schizophrenia, 48:79  
 growth hormone, diagnostic systems, 48:79  
 growth hormone, schizophrenia, 48:79  
 schizophrenia, diagnostic systems, 48:79  
 schizophrenia, growth hormone, 48:79  
**Clozapine**  
 dopamine, homovanillic acid, 46:139, 46:151  
 dopamine, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 dopamine, norepinephrine, 46:139, 46:151  
 dopamine, schizophrenia, 46:139, 46:151  
 dopamine, therapeutic response, 46:139, 46:151  
 homovanillic acid, dopamine, 46:139, 46:151  
 homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 homovanillic acid, norepinephrine, 46:139, 46:151  
 homovanillic acid, schizophrenia, 46:139, 46:151  
 homovanillic acid, therapeutic response, 46:139, 46:151  
 3-methoxy-4-hydroxyphenylglycol, dopamine, 46:139  
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:139  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:139  
 3-methoxy-4-hydroxyphenylglycol, schizophrenia, 46:139  
 3-methoxy-4-hydroxyphenylglycol, therapeutic response, 46:139

**Clozapine continued**

norepinephrine, dopamine, 46:139, 46:151  
 norepinephrine, homovanillic acid, 46:139, 46:151  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 norepinephrine, schizophrenia, 46:139, 46:151  
 norepinephrine, therapeutic response, 46:139, 46:151  
 schizophrenia, dopamine, 46:139, 46:151  
 schizophrenia, homovanillic acid, 46:139, 46:151  
 schizophrenia, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 schizophrenia, norepinephrine, 46:139, 46:151  
 schizophrenia, therapeutic response, 46:139, 46:151  
 therapeutic response, dopamine, 46:139, 46:151  
 therapeutic response, homovanillic acid, 46:139, 46:151  
 therapeutic response, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 therapeutic response, norepinephrine, 46:139, 46:151  
 therapeutic response, schizophrenia, 46:139, schizophrenia, 46:151

**Cocaine**

alcohol dependence, attention, 46:229  
 alcohol dependence, motor performance, 46:229  
 alcohol dependence, reaction time, 46:229  
 alcohol dependence, tremor and body sway, 47:69  
 alcohol dependence, visual and auditory suppression tasks, 46:229  
 alcohol dependence, withdrawal, 46:229  
 attention, alcohol dependence, 46:229  
 attention, reaction time, 46:229  
 attention, visual and auditory suppression tasks, 46:229  
 attention, withdrawal, 46:229  
 auditory P50 component, event related potentials, 47:243  
 auditory P50 component, paranoid subtype, 47:243  
 auditory P50 component, schizophrenia, 47:243  
 event related potentials, auditory P50 component, 47:243  
 event related potentials, paranoid subtype, 47:243  
 event related potentials, schizophrenia, 47:243

**Cocaine continued**

motor performance, alcohol dependence, 47:69  
 motor performance, tremor and body sway, 47:69  
 paranoid subtype, auditory P50 component, 47:243  
 paranoid subtype, event related potentials, 47:243  
 paranoid subtype, schizophrenia, 47:243  
 reaction time, alcohol dependence, 46:202  
 reaction time, attention, 46:202  
 reaction time, visual and auditory suppression tasks, 46:202  
 reaction time, withdrawal, 46:202  
 schizophrenia, auditory P50 component, 47:243  
 schizophrenia, event related potentials, 47:243  
 schizophrenia, paranoid subtype, 47:243  
 tremor and body sway, alcohol dependence, 47:69  
 tremor and body sway, motor performance, 47:69  
 visual and auditory suppression tasks, alcohol dependence, 46:202  
 visual and auditory suppression tasks, attention, 46:202  
 visual and auditory suppression tasks, reaction time, 46:202  
 visual and auditory suppression tasks, withdrawal, 46:202  
 withdrawal, alcohol dependence, 46:202  
 withdrawal, attention, 46:202  
 withdrawal, reaction time, 46:202  
 withdrawal, visual and auditory suppression tasks, 46:202

**Computed tomography**

alcohol intake, anxiety disorder, 48:135  
 alcohol intake, benzodiazepines, 48:135  
 alcohol intake, diazepam, 48:135  
 alcohol intake, lorazepam, 48:135  
 alcohol intake, ventricle-brain ratio, 48:135  
 anxiety disorder, alcohol intake, 48:135  
 anxiety disorder, benzodiazepines, 48:135  
 anxiety disorder, diazepam, 48:135  
 anxiety disorder, lorazepam, 48:135  
 anxiety disorder, ventricle-brain ratio, 48:135  
 benzodiazepines, alcohol intake, 48:135  
 benzodiazepines, anxiety disorder, 48:135  
 benzodiazepines, diazepam, 48:135  
 benzodiazepines, lorazepam, 48:135  
 benzodiazepines, ventricle-brain ratio, 48:135

**Computed tomography continued**

diazepam, alcohol intake, 48:135  
 diazepam, anxiety disorder, 48:135  
 diazepam, benzodiazepines, 48:135  
 diazepam, lorazepam, 48:135  
 diazepam, ventricle-brain ratio, 48:135  
 lorazepam, alcohol intake, 48:135  
 lorazepam, anxiety disorder, 48:135  
 lorazepam, benzodiazepines, 48:135  
 lorazepam, diazepam, 48:135  
 lorazepam, ventricle-brain ratio, 48:135  
 ventricle-brain ratio, alcohol intake, 48:135  
 ventricle-brain ratio, anxiety disorder, 48:135  
 ventricle-brain ratio, benzodiazepines, 48:135  
 ventricle-brain ratio, diazepam, 48:135  
 ventricle-brain ratio, lorazepam, 48:135

**Conduct disorder**

antisocial personality disorder, cortisol in saliva, 46:9  
 antisocial personality disorder, genetics, 46:9  
 antisocial personality disorder, substance abuse, 46:9  
 cortisol in saliva, antisocial personality disorder, 46:9  
 cortisol in saliva, substance abuse, 46:9  
 genetics, antisocial personality disorder, 46:9  
 genetics, substance abuse, 46:9  
 substance abuse, antisocial personality disorder, 46:9  
 substance abuse, cortisol in saliva, 46:9  
 substance abuse, genetics, 46:9

**Corticotropin releasing hormone**

cerebrospinal fluid, norepinephrine, 46:1  
 cortisol, desipramine, 46:1  
 cortisol, norepinephrine, 46:1  
 desipramine, cortisol, 46:1  
 desipramine, norepinephrine, 46:1  
 norepinephrine, cerebrospinal fluid, 46:1  
 norepinephrine, cortisol, 46:1  
 norepinephrine, desipramine, 46:1

**Cortisol**

adrenocorticotrophic hormone, affective disorder, 46:119  
 adrenocorticotrophic hormone, arginine vasopressin, 46:119  
 adrenocorticotrophic hormone, dexamethasone suppression test, 46:119  
 affective disorder, adrenocorticotrophic hormone, 46:119  
 affective disorder, antidepressant medication, 46:213  
 affective disorder, arginine vasopressin, 46:119

**Cortisol continued**

affective disorder, dexamethasone suppression test, 46:119, 47:7, 47:23, 47:163, 49:11  
 affective disorder, dysthymic disorder, 47:7  
 affective disorder, electrodermal activity, 47:23  
 affective disorder, haptoglobin, 49:11  
 affective disorder, hippocampus, 47:163  
 affective disorder, immune function, 49:11  
 affective disorder, interleukins, 49:11  
 affective disorder, magnetic resonance imaging, 47:163  
 affective disorder, prolactin, 46:213  
 affective disorder, sleep deprivation, 46:213  
 affective disorder, thyroid stimulating hormone, 46:213  
 affective disorder, thyroid stimulating hormone, 47:7, 47:23  
 affective disorder, thyroxine, 47:7, 47:23  
 affective disorder, transferrin, 49:11  
 affective disorder, triiodothyronine, 46:213, 47:7, 47:23  
 antidepressant medication, affective disorder, 46:213  
 antidepressant medication, prolactin, 46:213  
 antidepressant medication, sleep deprivation, 46:213  
 antidepressant medication, thyroid stimulating hormone, 46:213  
 antidepressant medication, triiodothyronine, 46:213  
 antisocial personality disorder, conduct disorder, 46:9  
 antisocial personality disorder, genetics, 46:9  
 antisocial personality disorder, substance abuse, 46:9  
 anxiety disorder, fluvoxamine, 48:119  
 anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 anxiety disorder, norepinephrine, 48:119  
 anxiety disorder, panic disorder, 48:119  
 anxiety disorder, reuptake inhibitor, 48:119  
 anxiety disorder, serotonin, 48:119  
 anxiety disorder, yohimbine, 48:119  
 arginine vasopressin, adrenocorticotrophic hormone, 46:119  
 arginine vasopressin, affective disorder, 46:119  
 arginine vasopressin, dexamethasone suppression test, 46:119  
 cerebrospinal fluid, norepinephrine, 46:1  
 conduct disorder, antisocial personality disorder, 46:9



**Cortisol continued**

conduct disorder, genetics, 46:9  
 conduct disorder, substance abuse, 46:9  
 corticotropin releasing factor, desipramine, 46:1  
 corticotropin releasing factor, norepinephrine, 46:1  
 desipramine, corticotropin releasing factor, 46:1  
 desipramine, norepinephrine, 46:1  
 dexamethasone suppression test, adrenocorticotrophic hormone, 46:119  
 dexamethasone suppression test, affective disorder, 46:119, 47:23, 47:7, 47:163, 49:11  
 dexamethasone suppression test, arginine vasopressin, 46:119  
 dexamethasone suppression test, dysthymic disorder, 47:7  
 dexamethasone suppression test, electrodermal activity, 47:23  
 dexamethasone suppression test, haptoglobin, 49:11  
 dexamethasone suppression test, hippocampus, 47:163  
 dexamethasone suppression test, immune function, 49:11  
 dexamethasone suppression test, interleukins, 49:11  
 dexamethasone suppression test, magnetic resonance imaging, 47:163  
 dexamethasone suppression test, thyroid stimulating hormone, 47:7, 47:23  
 dexamethasone suppression test, thyroxine, 47:7, 47:23  
 dexamethasone suppression test, transferrin, 49:11  
 dexamethasone suppression test, triiodothyronine, 47:7, 47:23  
 dysthymic disorder, affective disorder, 47:7  
 dysthymic disorder, dexamethasone suppression test, 47:7  
 dysthymic disorder, thyroid stimulating hormone, 47:7  
 dysthymic disorder, thyroxine, 47:7  
 dysthymic disorder, triiodothyronine, 47:7  
 electrodermal activity, affective disorder, 47:23  
 electrodermal activity, dexamethasone suppression test, 47:23  
 electrodermal activity, thyroid stimulating hormone, 47:23  
 electrodermal activity, thyroxine, 47:23

**Cortisol continued**

electrodermal activity, triiodothyronine, 47:23  
 fluvoxamine, anxiety disorder, 48:119  
 fluvoxamine, 3-methoxy-4-hydroxy-phenylglycol, 48:119  
 fluvoxamine, norepinephrine, 48:119  
 fluvoxamine, panic disorder, 48:119  
 fluvoxamine, reuptake inhibitor, 48:119  
 fluvoxamine, serotonin, 48:119  
 fluvoxamine, yohimbine, 48:119  
 genetics, antisocial personality disorder, 46:9  
 genetics, conduct disorder, 46:9  
 genetics, substance abuse, 46:9  
 haptoglobin, affective disorder, 49:11  
 haptoglobin, dexamethasone suppression test, 49:11  
 haptoglobin, immune function, 49:11  
 haptoglobin, interleukins, 49:11  
 haptoglobin, transferrin, 49:11  
 hippocampus, affective disorder, 47:163  
 hippocampus, dexamethasone suppression test, 47:163  
 hippocampus, magnetic resonance imaging, 47:163  
 immune function, affective disorder, 49:11  
 immune function, dexamethasone suppression test, 49:11  
 immune function, haptoglobin, 49:11  
 immune function, interleukins, 49:11  
 immune function, transferrin, 49:11  
 interleukins, affective disorder, 49:11  
 interleukins, dexamethasone suppression test, 49:11  
 interleukins, haptoglobin, 49:11  
 interleukins, hypothalamic-pituitary-adrenal axis, 49:11  
 interleukins, immune function, 49:11  
 interleukins, transferrin, 49:11  
 magnetic resonance imaging, affective disorder, 47:163  
 magnetic resonance imaging, dexamethasone suppression test, 47:163  
 magnetic resonance imaging, hippocampus, 47:163  
 3-methoxy-4-hydroxyphenylglycol, anxiety disorder, 48:119  
 3-methoxy-4-hydroxyphenylglycol, fluvoxamine, 48:119  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119  
 3-methoxy-4-hydroxyphenylglycol, panic disorder, 48:119

**Cortisol continued**

3-methoxy-4-hydroxyphenylglycol, reuptake inhibitor, 48:119  
 3-methoxy-4-hydroxyphenylglycol, serotonin, 48:119  
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 48:119  
 norepinephrine, anxiety disorder, 48:119  
 norepinephrine, cerebrospinal fluid, 46:1  
 norepinephrine, corticotropin releasing factor, 46:1  
 norepinephrine, desipramine, 46:1  
 norepinephrine, fluvoxamine, 48:119  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 norepinephrine, panic disorder, 48:119  
 norepinephrine, serotonin, 48:119  
 norepinephrine, yohimbine, 48:119  
 panic disorder, fluvoxamine, 48:119  
 panic disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 panic disorder, norepinephrine, 48:119  
 panic disorder, reuptake inhibitor, 48:119  
 panic disorder, serotonin, 48:119  
 panic disorder, yohimbine, 48:119  
 prolactin, affective disorder, 46:213  
 prolactin, antidepressant medication, 46:213  
 prolactin, sleep deprivation, 46:213  
 prolactin, thyroid stimulating hormone, 46:213  
 prolactin, triiodothyronine, 46:213  
 reuptake inhibitor, anxiety disorder, 48:119  
 reuptake inhibitor, fluvoxamine, 48:119  
 reuptake inhibitor, norepinephrine, 48:119  
 reuptake inhibitor, panic disorder, 48:119  
 reuptake inhibitor, serotonin, 48:119  
 reuptake inhibitor, yohimbine, 48:119  
 serotonin, anxiety disorder, 48:119  
 serotonin, fluvoxamine, 48:119  
 serotonin, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 serotonin, norepinephrine, 48:119  
 serotonin, panic disorder, 48:119  
 serotonin, reuptake inhibitor, 48:119  
 serotonin, yohimbine, 48:119  
 sleep deprivation, affective disorder, 46:213  
 sleep deprivation, antidepressant medication, 46:213  
 sleep deprivation, prolactin, 46:213  
 sleep deprivation, thyroid stimulating hormone, 46:213  
 sleep deprivation, triiodothyronine, 46:213

**Cortisol continued**

substance abuse, antisocial personality disorder, 46:9  
 substance abuse, conduct disorder, 46:9  
 substance abuse, genetics, 46:9  
 thyroid stimulating hormone, affective disorder, 46:213, 47:7, 47:23  
 thyroid stimulating hormone, antidepressant medication, 46:213  
 thyroid stimulating hormone, dexamethasone suppression test, 47:7, 47:23  
 thyroid stimulating hormone, dysthymic disorder, 47:7  
 thyroid stimulating hormone, electrodermal activity, 47:23  
 thyroid stimulating hormone, prolactin, 46:213  
 thyroid stimulating hormone, sleep deprivation, 46:213  
 thyroid stimulating hormone, thyroxine, 47:7, 47:23  
 thyroid stimulating hormone, triiodothyronine, 46:213, 47:7, 47:23  
 thyroxine, affective disorder, 47:7, 47:23  
 thyroxine, dexamethasone suppression test, 47:7, 47:23  
 thyroxine, dysthymic disorder, 47:7  
 thyroxine, electrodermal activity, 47:23  
 thyroxine, thyroid stimulating hormone, 47:7, 47:23  
 thyroxine, triiodothyronine, 47:7, 47:23  
 transferrin, affective disorder, 49:11  
 transferrin, dexamethasone suppression test, 49:11  
 transferrin, haptoglobin, 49:11  
 transferrin, immune function, 49:11  
 transferrin, interleukins, 49:11  
 triiodothyronine, affective disorder, 46:213, 47:7, 47:23  
 triiodothyronine, antidepressant medication, 46:213  
 triiodothyronine, dexamethasone suppression test, 47:7, 47:23  
 triiodothyronine, dysthymic disorder, 47:7  
 triiodothyronine, electrodermal activity, 47:23  
 triiodothyronine, prolactin, 46:213  
 triiodothyronine, sleep deprivation, 46:213  
 triiodothyronine, thyroid stimulating hormone, 46:213, 47:7, 47:23  
 triiodothyronine, thyroxine, 47:7, 47:23  
 yohimbine, anxiety disorder, 48:119  
 yohimbine, fluvoxamine, 48:119

**Cortisol continued**

yohimbine, 3-methoxy-4-hydroxyphenylglycol, 48:119

yohimbine, norepinephrine, 48:119

yohimbine, panic disorder, 48:119

yohimbine, serotonin, 48:119

**Dementia.** See also Alzheimer's disease

aging, agitation, 48:277

aging, circadian rhythms, 48:277

aging, circannual rhythms, 48:277

aging, sleep, 48:277

aging, sundowning, 48:277

agitation, aging, 48:277

agitation, circadian rhythms, 48:277

agitation, circannual rhythms, 48:277

agitation, sleep, 48:277

agitation, sundowning, 48:277

circadian rhythms, aging, 48:277

circadian rhythms, agitation, 48:277

circadian rhythms, sleep, 48:277

circadian rhythms, sundowning, 48:277

circannual rhythms, aging, 48:277

circannual rhythms, agitation, 48:277

circannual rhythms, sleep, 48:277

circannual rhythms, sundowning, 48:277

sleep, aging, 48:277

sleep, agitation, 48:277

sleep, circadian rhythms, 48:277

sleep, circannual rhythms, 48:277

sleep, sundowning, 48:277

sundowning, aging, 48:277

sundowning, agitation, 48:277

sundowning, circadian rhythms, 48:277

sundowning, circannual rhythms, 48:277

sundowning, sleep, 48:277

**Depression.** See Affective disorder.

**Desipramine**

blood pressure, normal subjects, 46:1

corticotropin releasing factor, cortisol, 46:1

corticotropin releasing factor, norepinephrine, 46:1

cortisol, corticotropin releasing factor, 46:1

cortisol, norepinephrine, 46:1

heart rate, normal subjects, 46:1

norepinephrine, corticotropin releasing factor, 46:1

norepinephrine, cortisol, 46:1

normal subjects, blood pressure, 46:1

normal subjects, heart rate, 46:1

**Dexamethasone suppression test.** See Cortisol.

**Diazepam**

alcohol intake, anxiety disorder, 48:135

alcohol intake, computed tomography, 48:135

alcohol intake, ventricle-brain ratio, 48:135

anxiety disorder, alcohol intake, 48:135

anxiety disorder, computed tomography, 48:135

anxiety disorder, panic disorder, 47:151

anxiety disorder, personality, 47:151

anxiety disorder, saccadic eye movement velocity, 47:151

anxiety disorder, Tridimensional Personality Questionnaire, 47:151

anxiety disorder, ventricle-brain ratio, 48:135

computed tomography, alcohol intake, 48:135

computed tomography, anxiety disorder, 48:135

computed tomography, ventricle-brain ratio, 48:135

eye movements, anxiety disorder, 47:151

eye movements, panic disorder, 47:151

eye movements, personality, 47:151

eye movements, saccadic eye movement velocity, 47:151

eye movements, Tridimensional Personality Questionnaire, 47:151

lorazepam, alcohol intake, 48:135

lorazepam, anxiety disorder, 48:135

lorazepam, computed tomography, 48:135

lorazepam, ventricle-brain ratio, 48:135

panic disorder, personality, 47:151

panic disorder, saccadic eye movement velocity, 47:151

panic disorder, Tridimensional Personality Questionnaire, 47:151

personality, anxiety disorder, 47:151

personality, panic disorder, 47:151

personality, saccadic eye movement velocity, 47:151

personality, Tridimensional Personality Questionnaire, 47:151

saccadic eye movement velocity, anxiety disorder, 47:151

saccadic eye movement velocity, panic disorder, 47:151

saccadic eye movement velocity, personality, 47:151

saccadic eye movement velocity, Tridimensional Personality Questionnaire, 47:151

Tridimensional Personality Questionnaire, anxiety disorder, 47:151

Tridimensional Personality Questionnaire, panic disorder, 47:151



**Diazepam** continued

- Tridimensional Personality Questionnaire, personality, 47:151
- Tridimensional Personality Questionnaire, saccadic eye movement velocity, 47:151
- ventricle-brain ratio, alcohol intake, 48:135
- ventricle-brain ratio, anxiety disorder, 48:135
- ventricle-brain ratio, computed tomography, 48:135

**Diet**

- affective disorder, carbohydrate craving, 46:107
  - affective disorder, circadian rhythms, 46:107
  - affective disorder, eating sweets, 46:107
  - affective disorder, phototherapy, 46:107
  - affective disorder, seasonal depression, 46:107
  - carbohydrate craving, affective disorder, 46:107
  - carbohydrate craving, circadian rhythms, 46:107
  - carbohydrate craving, eating sweets, 46:107
  - carbohydrate craving, phototherapy, 46:107
  - carbohydrate craving, seasonal depression, 46:107
  - circadian rhythms, affective disorder, 46:107
  - circadian rhythms, carbohydrate craving, 46:107
  - circadian rhythms, eating sweets, 46:107
  - circadian rhythms, phototherapy, 46:107
  - circadian rhythms, seasonal depression, 46:107
  - eating sweets, affective disorder, 46:107
  - eating sweets, carbohydrate craving, 46:107
  - eating sweets, circadian rhythms, 46:107
  - eating sweets, phototherapy, 46:107
  - eating sweets, seasonal depression, 46:107
  - phototherapy, affective disorder, 46:107
  - phototherapy, carbohydrate craving, 46:107
  - phototherapy, circadian rhythms, 46:107
  - phototherapy, eating sweets, 46:107
  - phototherapy, seasonal depression, 46:107
  - seasonal depression, carbohydrate craving, 46:107
  - seasonal depression, circadian rhythms, 46:107
  - seasonal depression, eating sweets, 46:107
  - seasonal depression, phototherapy, 46:107
- Dihydroxyphenylacetic acid**
- Alzheimer's disease, cognitive impairment, 49:211
  - Alzheimer's disease, dopamine, 49:211
  - Alzheimer's disease, homovanillic acid, 49:211
  - Alzheimer's disease, post-mortem study, 49:211

**Dihydroxyphenylacetic acid** continued

- Alzheimer's disease, psychiatric symptoms, 49:211
  - cognitive impairment, Alzheimer's disease, 49:211
  - cognitive impairment, dopamine, 49:211
  - cognitive impairment, homovanillic acid, 49:211
  - cognitive impairment, psychiatric symptoms, 49:211
  - dopamine, Alzheimer's disease, 49:211
  - dopamine, cognitive impairment, 49:211
  - dopamine, homovanillic acid, 49:211
  - dopamine, post-mortem study, 49:211
  - dopamine, psychiatric symptoms, 49:211
  - homovanillic acid, Alzheimer's disease, 49:211
  - homovanillic acid, cognitive impairment, 49:211
  - homovanillic acid, dopamine, 49:211
  - homovanillic acid, post-mortem study, 49:211
  - homovanillic acid, psychiatric symptoms, 49:211
  - psychiatric symptoms, Alzheimer's disease, 49:211
  - psychiatric symptoms, cognitive impairment, 49:211
  - psychiatric symptoms, dopamine, 49:211
  - psychiatric symptoms, homovanillic acid, 49:211
- Diurnal rhythms.** See Circadian rhythms.
- Domperidone**
- animal models, dysphoria, 47:37
  - animal models, haloperidol, 47:37
  - animal models, locomotor activity, 47:37
  - animal models, neuroleptic-induced defecation in rats, 47:37
  - dysphoria, animal models, 47:37
  - dysphoria, haloperidol, 47:37
  - dysphoria, locomotor activity, 47:37
  - dysphoria, neuroleptic-induced defecation in rats, 47:37
  - haloperidol, animal models, 47:37
  - haloperidol, dysphoria, 47:37
  - haloperidol, locomotor activity, 47:37
  - haloperidol, neuroleptic-induced defecation in rats, 47:37
  - locomotor activity, animal models, 47:37
  - locomotor activity, dysphoria, 47:37
  - locomotor activity, haloperidol, 47:37
  - locomotor activity, neuroleptic-induced defecation in rats, 47:37
  - neuroleptic-induced defecation in rats, animal models, 47:37
  - neuroleptic-induced defecation in rats, dysphoria, 47:37
  - neuroleptic-induced defecation in rats, haloperidol, 47:37

**Domperidone continued**

neuroleptic-induced defecation in rats,  
locomotor activity, 47:37  
neuroleptics, animal models, 47:37  
neuroleptics, defecation in rats, 47:37  
neuroleptics, dysphoria, 47:37  
neuroleptics, haloperidol, 47:37  
neuroleptics, locomotor activity, 47:37

**Dopamine**

affective disorder, bipolar subtype, 46:253  
affective disorder, D<sub>3</sub> receptor protein,  
46:253  
affective disorder, genetics, 46:253  
affective disorder, serine to glycine  
substitution on D<sub>3</sub>, 46:253  
age of onset, homovanillic acid, 48:93  
age of onset, positive and negative  
symptoms, 48:93  
age of onset, schizophrenia, 48:93  
aging, D<sub>2</sub> receptor density, 49:219  
aging, gender differences, 49:219  
aging, illness duration, 49:219  
aging, methylspiperone, 49:219  
aging, positron emission tomography, 49:219  
aging, schizophrenia, 49:219  
aging, striatum, 49:219  
Alzheimer's disease, cognitive impairment,  
49:211  
Alzheimer's disease, dihydroxyphenylacetic  
acid, 49:211  
Alzheimer's disease, homovanillic acid,  
49:211  
Alzheimer's disease, post-mortem study,  
49:211  
Alzheimer's disease, psychiatric symptoms,  
49:211  
amino acids, circadian rhythm, 47:187  
amino acids, neuroleptics, 47:187  
amino acids, neutral serum amino acids,  
47:187  
amino acids, phenylalanine, 47:187  
amino acids, schizophrenia, 47:187  
amino acids, therapeutic response, 47:187  
bipolar subtype, affective disorder, 46:253  
bipolar subtype, dopamine D<sub>3</sub> receptor  
protein, 46:253  
bipolar subtype, genetics, 46:253  
bipolar subtype, serine to glycine substitution  
on D<sub>3</sub>, 46:253  
circadian rhythms, amino acids, 47:187  
circadian rhythms, haloperidol, 47:141  
circadian rhythms, homovanillic acid, 47:141

**Dopamine continued**

circadian rhythms, neuroleptics, 47:141,  
47:187  
circadian rhythms, neutral serum amino  
acids, 47:187  
circadian rhythms, normal subjects, 47:141  
circadian rhythms, phenylalanine, 47:187  
circadian rhythms, schizophrenia, 47:187  
circadian rhythms, therapeutic response,  
47:187  
clozapine, homovanillic acid, 46:139, 46:151  
clozapine, 3-methoxy-4-hydroxyphenylglycol,  
46:139  
clozapine, norepinephrine, 46:139, 46:151  
clozapine, schizophrenia, 46:139, 46:151  
clozapine, therapeutic response, 46:139,  
46:151  
cognitive impairment, Alzheimer's disease,  
49:211  
cognitive impairment, dihydroxyphenylacetic  
acid, 49:211  
cognitive impairment, homovanillic acid,  
49:211  
cognitive impairment, psychiatric symptoms,  
49:211  
D<sub>2</sub> receptor density, aging, 49:219  
D<sub>2</sub> receptor density, gender differences,  
49:219  
D<sub>2</sub> receptor density, illness duration, 49:219  
D<sub>2</sub> receptor density, positron emission  
tomography, 49:219  
D<sub>2</sub> receptor density, schizophrenia, 49:219  
D<sub>2</sub> receptor density, striatum, 49:219  
D<sub>2</sub> receptor gene linkage, Icelandic pedigrees,  
46:69  
D<sub>3</sub> receptor gene linkage, schizophrenia,  
46:69  
D<sub>3</sub> receptor protein, affective disorder,  
46:253  
D<sub>3</sub> receptor protein, bipolar subtype, 46:253  
D<sub>3</sub> receptor protein, genetics, 46:253  
dihydroxyphenylacetic acid, Alzheimer's  
disease, 49:211  
dihydroxyphenylacetic acid, cognitive  
impairment, 49:211  
dihydroxyphenylacetic acid, homovanillic  
acid, 49:211  
dihydroxyphenylacetic acid, post-mortem  
study, 49:211  
dihydroxyphenylacetic acid, psychiatric  
symptoms, 49:211  
gender differences, aging, 49:219

**Dopamine continued**

gender differences, D<sub>2</sub> receptor density, 49:219

gender differences, illness duration, 49:219

gender differences, methylspiperone, 49:219

gender differences, positron emission tomography, 49:219

gender differences, schizophrenia, 49:219

gender differences, striatum, 49:219

genetics, affective disorder, 46:253

genetics, bipolar subtype, 46:253

genetics, D<sub>3</sub> receptor gene linkage, 46:69

genetics, D<sub>3</sub> receptor protein, 46:253

genetics, Icelandic pedigrees, 46:69

genetics, linkage of D<sub>3</sub> receptor gene, 46:69

genetics, schizophrenia, 46:69

genetics, serine to glycine substitution on D<sub>3</sub>, 46:253

haloperidol, circadian rhythms, 47:141

haloperidol, homovanillic acid, 47:141

haloperidol, normal subjects, 47:141

homovanillic acid, age of onset, 48:93

homovanillic acid, Alzheimer's disease, 49:211

homovanillic acid, circadian rhythms, 47:141

homovanillic acid, clozapine, 46:139, 46:151

homovanillic acid, cognitive impairment, 49:211

homovanillic acid, dihydroxyphenylacetic acid, 49:211

homovanillic acid, haloperidol, 47:141

homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 46:139

homovanillic acid, norepinephrine, 46:139, 46:151

homovanillic acid, normal subjects, 47:141

homovanillic acid, positive and negative symptoms, 48:93

homovanillic acid, post-mortem study, 49:211

homovanillic acid, psychiatric symptoms, 49:211

homovanillic acid, schizophrenia, 46:139, 46:151, 48:93

homovanillic acid, therapeutic response, 46:139, 46:151

illness duration, aging, 49:219

illness duration, D<sub>2</sub> receptor density, 49:219

illness duration, gender differences, 49:219

illness duration, methylspiperone, 49:219

illness duration, positron emission tomography, 49:219

illness duration, schizophrenia, 49:219

**Dopamine continued**

illness duration, striatum, 49:219

linkage of D<sub>3</sub> receptor gene, Icelandic pedigrees, 46:69

linkage of D<sub>3</sub> receptor gene, schizophrenia, 46:69

3-methoxy-4-hydroxyphenylglycol, clozapine, 46:139

3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:139

3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:139

3-methoxy-4-hydroxyphenylglycol, schizophrenia, 46:139

3-methoxy-4-hydroxyphenylglycol, therapeutic response, 46:139

methylspiperone, aging, 49:219

methylspiperone, D<sub>2</sub> receptor density, 49:219

methylspiperone, gender differences, 49:219

methylspiperone, illness duration, 49:219

methylspiperone, positron emission tomography, 49:219

methylspiperone, schizophrenia, 49:219

methylspiperone, striatum, 49:219

neuroleptics, amino acids, 47:187

neuroleptics, circadian rhythm, 47:187

neuroleptics, neutral serum amino acids, 47:187

neuroleptics, phenylalanine, 47:187

neuroleptics, schizophrenia, 47:187

neuroleptics, therapeutic response, 47:187

neutral serum amino acids, circadian rhythms, 47:187

neutral serum amino acids, neuroleptics, 47:187

neutral serum amino acids, phenylalanine, 47:187

neutral serum amino acids, schizophrenia, 47:187

neutral serum amino acids, therapeutic response, 47:187

norepinephrine, clozapine, 46:139, 46:151

norepinephrine, homovanillic acid, 46:139, 46:151

norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:139

norepinephrine, schizophrenia, 46:139, 46:151

norepinephrine, therapeutic response, 46:139, 46:151

normal subjects, circadian rhythms, 47:141

normal subjects, haloperidol, 47:141

normal subjects, homovanillic acid, 47:141



**Dopamine continued**

phenylalanine, amino acids, 47:187  
 phenylalanine, circadian rhythms, 47:187  
 phenylalanine, neuroleptics, 47:187  
 phenylalanine, neutral serum amino acids, 47:187  
 phenylalanine, schizophrenia, 47:187  
 phenylalanine, therapeutic response, 47:187  
 positive and negative symptoms, age of onset, 48:93  
 positive and negative symptoms, homovanillic acid, 48:93  
 positive and negative symptoms, schizophrenia, 48:93  
 positron emission tomography, aging, 49:219  
 positron emission tomography, D<sub>2</sub> receptor density, 49:219  
 positron emission tomography, gender differences, 49:219  
 positron emission tomography, illness duration, 49:219  
 positron emission tomography, methylspiperone, 49:219  
 positron emission tomography, schizophrenia, 49:219  
 positron emission tomography, striatum, 49:219  
 post-mortem study, Alzheimer's disease, 49:211  
 post-mortem study, cognitive impairment, 49:211  
 post-mortem study, dihydroxyphenylacetic acid, 49:211  
 post-mortem study, homovanillic acid, 49:211  
 psychiatric symptoms, Alzheimer's disease, 49:211  
 psychiatric symptoms, cognitive impairment, 49:211  
 psychiatric symptoms, dihydroxyphenylacetic acid, 49:211  
 psychiatric symptoms, homovanillic acid, 49:211  
 schizophrenia, age of onset, 48:93  
 schizophrenia, aging, 49:219  
 schizophrenia, amino acids, 47:187  
 schizophrenia, circadian rhythms, 47:187  
 schizophrenia, clozapine, 46:139, 46:151  
 schizophrenia, D<sub>2</sub> receptor density, 49:219  
 schizophrenia, D<sub>3</sub> receptor gene linkage, 46:69  
 schizophrenia, gender differences, 49:219  
 schizophrenia, genetics, 46:69

**Dopamine continued**

schizophrenia, homovanillic acid, 46:139, 46:151, 48:93  
 schizophrenia, Icelandic pedigrees, 46:69  
 schizophrenia, illness duration, 49:219  
 schizophrenia, linkage of D<sub>3</sub> receptor gene, 46:69  
 schizophrenia, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 schizophrenia, methylspiperone, 49:219  
 schizophrenia, neuroleptics, 47:187  
 schizophrenia, neutral serum amino acids, 47:187  
 schizophrenia, norepinephrine, 46:139, 46:151  
 schizophrenia, phenylalanine, 47:187  
 schizophrenia, positive and negative symptoms, 48:93  
 schizophrenia, positron emission tomography, 49:219  
 schizophrenia, striatum, 49:219  
 schizophrenia, therapeutic response, 46:139, 46:151, 47:187  
 serine to glycine substitution on D<sub>3</sub>, affective disorder, 46:253  
 serine to glycine substitution on D<sub>3</sub>, bipolar subtype, 46:253  
 serine to glycine substitution on D<sub>3</sub>, genetics, 46:253  
 striatum, aging, 49:219  
 striatum, D<sub>2</sub> receptor density, 49:219  
 striatum, gender differences, 49:219  
 striatum, illness duration, 49:219  
 striatum, methylspiperone, 49:219  
 striatum, positron emission tomography, 49:219  
 striatum, schizophrenia, 49:219  
 therapeutic response, amino acids, 47:187  
 therapeutic response, circadian rhythms, 47:187  
 therapeutic response, clozapine, 46:139, 46:151  
 therapeutic response, homovanillic acid, 46:139, 46:151  
 therapeutic response, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 therapeutic response, neuroleptics, 47:187  
 therapeutic response, neutral serum amino acids, 47:187  
 therapeutic response, norepinephrine, 46:139, 46:151  
 therapeutic response, phenylalanine, 47:187  
 therapeutic response, schizophrenia, 46:139, 46:151, 47:187

**Dopamine-beta-hydroxylase**

- autism, c-Harvey-Ras-1 marker, 46:261
- autism, genetics, 46:261
- autism, restriction fragment length polymorphism, 46:261
- autism, tryptophan hydroxylase, 46:261
- autism, tyrosine hydroxylase, 46:261
- c-Harvey-Ras-1 marker, autism, 46:261
- c-Harvey-Ras-1 marker, genetics, 46:261
- c-Harvey-Ras-1 marker, restriction fragment length polymorphism, 46:261
- c-Harvey-Ras-1 marker, tryptophan hydroxylase, 46:261
- c-Harvey-Ras-1 marker, tyrosine hydroxylase, 46:261
- genetics, autism, 46:261
- genetics, c-Harvey-Ras-1 marker, 46:261
- genetics, restriction fragment length polymorphism, 46:261
- genetics, tryptophan hydroxylase, 46:261
- genetics, tyrosine hydroxylase, 46:261
- restriction fragment length polymorphism, autism, 46:261
- restriction fragment length polymorphism, c-Harvey-Ras-1 marker, 46:261
- restriction fragment length polymorphism, genetics, 46:261
- restriction fragment length polymorphism, tryptophan hydroxylase, 46:261
- restriction fragment length polymorphism, tyrosine hydroxylase, 46:261
- tryptophan hydroxylase, autism, 46:261
- tryptophan hydroxylase, c-Harvey-Ras-1 marker, 46:261
- tryptophan hydroxylase, genetics, 46:261
- tryptophan hydroxylase, restriction fragment length polymorphism, 46:261
- tryptophan hydroxylase, tyrosine hydroxylase, 46:261
- tyrosine hydroxylase, autism, 46:261
- tyrosine hydroxylase, c-Harvey-Ras-1 marker, 46:261
- tyrosine hydroxylase, genetics, 46:261
- tyrosine hydroxylase, restriction fragment length polymorphism, 46:261
- tyrosine hydroxylase, tryptophan hydroxylase, 46:261

**Drug abuse.** See Cocaine

**Eating disorders**

- bulimia nervosa, migraine, 46:201
- bulimia, novelty seeking, 48:9
- bulimia, serotonin, 48:9

**Eating disorders continued**

- bulimia, Tridimensional Personality Questionnaire, 48:9
- bulimia, whole blood serotonin levels, 48:9
- dissociative phenomena, endorphins, 49:1
- dissociative phenomena, homovanillic acid, 49:1
- dissociative phenomena, 5-hydroxyindoleacetic acid, 49:1
- dissociative phenomena, 3-methoxy-4-hydroxyphenylglycol, 49:1
- endorphins, cerebrospinal fluid, 49:1
- endorphins, dissociative phenomena, 49:1
- endorphins, homovanillic acid, 49:1
- endorphins, 5-hydroxyindoleacetic acid, 49:1
- endorphins, 3-methoxy-4-hydroxyphenylglycol, 49:1
- homovanillic acid, cerebrospinal fluid, 49:1
- homovanillic acid, dissociative phenomena, 49:1
- homovanillic acid, endorphins, 49:1
- homovanillic acid, 5-hydroxyindoleacetic acid, 49:1
- homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 49:1
- 5-hydroxyindoleacetic acid, cerebrospinal fluid, 49:1
- 5-hydroxyindoleacetic acid, dissociative phenomena, 49:1
- 5-hydroxyindoleacetic acid, endorphins, 49:1
- 5-hydroxyindoleacetic acid, homovanillic acid, 49:1
- 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 49:1
- 3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 49:1
- 3-methoxy-4-hydroxyphenylglycol, dissociative phenomena, 49:1
- 3-methoxy-4-hydroxyphenylglycol, endorphins, 49:1
- 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 49:1
- 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, 49:1
- migraine, bulimia nervosa, 46:201
- novelty seeking, bulimia, 48:9
- novelty seeking, serotonin, 48:9
- novelty seeking, Tridimensional Personality Questionnaire, 48:9
- serotonin, bulimia, 48:9
- serotonin, novelty seeking, 48:9

**Eating disorders continued**

serotonin, Tridimensional Personality

Questionnaire, 48:9

serotonin, whole blood levels, 48:9

Tridimensional Personality Questionnaire,  
bulimia, 48:9

Tridimensional Personality Questionnaire,  
novelty seeking, 48:9

Tridimensional Personality Questionnaire,  
serotonin, 48:9

**Electrodermal activity**

affective disorder, cortisol, 47:23

affective disorder, dexamethasone suppression  
test, 47:23

affective disorder, thyroid stimulating  
hormone, 47:23

affective disorder, thyroxine, 47:23

affective disorder, triiodothyronine, 47:23

arginine vasopressin, electromyography,  
48:107

arginine vasopressin, heart rate response,  
48:107

arginine vasopressin, oxytocin, 48:107

arginine vasopressin, personal combat  
imagery, 48:107

arginine vasopressin, posttraumatic stress  
syndrome, 48:107

cortisol, affective disorder, 47:23

cortisol, dexamethasone suppression test,  
47:23

cortisol, thyroid stimulating hormone, 47:23

cortisol, thyroxine, 47:23

cortisol, triiodothyronine, 47:23

dexamethasone suppression test, affective  
disorder, 47:23

dexamethasone suppression test, cortisol,  
47:23

dexamethasone suppression test, thyroid  
stimulating hormone, 47:23

dexamethasone suppression test, thyroxine,  
47:23

dexamethasone suppression test,  
triiodothyronine, 47:23

electromyography, arginine vasopressin,  
48:107

electromyography, heart rate response,  
48:107

electromyography, oxytocin, 48:107

electromyography, personal combat imagery,  
48:107

electromyography, posttraumatic stress  
syndrome, 48:107

**Electrodermal activity continued**

heart rate response, arginine vasopressin,  
48:107

heart rate response, electromyography, 48:107

heart rate response, oxytocin, 48:107

heart rate response, personal combat  
imagery, 48:107

heart rate response, posttraumatic stress  
syndrome, 48:107

oxytocin, arginine vasopressin, 48:107

oxytocin, electromyography, 48:107

oxytocin, heart rate response, 48:107

oxytocin, personal combat imagery, 48:107

oxytocin, posttraumatic stress syndrome,  
48:107

personal combat imagery, arginine  
vasopressin, 48:107

personal combat imagery, electromyography,  
48:107

personal combat imagery, heart rate  
response, 48:107

personal combat imagery, oxytocin, 48:107

personal combat imagery, posttraumatic  
stress syndrome, 48:107

posttraumatic stress syndrome, arginine  
vasopressin, 48:107

posttraumatic stress syndrome,  
electromyography, 48:107

posttraumatic stress syndrome, heart rate  
response, 48:107

posttraumatic stress syndrome, oxytocin,  
48:107

posttraumatic stress syndrome, personal  
combat imagery, 48:107

posttraumatic stress syndrome, Vietnam  
veterans, 48:107

thyroid stimulating hormone, affective  
disorder, 47:23

thyroid stimulating hormone, cortisol, 47:23

thyroid stimulating hormone, dexamethasone  
suppression test, 47:23

thyroid stimulating hormone, thyroxine,  
47:23

thyroid stimulating hormone, triiodothyronine,  
47:23

thyroxine, affective disorder, 47:23

thyroxine, cortisol, 47:23

thyroxine, dexamethasone suppression test,  
47:23

thyroxine, thyroid stimulating hormone,  
47:23

thyroxine, triiodothyronine, 47:23



**Electrodermal activity** continued

triiodothyronine, affective disorder, 47:23

triiodothyronine, cortisol, 47:23

triiodothyronine, dexamethasone suppression test, 47:23

triiodothyronine, thyroxine, 47:23

**Electroencephalography.** See Event related potentials

**Electromyography**

arginine vasopressin, electrodermal response, 48:107

arginine vasopressin, heart rate response, 48:107

arginine vasopressin, oxytocin, 48:107

arginine vasopressin, personal combat imagery, 48:107

arginine vasopressin, posttraumatic stress syndrome, 48:107

electrodermal response, arginine vasopressin, 48:107

electrodermal response, heart rate response, 48:107

electrodermal response, oxytocin, 48:107

electrodermal response, personal combat imagery, 48:107

electrodermal response, posttraumatic stress syndrome, 48:107

heart rate response, arginine vasopressin, 48:107

heart rate response, electrodermal response, 48:107

heart rate response, oxytocin, 48:107

heart rate response, personal combat imagery, 48:107

heart rate response, posttraumatic stress syndrome, 48:107

oxytocin, arginine vasopressin, 48:107

oxytocin, electrodermal response, 48:107

oxytocin, heart rate response, 48:107

oxytocin, personal combat imagery, 48:107

oxytocin, posttraumatic stress syndrome, 48:107

personal combat imagery, arginine vasopressin, 48:107

personal combat imagery, electrodermal response, 48:107

personal combat imagery, heart rate response, 48:107

personal combat imagery, oxytocin, 48:107

personal combat imagery, posttraumatic stress syndrome, 48:107

**Electromyography** continued

posttraumatic stress syndrome, arginine vasopressin, 48:107

posttraumatic stress syndrome, electrodermal response, 48:107

posttraumatic stress syndrome, heart rate response, 48:107

posttraumatic stress syndrome, oxytocin, 48:107

posttraumatic stress syndrome, personal combat imagery, 48:107

posttraumatic stress syndrome, Vietnam veterans, 48:107

**Electrooculography.** See also Eye movements

affective disorder, phototherapy, 49:99

affective disorder, seasonal depression, 49:99

phototherapy, affective disorder, 49:99

phototherapy, seasonal depression, 49:99

seasonal depression, phototherapy, 49:99

**Endorphins**

dissociative phenomena, eating disorder, 49:1

dissociative phenomena, homovanillic acid, 49:1

dissociative phenomena, 5-hydroxy-indoleacetic acid, 49:1

dissociative phenomena, 3-methoxy-4-hydroxyphenylglycol, 49:1

eating disorder, dissociative phenomena, 49:1

eating disorder, homovanillic acid, 49:1

eating disorder, 5-hydroxyindoleacetic acid, 49:1

eating disorder, 3-methoxy-4-hydroxyphenylglycol, 49:1

homovanillic acid, cerebrospinal fluid, 49:1

homovanillic acid, dissociative phenomena, 49:1

homovanillic acid, eating disorder, 49:1

homovanillic acid, 5-hydroxyindoleacetic acid, 49:1

homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 49:1

5-hydroxyindoleacetic acid, cerebrospinal fluid, 49:1

5-hydroxyindoleacetic acid, dissociative phenomena, 49:1

5-hydroxyindoleacetic acid, eating disorder, 49:1

5-hydroxyindoleacetic acid, homovanillic acid, 49:1

5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 49:1

3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 49:1

**Endorphins** continued

- 3-methoxy-4-hydroxyphenylglycol, dissociative phenomena, 49:1
- 3-methoxy-4-hydroxyphenylglycol, eating disorder, 49:1
- 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 49:1
- 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, 49:1

**Epidemiology**

- admixture analysis, hebephrenic subtype, 49:199
- admixture analysis, paranoid subtype, 49:199
- admixture analysis, schizophrenia, 49:199
- affective disorder, American Indians, 47:255
- affective disorder, Center for Epidemiologic Studies Depression Scale, 47:255
- affective disorder, cross-cultural assessment, 47:255
- affective disorder, diagnosis, 47:255
- American Indians, affective disorder, 47:255
- American Indians, Center for Epidemiologic Studies Depression Scale, 47:255
- American Indians, cross-cultural assessment, 47:255
- American Indians, diagnosis, 47:255
- cancer patients, caregivers of chronically ill, 49:239
- cancer patients, Center for Epidemiologic Studies Depression Scale, 49:239
- cancer patients, depressed mood, 49:239
- cancer patients, gender differences, 49:239
- caregivers of chronically ill, cancer patients, 49:239
- caregivers of chronically ill, Center for Epidemiologic Studies Depression Scale, 49:239
- caregivers of chronically ill, depressed mood, 49:239
- caregivers of chronically ill, gender differences, 49:239
- Center for Epidemiologic Studies Depression Scale, American Indians, 47:255
- Center for Epidemiologic Studies Depression Scale, cancer patients, 49:239
- Center for Epidemiologic Studies Depression Scale, caregivers of chronically ill, 49:239
- Center for Epidemiologic Studies Depression Scale, cross-cultural assessment, 47:255
- Center for Epidemiologic Studies Depression Scale, diagnosis, 47:255
- Center for Epidemiologic Studies Depression Scale, gender differences, 49:239

**Epidemiology** continued

- cross-cultural assessment, affective disorder, 47:255
  - cross-cultural assessment, American Indians, 47:255
  - cross-cultural assessment, Center for Epidemiologic Studies Depression Scale, 47:255
  - cross-cultural assessment, diagnosis, 47:255
  - depressed mood, cancer patients, 49:239
  - depressed mood, caregivers of chronically ill, 49:239
  - depressed mood, gender differences, 49:239
  - diagnosis, affective disorder, 47:255
  - diagnosis, American Indians, 47:255
  - diagnosis, Center for Epidemiologic Studies Depression Scale, 47:255
  - diagnosis, cross-cultural assessment, 47:255
  - gender differences, cancer patients, 49:239
  - gender differences, caregivers of chronically ill, 49:239
  - gender differences, Center for Epidemiologic Studies Depression Scale, 49:239
  - gender differences, depressed mood, 49:239
  - hebephrenic subtype, admixture analysis, 49:199
  - hebephrenic subtype, paranoid subtype, 49:199
  - hebephrenic subtype, schizophrenia, 49:199
  - paranoid subtype, admixture analysis, 49:199
  - paranoid subtype, hebephrenic subtype, 49:199
  - paranoid subtype, schizophrenia, 49:199
  - schizophrenia, admixture analysis, 49:199
  - schizophrenia, hebephrenic subtype, 49:199
  - schizophrenia, paranoid subtype, 49:199
- Erythrocytes**
- Alzheimer's disease, lipids, 46:203
  - lipids, Alzheimer's disease, 46:203
  - membrane phospholipids, phosphatidylethanolamine, 49:89
  - membrane phospholipids, schizophrenia, 49:89
  - membrane phospholipids, sphingomyelin, 49:89
  - phosphatidylethanolamine, membrane phospholipids, 49:89
  - phosphatidylethanolamine, schizophrenia, 49:89
  - phosphatidylethanolamine, sphingomyelin, 49:89
  - schizophrenia, membrane phospholipids, 49:89
  - schizophrenia, phosphatidylethanolamine, 49:89
  - schizophrenia, sphingomyelin, 49:89

**Erythrocytes** continued

sphingomyelin, membrane phospholipids, 49:89

sphingomyelin, phosphatidylethanolamine, 49:89

sphingomyelin, schizophrenia, 49:89

**Estradiol**

follicle stimulating hormone, growth hormone, 48:153

follicle stimulating hormone, luteinizing hormone, 48:153

follicle stimulating hormone, normal volunteers, 48:153

follicle stimulating hormone, prolactin, 48:153

follicle stimulating hormone, sleep deprivation, 48:153

follicle stimulating hormone, thyroid stimulating hormone, 48:153

follicle stimulating hormone, thyroxine, 48:153

follicle stimulating hormone, triiodothyronine, 48:153

growth hormone, follicle stimulating hormone, 48:153

growth hormone, luteinizing hormone, 48:153

growth hormone, normal volunteers, 48:153

growth hormone, prolactin, 48:153

growth hormone, sleep deprivation, 48:153

growth hormone, thyroid stimulating hormone, 48:153

growth hormone, thyroxine, 48:153

growth hormone, triiodothyronine, 48:153

luteinizing hormone, follicle stimulating hormone, 48:153

luteinizing hormone, growth hormone, 48:153

luteinizing hormone, normal volunteers, 48:153

luteinizing hormone, prolactin, 48:153

luteinizing hormone, sleep deprivation, 48:153

luteinizing hormone, thyroid stimulating hormone, 48:153

luteinizing hormone, thyroxine, 48:153

luteinizing hormone, triiodothyronine, 48:153

normal volunteers, follicle stimulating hormone, 48:153

normal volunteers, growth hormone, 48:153

normal volunteers, luteinizing hormone, 48:153

**Estradiol** continued

normal volunteers, prolactin, 48:153

normal volunteers, sleep deprivation, 48:153

normal volunteers, thyroid stimulating hormone, 48:153

normal volunteers, thyroxine, 48:153

normal volunteers, triiodothyronine, 48:153

prolactin, follicle stimulating hormone, 48:153

prolactin, growth hormone, 48:153

prolactin, luteinizing hormone, 48:153

prolactin, normal volunteers, 48:153

prolactin, sleep deprivation, 48:153

prolactin, thyroid stimulating hormone, 48:153

prolactin, thyroxine, 48:153

prolactin, triiodothyronine, 48:153

sleep deprivation, follicle stimulating hormone, 48:153

sleep deprivation, growth hormone, 48:153

sleep deprivation, luteinizing hormone, 48:153

sleep deprivation, normal volunteers, 48:153

sleep deprivation, prolactin, 48:153

sleep deprivation, thyroid stimulating hormone, 48:153

sleep deprivation, thyroxine, 48:153

sleep deprivation, triiodothyronine, 48:153

thyroid stimulating hormone, follicle stimulating hormone, 48:153

thyroid stimulating hormone, growth hormone, 48:153

thyroid stimulating hormone, luteinizing hormone, 48:153

thyroid stimulating hormone, normal volunteers, 48:153

thyroid stimulating hormone, prolactin, 48:153

thyroid stimulating hormone, sleep deprivation, 48:153

thyroid stimulating hormone, thyroxine, 48:153

thyroid stimulating hormone, triiodothyronine, 48:153

thyroxine, follicle stimulating hormone, 48:153

thyroxine, growth hormone, 48:153

thyroxine, luteinizing hormone, 48:153

thyroxine, normal volunteers, 48:153

thyroxine, prolactin, 48:153

thyroxine, sleep deprivation, 48:153

thyroxine, thyroid stimulating hormone, 48:153



**Estradiol continued**

thyroxine, triiodothyronine, 48:153  
 triiodothyronine, follicle stimulating hormone, 48:153  
 triiodothyronine, growth hormone, 48:153  
 triiodothyronine, luteinizing hormone, 48:153  
 triiodothyronine, normal volunteers, 48:153  
 triiodothyronine, prolactin, 48:153  
 triiodothyronine, sleep deprivation, 48:153  
 triiodothyronine, thyroid stimulating hormone, 48:153  
 triiodothyronine, thyroxine, 48:153

**Event related potentials**

anxiety disorder, auditory N200, 49:167  
 anxiety disorder, laterality, 49:167  
 anxiety disorder, neurological soft signs, 49:167  
 anxiety disorder, obsessive-compulsive disorder, 49:167  
 anxiety disorder, P3 component, 49:167  
 auditory evoked potential P3, cortical atrophy, 47:175  
 auditory evoked potential P3, human immunodeficiency virus, 47:175  
 auditory evoked potential P3, magnetic resonance imaging, 47:175  
 auditory evoked potential P3, neuropsychology, 47:175  
 auditory evoked potential P3, substance abuse, 47:175  
 auditory N200, anxiety disorder, 49:167  
 auditory N200, laterality, 49:167  
 auditory N200, neurological soft signs, 49:167  
 auditory N200, obsessive-compulsive disorder, 49:167  
 auditory N200, P3 component, 49:167  
 auditory P50 component, cocaine, 47:243  
 auditory P50 component, paranoid subtype, 47:243  
 auditory P50 component, schizophrenia, 47:243  
 auditory P50 component, substance abuse, 47:243  
 auditory sensory gating, P50 component, 49:29  
 auditory sensory gating, schizophrenia, 49:29  
 auditory sensory gating, sleep, 49:29  
 cocaine, auditory P50 component, 47:243  
 cocaine, paranoid subtype, 47:243  
 cocaine, schizophrenia, 47:243  
 cortical atrophy, auditory evoked potential P3, 47:175

**Event related potentials continued**

cortical atrophy, human immunodeficiency virus, 47:175  
 cortical atrophy, magnetic resonance imaging, 47:175  
 cortical atrophy, neuropsychology, 47:175  
 cortical atrophy, substance abuse, 47:175  
 human immunodeficiency virus, auditory evoked potential P3, 47:175  
 human immunodeficiency virus, cortical atrophy, 47:175  
 human immunodeficiency virus, magnetic resonance imaging, 47:175  
 human immunodeficiency virus, neuropsychology, 47:175  
 human immunodeficiency virus, substance abuse, 47:175  
 laterality, anxiety disorder, 49:167  
 laterality, auditory N200, 49:167  
 laterality, neurological soft signs, 49:167  
 laterality, obsessive-compulsive disorder, 49:167  
 laterality, P3 component, 49:167  
 magnetic resonance imaging, auditory evoked potential P3, 47:175  
 magnetic resonance imaging, cortical atrophy, 47:175  
 magnetic resonance imaging, human immunodeficiency virus, 47:175  
 magnetic resonance imaging, neuropsychology, 47:175  
 magnetic resonance imaging, substance abuse, 47:175  
 neurological soft signs, anxiety disorder, 49:167  
 neurological soft signs, auditory N200, 49:167  
 neurological soft signs, laterality, 49:167  
 neurological soft signs, obsessive-compulsive disorder, 49:167  
 neurological soft signs, P3 component, 49:167  
 neuropsychology, auditory evoked potential P3, 47:175  
 neuropsychology, cortical atrophy, 47:175  
 neuropsychology, human immunodeficiency virus, 47:175  
 neuropsychology, magnetic resonance imaging, 47:175  
 neuropsychology, substance abuse, 47:175  
 obsessive-compulsive disorder, anxiety disorder, 49:167

**Event related potentials continued**

- obsessive-compulsive disorder, auditory N200, 49:167
- obsessive-compulsive disorder, laterality, 49:167
- obsessive-compulsive disorder, neurological soft signs, 49:167
- obsessive-compulsive disorder, P3 component, 49:167
- P3 component, anxiety disorder, 49:167
- P3 component, auditory N200, 49:167
- P3 component, laterality, 49:167
- P3 component, neurological soft signs, 49:167
- P3 component, obsessive-compulsive disorder, 49:167
- P50 component, auditory sensory gating, 49:29
- P50 component, schizophrenia, 49:29
- P50 component, sleep, 49:29
- paranoid subtype, auditory P50 component, 47:243
- paranoid subtype, cocaine, 47:243
- paranoid subtype, schizophrenia, 47:243
- paranoid subtype, substance abuse, 47:243
- schizophrenia, auditory P50 component, 47:243
- schizophrenia, auditory sensory gating, 49:29
- schizophrenia, cocaine, 47:243
- schizophrenia, P50 component, 49:29
- schizophrenia, paranoid subtype, 47:243
- schizophrenia, sleep, 49:29
- schizophrenia, substance abuse, 47:243
- sleep, auditory sensory gating, 49:29
- sleep, P50 component, 49:29
- sleep, schizophrenia, 49:29
- substance abuse, auditory evoked potential P3, 47:175
- substance abuse, auditory P50 component, 47:243
- substance abuse, cocaine, 47:243
- substance abuse, cortical atrophy, 47:175
- substance abuse, human immunodeficiency virus, 47:175
- substance abuse, magnetic resonance imaging, 47:175
- substance abuse, neuropsychology, 47:175
- substance abuse, paranoid subtype, 47:243
- substance abuse, schizophrenia, 47:243

**Eye blinks**

- affective disorder, circannual rhythms, 47:79

**Eye blinks continued**

- affective disorder, gender differences, 47:79
- affective disorder, phototherapy, 47:79
- affective disorder, seasonal depression, 47:79
- circannual rhythms, affective disorder, 47:79
- circannual rhythms, gender differences, 47:79
- circannual rhythms, phototherapy, 47:79
- circannual rhythms, seasonal depression, 47:79
- gender differences, affective disorder, 47:79
- gender differences, circannual rhythms, 47:79
- gender differences, phototherapy, 47:79
- gender differences, seasonal depression, 47:79
- phototherapy, affective disorder, 47:79
- phototherapy, circannual rhythms, 47:79
- phototherapy, gender differences, 47:79
- phototherapy, seasonal depression, 47:79
- seasonal depression, circannual rhythms, 47:79
- seasonal depression, gender differences, 47:79
- seasonal depression, phototherapy, 47:79
- Eye movements.** See also Electrooculography
  - anxiety disorder, diazepam response, 47:151
  - anxiety disorder, panic disorder, 47:151
  - anxiety disorder, personality, 47:151
  - anxiety disorder, saccadic eye movement velocity, 47:151
  - anxiety disorder, Tridimensional Personality Questionnaire, 47:151
  - diazepam response, anxiety disorder, 47:151
  - diazepam response, panic disorder, 47:151
  - diazepam response, personality, 47:151
  - diazepam response, saccadic eye movement velocity, 47:151
  - diazepam response, Tridimensional Personality Questionnaire, 47:151
  - frontal lobe, neuropsychology, 48:191
  - frontal lobe, obsessive-compulsive disorder, 48:191
  - frontal lobe, saccadic, 48:191
  - frontal lobe, smooth pursuit, 48:191
  - frontal lobe, Wisconsin Card Sorting Test, 48:191
  - neuropsychology, frontal lobe, 48:191
  - neuropsychology, obsessive-compulsive disorder, 48:191
  - neuropsychology, saccadic, 48:191
  - neuropsychology, smooth pursuit, 48:191
  - neuropsychology, Wisconsin Card Sorting Test, 48:191

**Eye movements continued**

obsessive-compulsive disorder, frontal lobe, 48:191

obsessive-compulsive disorder, neuropsychology, 48:191

obsessive-compulsive disorder, saccadic, 48:191

obsessive-compulsive disorder, smooth pursuit, 48:191

obsessive-compulsive disorder, Wisconsin Card Sorting Test, 48:191

panic disorder, anxiety disorder, 47:151

panic disorder, diazepam response, 47:151

panic disorder, personality, 47:151

panic disorder, saccadic eye movement velocity, 47:151

panic disorder, Tridimensional Personality Questionnaire, 47:151

personality, anxiety disorder, 47:151

personality, diazepam response, 47:151

personality, panic disorder, 47:151

personality, saccadic eye movement velocity, 47:151

personality, Tridimensional Personality Questionnaire, 47:151

saccadic eye movement velocity, anxiety disorder, 47:151

saccadic eye movement velocity, diazepam response, 47:151

saccadic eye movement velocity, panic disorder, 47:151

saccadic eye movement velocity, personality, 47:151

saccadic eye movement velocity, Tridimensional Personality Questionnaire, 47:151

saccadic, frontal lobe, 48:191

saccadic, neuropsychology, 48:191

saccadic, obsessive-compulsive disorder, 48:191

saccadic, smooth pursuit, 48:191

saccadic, Wisconsin Card Sorting Test, 48:191

smooth pursuit, frontal lobe, 48:191

smooth pursuit, neuropsychology, 48:191

smooth pursuit, obsessive-compulsive disorder, 48:191

smooth pursuit, saccadic, 48:191

smooth pursuit, Wisconsin Card Sorting Test, 48:191

Tridimensional Personality Questionnaire, anxiety disorder, 47:151

Tridimensional Personality Questionnaire, diazepam response, 47:151

**Eye movements continued**

Tridimensional Personality Questionnaire, panic disorder, 47:151

Tridimensional Personality Questionnaire, personality, 47:151

Tridimensional Personality Questionnaire, saccadic eye movement velocity, 47:151

Wisconsin Card Sorting Test, frontal lobe, 48:191

Wisconsin Card Sorting Test, neuropsychology, 48:191

Wisconsin Card Sorting Test, obsessive-compulsive disorder, 48:191

Wisconsin Card Sorting Test, saccadic, 48:191

Wisconsin Card Sorting Test, smooth pursuit, 48:191

**Fatigue**

sleep disorders, visual analogue scale, 46:207

visual analogue scale, sleep disorders, 46:207

**Fluoxetine**

affective disorder, sleep deprivation, 46:213

sleep deprivation, affective disorder, 46:213

**Fluvoxamine**

anxiety disorder, cortisol, 48:119

anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119

anxiety disorder, norepinephrine, 48:119

anxiety disorder, panic, 48:119

anxiety disorder, serotonin, 48:119

anxiety disorder, yohimbine, 48:119

behavior therapy, exposure, 49:63

behavior therapy, obsessive-compulsive disorder, 49:63

blood pressure, heart rate, 48:119

blood pressure, panic disorder, 48:119

blood pressure, yohimbine, 48:119

cortisol, anxiety disorder, 48:119

cortisol, 3-methoxy-4-hydroxyphenylglycol, 48:119

cortisol, norepinephrine, 48:119

cortisol, panic disorder, 48:119

cortisol, serotonin, 48:119

cortisol, yohimbine, 48:119

exposure therapy, obsessive-compulsive disorder, 49:63

heart rate, blood pressure, 48:119

heart rate, panic disorder, 48:119

heart rate, yohimbine, 48:119

3-methoxy-4-hydroxyphenylglycol, anxiety disorder, 48:119



**Fluvoxamine continued**

3-methoxy-4-hydroxyphenylglycol, cortisol, 48:119  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119  
 3-methoxy-4-hydroxyphenylglycol, panic disorder, 48:119  
 3-methoxy-4-hydroxyphenylglycol, serotonin, 48:119  
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 48:119  
 norepinephrine, anxiety disorder, 48:119  
 norepinephrine, cortisol, 48:119  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 norepinephrine, panic disorder, 48:119  
 norepinephrine, serotonin, 48:119  
 norepinephrine, yohimbine, 48:119  
 obsessive-compulsive disorder, behavior therapy, 49:63  
 obsessive-compulsive disorder, exposure, 49:63  
 panic disorder, blood pressure, 48:119  
 panic disorder, heart rate, 48:119  
 panic disorder, yohimbine, 48:119  
 panic disorder, anxiety disorder, 48:119  
 panic disorder, cortisol, 48:119  
 panic disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 panic disorder, norepinephrine, 48:119  
 panic disorder, serotonin, 48:119  
 panic disorder, yohimbine, 48:119  
 serotonin, anxiety disorder, 48:119  
 serotonin, cortisol, 48:119  
 serotonin, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 serotonin, norepinephrine, 48:119  
 serotonin, panic disorder, 48:119  
 serotonin, reuptake inhibitor, 48:119  
 serotonin, yohimbine, 48:119  
 yohimbine, anxiety disorder, 48:119  
 yohimbine, blood pressure, 48:119  
 yohimbine, cortisol, 48:119  
 yohimbine, heart rate, 48:119  
 yohimbine, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 yohimbine, norepinephrine, 48:119  
 yohimbine, panic disorder, 48:119  
 yohimbine, serotonin, 48:119  
**Follicle stimulating hormone**  
 estradiol, growth hormone, 48:153

**Follicle stimulating hormone continued**

estradiol, luteinizing hormone, 48:153  
 estradiol, normal volunteers, 48:153  
 estradiol, prolactin, 48:153  
 estradiol, sleep deprivation, 48:153  
 estradiol, thyroid stimulating hormone, 48:153  
 estradiol, thyroxine, 48:153  
 estradiol, triiodothyronine, 48:153  
 growth hormone, estradiol, 48:153  
 growth hormone, luteinizing hormone, 48:153  
 growth hormone, normal volunteers, 48:153  
 growth hormone, prolactin, 48:153  
 growth hormone, sleep deprivation, 48:153  
 growth hormone, thyroid stimulating hormone, 48:153  
 growth hormone, thyroxine, 48:153  
 growth hormone, triiodothyronine, 48:153  
 luteinizing hormone, estradiol, 48:153  
 luteinizing hormone, growth hormone, 48:153  
 luteinizing hormone, normal volunteers, 48:153  
 luteinizing hormone, prolactin, 48:153  
 luteinizing hormone, sleep deprivation, 48:153  
 luteinizing hormone, thyroid stimulating hormone, 48:153  
 luteinizing hormone, thyroxine, 48:153  
 luteinizing hormone, triiodothyronine, 48:153  
 normal volunteers, estradiol, 48:153  
 normal volunteers, growth hormone, 48:153  
 normal volunteers, luteinizing hormone, 48:153  
 normal volunteers, prolactin, 48:153  
 normal volunteers, sleep deprivation, 48:153  
 normal volunteers, thyroid stimulating hormone, 48:153  
 normal volunteers, thyroxine, 48:153  
 normal volunteers, triiodothyronine, 48:153  
 prolactin, estradiol, 48:153  
 prolactin, growth hormone, 48:153  
 prolactin, luteinizing hormone, 48:153  
 prolactin, normal volunteers, 48:153  
 prolactin, sleep deprivation, 48:153  
 prolactin, thyroid stimulating hormone, 48:153  
 prolactin, thyroxine, 48:153  
 prolactin, triiodothyronine, 48:153  
 sleep deprivation, estradiol, 48:153

**Follicle stimulating hormone** continued

- sleep deprivation, growth hormone, 48:153
- sleep deprivation, luteinizing hormone, 48:153
- sleep deprivation, normal volunteers, 48:153
- sleep deprivation, prolactin, 48:153
- sleep deprivation, thyroid stimulating hormone, 48:153
- sleep deprivation, thyroxine, 48:153
- sleep deprivation, triiodothyronine, 48:153
- thyroid stimulating hormone, estradiol, 48:153
- thyroid stimulating hormone, growth hormone, 48:153
- thyroid stimulating hormone, luteinizing hormone, 48:153
- thyroid stimulating hormone, normal volunteers, 48:153
- thyroid stimulating hormone, prolactin, 48:153
- thyroid stimulating hormone, sleep deprivation, 48:153
- thyroid stimulating hormone, thyroxine, 48:153
- thyroid stimulating hormone, triiodothyronine, 48:153
- thyroxine, estradiol, 48:153
- thyroxine, growth hormone, 48:153
- thyroxine, luteinizing hormone, 48:153
- thyroxine, normal volunteers, 48:153
- thyroxine, prolactin, 48:153
- thyroxine, sleep deprivation, 48:153
- thyroxine, thyroid stimulating hormone, 48:153
- thyroxine, triiodothyronine, 48:153
- triiodothyronine, estradiol, 48:153
- triiodothyronine, growth hormone, 48:153
- triiodothyronine, luteinizing hormone, 48:153
- triiodothyronine, normal volunteers, 48:153
- triiodothyronine, prolactin, 48:153
- triiodothyronine, sleep deprivation, 48:153
- triiodothyronine, thyroid stimulating hormone, 48:153
- triiodothyronine, thyroxine, 48:153

**Frontal lobe**

- alcohol dependence, memory, 46:175
- alcohol dependence, neuropsychology, 46:175
- alcohol dependence, schizophrenia, 46:175
- alcohol dependence, Wisconsin Card Sorting Test, 46:175
- eye movements, neuropsychology, 48:191
- eye movements, obsessive-compulsive disorder, 48:191

**Frontal lobe** continued

- eye movements, saccadic, 48:191
- eye movements, smooth pursuit, 48:191
- eye movements, Wisconsin Card Sorting Test, 48:191
- memory, alcohol dependence, 46:175
- memory, neuropsychology, 46:175
- memory, schizophrenia, 46:175
- memory, Wisconsin Card Sorting Test, 46:175
- neurodegeneration, post-mortem study, 48:145
- neurodegeneration, schizophrenia, 48:145
- neurodegeneration, ubiquitin, 48:145
- neuropsychology, alcohol dependence, 46:175
- neuropsychology, eye movements, 48:191
- neuropsychology, memory, 46:175
- neuropsychology, obsessive-compulsive disorder, 48:191
- neuropsychology, saccadic, 48:191
- neuropsychology, schizophrenia, 46:175
- neuropsychology, smooth pursuit, 48:191
- neuropsychology, Wisconsin Card Sorting Test, 46:175, 48:191
- obsessive-compulsive disorder, eye movements, 48:191
- obsessive-compulsive disorder, neuropsychology, 48:191
- obsessive-compulsive disorder, saccadic eye movements, 48:191
- obsessive-compulsive disorder, smooth pursuit eye movements, 48:191
- obsessive-compulsive disorder, Wisconsin Card Sorting Test, 48:191
- post-mortem study, ubiquitin, schizophrenia, 48:145
- saccadic eye movements, neuropsychology, 48:191
- saccadic eye movements, obsessive-compulsive disorder, 48:191
- saccadic eye movements, Wisconsin Card Sorting Test, 48:191
- schizophrenia, alcohol dependence, 46:175
- schizophrenia, memory, 46:175
- schizophrenia, neurodegeneration, 48:145
- schizophrenia, neuropsychology, 46:175
- schizophrenia, post-mortem study, 48:145
- schizophrenia, ubiquitin, 48:145
- schizophrenia, Wisconsin Card Sorting Test, 46:175
- smooth pursuit eye movements, neuropsychology, 48:191
- smooth pursuit eye movements, obsessive-compulsive disorder, 48:191

**Frontal lobe continued**

- smooth pursuit eye movements, Wisconsin Card Sorting Test, 48:191
- ubiquitin, neurodegeneration, 48:145
- ubiquitin, post-mortem study, 48:145
- ubiquitin, schizophrenia, 48:145
- Wisconsin Card Sorting Test, alcohol dependence, 46:175
- Wisconsin Card Sorting Test, eye movements, 48:191
- Wisconsin Card Sorting Test, memory, 46:175
- Wisconsin Card Sorting Test, neuropsychology, 46:175
- Wisconsin Card Sorting Test, neuropsychology, 48:191
- Wisconsin Card Sorting Test, obsessive-compulsive disorder, 48:191
- Wisconsin Card Sorting Test, saccadic eye movements, 48:191
- Wisconsin Card Sorting Test, schizophrenia, 46:175
- Wisconsin Card Sorting Test, smooth pursuit eye movements, 48:191

**Genetics**

- affective disorder, bipolar subtype, 46:253, 48:37, 48:47
- affective disorder, dopamine D<sub>3</sub> receptor protein, 46:253
- affective disorder, family history of personality disorder, 48:243
- affective disorder, human leukocyte antigen, 48:201
- affective disorder, immune function, 48:201
- affective disorder, lymphocytes, 48:201
- affective disorder, obstetric complications, 48:47
- affective disorder, rapid cycling, 48:37
- affective disorder, schizophrenia, 48:201, 48:243
- affective disorder, serine to glycine substitution on dopamine D<sub>3</sub>, 46:253
- affective disorder, substance abuse, 48:37
- aggression, impulsivity, 48:229
- aggression, personality, 48:229
- aggression, twin studies, 48:229
- antisocial personality disorder, children, 46:9
- antisocial personality disorder, conduct disorder, 46:9
- antisocial personality disorder, cortisol in saliva, 46:9
- antisocial personality disorder, sadistic personality, 48:267

**Genetics continued**

- antisocial personality disorder, substance abuse, 46:9
- autism, c-Harvey-Ras-1 marker, 46:261
- autism, dopamine-beta-hydroxylase, 46:261
- autism, restriction fragment length polymorphism, 46:261
- autism, tryptophan hydroxylase, 46:261
- autism, tyrosine hydroxylase, 46:261
- bipolar subtype, affective disorder, 46:253, 48:37, 48:47
- bipolar subtype, dopamine D<sub>3</sub> receptor protein, 46:253
- bipolar subtype, family history, 48:37, 48:47
- bipolar subtype, obstetric complications, 48:47
- bipolar subtype, rapid cycling, 48:37
- bipolar subtype, serine to glycine substitution on dopamine D<sub>3</sub>, 46:253
- bipolar subtype, substance abuse, 48:37
- c-Harvey-Ras-1 marker, autism, 46:261
- c-Harvey-Ras-1 marker, dopamine-beta-hydroxylase, 46:261
- c-Harvey-Ras-1 marker, restriction fragment length polymorphism, 46:261
- c-Harvey-Ras-1 marker, tryptophan hydroxylase, 46:261
- c-Harvey-Ras-1 marker, tyrosine hydroxylase, 46:261
- children, antisocial personality disorder, 46:9
- children, conduct disorder, 46:9
- conduct disorder, antisocial personality disorder, 46:9
- conduct disorder, children, 46:9
- conduct disorder, substance abuse, 46:9
- D<sub>3</sub> receptor gene linkage, dopamine, 46:69
- D<sub>3</sub> receptor gene linkage, Icelandic pedigrees, 46:69
- D<sub>3</sub> receptor gene linkage, schizophrenia, 46:69
- D<sub>3</sub> receptor protein, affective disorder, 46:253
- D<sub>3</sub> receptor protein, bipolar subtype, 46:253
- D<sub>3</sub> receptor protein, dopamine, 46:253
- D<sub>3</sub> receptor protein, serine to glycine substitution on dopamine D<sub>3</sub>, 46:253
- discordant monozygotic twins, microsatellite repeats, 48:27
- discordant monozygotic twins, polymorphic markers, 48:27
- discordant monozygotic twins, schizophrenia, 48:27
- dopamine, affective disorder, 46:253
- dopamine, bipolar subtype, 46:253



**Genetics continued**

dopamine, D<sub>3</sub> receptor gene linkage, 46:69  
 dopamine, D<sub>3</sub> receptor protein, 46:253  
 dopamine, Icelandic pedigrees, 46:69  
 dopamine, linkage of D<sub>3</sub> receptor gene, 46:69  
 dopamine, schizophrenia, 46:69  
 dopamine, serine to glycine substitution on dopamine D<sub>3</sub>, 46:253  
 dopamine-beta-hydroxylase, autism, 46:261  
 dopamine-beta-hydroxylase, c-Harvey-Ras-1 marker, 46:261  
 dopamine-beta-hydroxylase, restriction fragment length polymorphism, 46:261  
 dopamine-beta-hydroxylase, tryptophan hydroxylase, 46:261  
 dopamine-beta-hydroxylase, tyrosine hydroxylase, 46:261  
 family history, affective disorder, 48:37, 48:47, 48:201  
 family history, antisocial disorder, 48:267  
 family history, bipolar subtype, 48:37, 48:47  
 family history, human leukocyte antigen, 48:201  
 family history, immune function, 48:201  
 family history, lymphocytes, 48:201  
 family history, obstetric complications, 48:47  
 family history of personality disorder, affective disorder, 48:243  
 family history of personality disorder, schizophrenia, 48:243  
 family history, personality disorder, 48:267  
 family history, rapid cycling bipolar subtype, 48:37  
 family history, sadistic personality disorder, 48:267  
 family history, schizophrenia, 48:201  
 family history, substance abuse, 48:37  
 human leukocyte antigen, affective disorder, 48:201  
 human leukocyte antigen, immune function, 48:201  
 human leukocyte antigen, lymphocytes, 48:201  
 human leukocyte antigen, schizophrenia, 48:201  
 immune function, affective disorder, 48:201  
 immune function, human leukocyte antigen, 48:201  
 immune function, lymphocytes, 48:201  
 immune function, schizophrenia, 48:201  
 impulsivity, aggression, 48:229  
 impulsivity, personality, 48:229

**Genetics continued**

impulsivity, twin studies, 48:229  
 linkage of dopamine D<sub>3</sub> receptor gene, Icelandic pedigrees, 46:69  
 linkage of dopamine D<sub>3</sub> receptor gene, schizophrenia, 46:69  
 lymphocytes, affective disorder, 48:201  
 lymphocytes, human leukocyte antigen, 48:201  
 lymphocytes, immune function, 48:201  
 lymphocytes, schizophrenia, 48:201  
 microsatellite repeats, discordant monozygotic twins, 48:27  
 microsatellite repeats, polymorphic markers, 48:27  
 microsatellite repeats, schizophrenia, 48:27  
 microsatellite repeats, twin studies, 48:27  
 monoamine oxidase, platelets, 46:239  
 monoamine oxidase, twin studies, 46:239  
 monoamine oxidase, twins reared together and apart, 46:239  
 obstetric complications, affective disorder, 48:47  
 obstetric complications, bipolar subtype, 48:47  
 obstetric complications, family history, 48:47  
 personality, aggression, 48:229  
 personality disorder, antisocial disorder, 48:267  
 personality disorder, family history, 48:267  
 personality disorder, physical anhedonia, 46:47  
 personality disorder, psychosis proneness scales, 46:47  
 personality disorder, sadistic personality disorder, 48:267  
 personality disorder, schizotypy, 46:47  
 personality, impulsivity, 48:229  
 personality, twin studies, 48:229  
 physical anhedonia, personality disorder, 46:47  
 physical anhedonia, psychosis proneness scales, 46:47  
 physical anhedonia, schizotypy, 46:47  
 polymorphic markers, discordant monozygotic twins, 48:27  
 polymorphic markers, microsatellite repeats, 48:27  
 polymorphic markers, schizophrenia, 48:27  
 polymorphic markers, twin studies, 48:27  
 psychosis proneness scales, personality disorder, 46:47

**Genetics continued**

psychosis proneness scales, physical anhedonia, 46:47  
 psychosis proneness scales, schizotypy, 46:47  
 rapid cycling, affective disorder, 48:37  
 rapid cycling, bipolar subtype, 48:37  
 restriction fragment length polymorphism, autism, 46:261  
 restriction fragment length polymorphism, c-Harvey-Ras-1 marker, 46:261  
 restriction fragment length polymorphism, dopamine-beta-hydroxylase, 46:261  
 restriction fragment length polymorphism, tryptophan hydroxylase, 46:261  
 restriction fragment length polymorphism, tyrosine hydroxylase, 46:261  
 sadistic personality disorder, antisocial personality disorder, 48:267  
 schizophrenia, affective disorder, 48:201, 48:243  
 schizophrenia, discordant monozygotic twins, 48:27  
 schizophrenia, dopamine D<sub>3</sub> receptor gene linkage, 46:69  
 schizophrenia, family history, 48:201  
 schizophrenia, family history of personality disorder, 48:243  
 schizophrenia, human leukocyte antigen, 48:201  
 schizophrenia, immune function, 48:201  
 schizophrenia, linkage of dopamine D<sub>3</sub> receptor gene, 46:69  
 schizophrenia, lymphocytes, 48:201  
 schizophrenia, microsatellite repeats, 48:27  
 schizophrenia, polymorphic markers, 48:27  
 schizophrenia, twin studies, 48:27  
 schizotypy, personality disorder, 46:47  
 schizotypy, physical anhedonia, 46:47  
 schizotypy, psychosis proneness scales, 46:47  
 serine to glycine substitution on dopamine D<sub>3</sub>, affective disorder, 46:253  
 serine to glycine substitution on dopamine D<sub>3</sub>, bipolar subtype, 46:253  
 substance abuse, affective disorder, bipolar subtype, 48:37  
 substance abuse, antisocial personality disorder, 46:9  
 substance abuse, conduct disorder, 46:9  
 substance abuse, family history, 48:37  
 tryptophan hydroxylase, autism, 46:261  
 tryptophan hydroxylase, c-Harvey-Ras-1 marker, 46:261

**Genetics continued**

tryptophan hydroxylase, dopamine-beta-hydroxylase, 46:261  
 tryptophan hydroxylase, restriction fragment length polymorphism, 46:261  
 tryptophan hydroxylase, tyrosine hydroxylase, 46:261  
 twin studies, aggression, 48:229  
 twin studies, discordant monozygotic twins, 48:27  
 twin studies, impulsivity, 48:229  
 twin studies, microsatellite repeats, 48:27  
 twin studies, monoamine oxidase in platelets, 46:239  
 twin studies, personality, 48:229  
 twin studies, polymorphic markers, 48:27  
 twin studies, schizophrenia, 48:27  
 twins reared together and apart, monoamine oxidase in platelets, 46:239  
 twins reared together and apart, twin studies, 46:239  
 tyrosine hydroxylase, autism, 46:261  
 tyrosine hydroxylase, c-Harvey-Ras-1 marker, 46:261  
 tyrosine hydroxylase, dopamine-beta-hydroxylase, 46:261  
 tyrosine hydroxylase, restriction fragment length polymorphism, 46:261  
 tyrosine hydroxylase, tryptophan hydroxylase, 46:261  
**Glutamyltransferase**  
 alcohol dependence, depression, 47:57  
 alcohol dependence, impulse control disorder, 47:57  
 alcohol dependence, serotonin, 47:57  
 alcohol dependence, withdrawal, 47:57  
 depression, alcohol dependence, 47:57  
 depression, impulse control disorder, 47:57  
 depression, serotonin, 47:57  
 impulse control disorder, alcohol dependence, 47:57  
 impulse control disorder, depression, 47:57  
 impulse control disorder, serotonin, 47:57  
 platelets, serotonin, 47:57  
 serotonin, alcohol dependence, 47:57  
 serotonin, depression, 47:57  
 serotonin, impulse control disorder, 47:57  
 serotonin, platelets, 47:57

**Growth hormone**

affective disorder, circadian rhythms, 47:215  
 affective disorder, endogenous subtype, 47:215  
 affective disorder, growth hormone releasing hormone, 47:215  
 affective disorder, sleep, 47:215  
 circadian rhythms, affective disorder, 47:215  
 circadian rhythms, endogenous subtype, 47:215  
 circadian rhythms, growth hormone releasing hormone, 47:215  
 circadian rhythms, sleep, 47:215  
 clonidine, diagnostic systems, 48:79  
 clonidine, schizophrenia, 48:79  
 diagnostic systems, clonidine, 48:79  
 diagnostic systems, schizophrenia, 48:79  
 endogenous subtype, affective disorder, 47:215  
 endogenous subtype, circadian rhythms, 47:215  
 endogenous subtype, growth hormone releasing hormone, 47:215  
 endogenous subtype, sleep, 47:215  
 estradiol, follicle stimulating hormone, 48:153  
 estradiol, luteinizing hormone, 48:153  
 estradiol, normal volunteers, 48:153  
 estradiol, prolactin, 48:153  
 estradiol, sleep deprivation, 48:153  
 estradiol, thyroid stimulating hormone, 48:153  
 estradiol, thyroxine, 48:153  
 estradiol, triiodothyronine, 48:153  
 follicle stimulating hormone, estradiol, 48:153  
 follicle stimulating hormone, luteinizing hormone, 48:153  
 follicle stimulating hormone, normal volunteers, 48:153  
 follicle stimulating hormone, prolactin, 48:153  
 follicle stimulating hormone, sleep deprivation, 48:153  
 follicle stimulating hormone, thyroid stimulating hormone, 48:153  
 follicle stimulating hormone, thyroxine, 48:153  
 follicle stimulating hormone, triiodothyronine, 48:153  
 growth hormone releasing hormone, affective disorder, 47:215

**Growth hormone continued**

growth hormone releasing hormone, circadian rhythms, 47:215  
 growth hormone releasing hormone, endogenous subtype, 47:215  
 growth hormone releasing hormone, sleep, 47:215  
 kappa agonist, motor tics, 47:267  
 kappa agonist, opioids, 47:267  
 kappa agonist, prolactin, 47:267  
 kappa agonist, spiradoline, 47:267  
 kappa agonist, Tourette's syndrome, 47:267  
 luteinizing hormone, estradiol, 48:153  
 luteinizing hormone, follicle stimulating hormone, 48:153  
 luteinizing hormone, normal volunteers, 48:153  
 luteinizing hormone, prolactin, 48:153  
 luteinizing hormone, sleep deprivation, 48:153  
 luteinizing hormone, thyroid stimulating hormone, 48:153  
 luteinizing hormone, thyroxine, 48:153  
 luteinizing hormone, triiodothyronine, 48:153  
 motor tics, kappa agonist, 47:267  
 motor tics, opioids, 47:267  
 motor tics, prolactin, 47:267  
 motor tics, spiradoline, 47:267  
 motor tics, Tourette's syndrome, 47:267  
 normal volunteers, estradiol, 48:153  
 normal volunteers, follicle stimulating hormone, 48:153  
 normal volunteers, luteinizing hormone, 48:153  
 normal volunteers, prolactin, 48:153  
 normal volunteers, sleep deprivation, 48:153  
 normal volunteers, thyroid stimulating hormone, 48:153  
 normal volunteers, thyroxine, 48:153  
 normal volunteers, triiodothyronine, 48:153  
 opioids, kappa agonist, 47:267  
 opioids, motor tics, 47:267  
 opioids, prolactin, 47:267  
 opioids, spiradoline, 47:267  
 opioids, Tourette's syndrome, 47:267  
 prolactin, estradiol, 48:153  
 prolactin, follicle stimulating hormone, 48:153  
 prolactin, kappa agonist, 47:267  
 prolactin, luteinizing hormone, 48:153  
 prolactin, motor tics, 47:267  
 prolactin, normal volunteers, 48:153



**Growth hormone continued**

prolactin, opioids, 47:267  
 prolactin, sleep deprivation, 48:153  
 prolactin, spiradoline, 47:267  
 prolactin, thyroid stimulating hormone, 48:153  
 prolactin, thyroxine, 48:153  
 prolactin, Tourette's syndrome, 47:267  
 prolactin, triiodothyronine, 48:153  
 schizophrenia, clonidine, 48:79  
 schizophrenia, diagnostic systems, 48:79  
 sleep, affective disorder, 47:215  
 sleep, circadian rhythms, 47:215  
 sleep, endogenous subtype, 47:215  
 sleep, growth hormone releasing hormone, 47:215  
 sleep deprivation, estradiol, 48:153  
 sleep deprivation, follicle stimulating hormone, 48:153  
 sleep deprivation, luteinizing hormone, 48:153  
 sleep deprivation, normal volunteers, 48:153  
 sleep deprivation, prolactin, 48:153  
 sleep deprivation, thyroid stimulating hormone, 48:153  
 sleep deprivation, thyroxine, 48:153  
 sleep deprivation, triiodothyronine, 48:153  
 spiradoline, motor tics, 47:267  
 spiradoline, prolactin, 47:267  
 spiradoline, Tourette's syndrome, 47:267  
 thyroid stimulating hormone, estradiol, 48:153  
 thyroid stimulating hormone, follicle stimulating hormone, 48:153  
 thyroid stimulating hormone, luteinizing hormone, 48:153  
 thyroid stimulating hormone, normal volunteers, 48:153  
 thyroid stimulating hormone, prolactin, 48:153  
 thyroid stimulating hormone, sleep deprivation, 48:153  
 thyroid stimulating hormone, thyroxine, 48:153  
 thyroid stimulating hormone, triiodothyronine, 48:153  
 thyroxine, estradiol, 48:153  
 thyroxine, follicle stimulating hormone, 48:153  
 thyroxine, luteinizing hormone, 48:153  
 thyroxine, normal volunteers, 48:153  
 thyroxine, prolactin, 48:153

**Growth hormone continued**

thyroxine, sleep deprivation, 48:153  
 thyroxine, thyroid stimulating hormone, 48:153  
 thyroxine, triiodothyronine, 48:153  
 Tourette's syndrome, kappa agonist, 47:267  
 Tourette's syndrome, motor tics, 47:267  
 Tourette's syndrome, opioids, 47:267  
 Tourette's syndrome, prolactin, 47:267  
 Tourette's syndrome, spiradoline, 47:267  
 triiodothyronine, estradiol, 48:153  
 triiodothyronine, follicle stimulating hormone, 48:153  
 triiodothyronine, luteinizing hormone, 48:153  
 triiodothyronine, normal volunteers, 48:153  
 triiodothyronine, prolactin, 48:153  
 triiodothyronine, sleep deprivation, 48:153  
 triiodothyronine, thyroid stimulating hormone, 48:153  
 triiodothyronine, thyroxine, 48:153  
**Haloperidol**  
 animal models, domperidone, 47:37  
 animal models, dysphoria, 47:37  
 animal models, locomotor activity, 47:37  
 animal models, neuroleptic-induced defecation in rats, 47:37  
 circadian rhythms, dopamine, 47:141  
 circadian rhythms, homovanillic acid, 47:141  
 circadian rhythms, normal subjects, 47:141  
 domperidone, animal models, 47:37  
 domperidone, dysphoria, 47:37  
 domperidone, locomotor activity, 47:37  
 domperidone, neuroleptic-induced defecation in rats, 47:37  
 dopamine, circadian rhythms, 47:141  
 dopamine, homovanillic acid, 47:141  
 dopamine, normal subjects, 47:141  
 dysphoria, animal models, 47:37  
 dysphoria, domperidone, 47:37  
 dysphoria, locomotor activity, 47:37  
 dysphoria, neuroleptic-induced defecation in rats, 47:37  
 homovanillic acid, circadian rhythms, 47:141  
 homovanillic acid, dopamine, 47:141  
 homovanillic acid, normal subjects, 47:141  
 locomotor activity, animal models, 47:37  
 locomotor activity, domperidone, 47:37  
 locomotor activity, dysphoria, 47:37  
 locomotor activity, neuroleptic-induced defecation in rats, 47:37  
 neuroleptic-induced defecation in rats, animal models, 47:37

**Haloperidol continued**

neuroleptic-induced defecation in rats,  
domperidone, 47:37  
neuroleptic-induced defecation in rats,  
dysphoria, 47:37  
neuroleptic-induced defecation in rats,  
locomotor activity, 47:37  
normal subjects, circadian rhythms, 47:141  
normal subjects, dopamine, 47:141  
normal subjects, homovanillic acid, 47:141

**Haptoglobin**

affective disorder, amino acids, 49:151  
affective disorder, cortisol, 49:11  
affective disorder, dexamethasone suppression  
test, 49:11  
affective disorder, immune function, 47:229,  
49:11, 49:151  
affective disorder, interleukin, 49:11, 49:151  
affective disorder, serotonin, 49:151  
affective disorder, sleep, 47:229  
affective disorder, somatic symptoms, 47:229  
affective disorder, transferrin, 49:11, 49:151  
affective disorder, tryptophan, 49:151  
affective disorder, weight and anorexia,  
47:229  
amino acids, affective disorder, 49:151  
amino acids, immune function, 49:151  
amino acids, interleukin, 49:151  
amino acids, serotonin, 49:151  
amino acids, transferrin, 49:151  
amino acids, tryptophan, 49:151  
cortisol, affective disorder, 49:11  
cortisol, dexamethasone suppression test,  
49:11  
cortisol, immune function, 49:11  
cortisol, interleukins, 49:11  
cortisol, transferrin, 49:11  
dexamethasone suppression test, affective  
disorder, 49:11  
dexamethasone suppression test, cortisol, 49:11  
dexamethasone suppression test, immune  
function, 49:11  
dexamethasone suppression test, interleukins,  
49:11  
dexamethasone suppression test, transferrin,  
49:11  
immune function, affective disorder, 47:229,  
49:11, 49:151  
immune function, amino acids, 49:151  
immune function, cortisol, 49:11  
immune function, dexamethasone suppression  
test, 49:11

**Haptoglobin continued**

immune function, interleukins, 49:11, 49:151  
immune function, serotonin, 49:151  
immune function, sleep, 47:229  
immune function, somatic symptoms, 47:229  
immune function, transferrin, 49:11, 49:151  
immune function, tryptophan, 49:151  
immune function, weight and anorexia, 47:229  
interleukins, affective disorder, 49:11, 49:151  
interleukins, amino acids, 49:151  
interleukins, cortisol, 49:11  
interleukins, dexamethasone suppression  
test, 49:11  
interleukins, immune function, 49:11, 49:151  
interleukins, serotonin, 49:151  
interleukins, transferrin, 49:11, 49:151  
interleukins, tryptophan, 49:151  
serotonin, affective disorder, 49:151  
serotonin, amino acids, 49:151  
serotonin, immune function, 49:151  
serotonin, interleukins, 49:151  
serotonin, transferrin, 49:151  
serotonin, tryptophan, 49:151  
sleep, affective disorder, 47:229  
sleep, immune function, 47:229  
sleep, somatic symptoms, 47:229  
sleep, weight and anorexia, 47:229  
somatic symptoms, affective disorder, 47:229  
somatic symptoms, immune function, 47:229  
somatic symptoms, sleep, 47:229  
somatic symptoms, weight and anorexia, 47:229  
transferrin, affective disorder, 49:11, 49:151  
transferrin, amino acids, 49:151  
transferrin, cortisol, 49:11  
transferrin, dexamethasone suppression test,  
49:11  
transferrin, immune function, 49:11, 49:151  
transferrin, interleukins, 49:11, 49:151  
transferrin, serotonin, 49:151  
transferrin, tryptophan, 49:151  
tryptophan, affective disorder, 49:151  
tryptophan, amino acids, 49:151  
tryptophan, immune function, 49:151  
tryptophan, interleukins, 49:151  
tryptophan, serotonin, 49:151  
tryptophan, transferrin, 49:151  
weight and anorexia, affective disorder,  
47:229  
weight and anorexia, immune function, 47:229  
**Heart rate**  
anxiety disorder, autonomic nervous system,  
46:89

**Heart rate continued**

anxiety disorder, orthostatic challenge, 46:89  
 anxiety disorder, panic, 46:89  
 anxiety disorder, power spectral analysis of heart rate, 46:89  
 arginine vasopressin, electrodermal response, 48:107  
 arginine vasopressin, electromyography, 48:107  
 arginine vasopressin, oxytocin, 48:107  
 arginine vasopressin, personal combat imagery, 48:107  
 arginine vasopressin, posttraumatic stress syndrome, 48:107  
 autonomic nervous system, anxiety disorder, 46:89  
 autonomic nervous system, orthostatic challenge, 46:89  
 autonomic nervous system, panic disorder, 46:89  
 autonomic nervous system, power spectral analysis of heart rate, 46:89  
 blood pressure, fluvoxamine, 48:119  
 blood pressure, panic disorder, 48:119  
 blood pressure, yohimbine, 48:119  
 desipramine, normal subjects, 46:1  
 electrodermal response, arginine vasopressin, 48:107  
 electrodermal response, electromyography, 48:107  
 electrodermal response, oxytocin, 48:107  
 electrodermal response, personal combat imagery, 48:107  
 electrodermal response, posttraumatic stress syndrome, 48:107  
 electromyography, arginine vasopressin, 48:107  
 electromyography, electrodermal response, 48:107  
 electromyography, oxytocin, 48:107  
 electromyography, personal combat imagery, 48:107  
 electromyography, posttraumatic stress syndrome, 48:107  
 fluvoxamine, blood pressure, 48:119  
 fluvoxamine, panic disorder, 48:119  
 fluvoxamine, yohimbine, 48:119  
 normal subjects, desipramine, 46:1  
 orthostatic challenge, anxiety disorder, 46:89  
 orthostatic challenge, autonomic nervous system, 46:89  
 orthostatic challenge, panic disorder, 46:89  
 orthostatic challenge, power spectral analysis of heart rate, 46:89

**Heart rate continued**

oxytocin, arginine vasopressin, 48:107  
 oxytocin, electrodermal response, 48:107  
 oxytocin, electromyography, 48:107  
 oxytocin, personal combat imagery, 48:107  
 oxytocin, posttraumatic stress syndrome, 48:107  
 panic disorder, blood pressure, 48:119  
 panic disorder, fluvoxamine, 48:119  
 panic disorder, yohimbine, 48:119  
 panic disorder, autonomic nervous system, 46:89  
 panic disorder, orthostatic challenge, 46:89  
 panic disorder, power spectral analysis of heart rate, 46:89  
 personal combat imagery, arginine vasopressin, 48:107  
 personal combat imagery, electrodermal response, 48:107  
 personal combat imagery, electromyography, 48:107  
 personal combat imagery, oxytocin, 48:107  
 personal combat imagery, posttraumatic stress syndrome, 48:107  
 posttraumatic stress syndrome, arginine vasopressin, 48:107  
 posttraumatic stress syndrome, electrodermal response, 48:107  
 posttraumatic stress syndrome, electromyography, 48:107  
 posttraumatic stress syndrome, oxytocin, 48:107  
 posttraumatic stress syndrome, personal combat imagery, 48:107  
 posttraumatic stress syndrome, Vietnam veterans, 48:107  
 power spectral analysis, anxiety disorder, 46:89  
 power spectral analysis, autonomic nervous system, 46:89  
 power spectral analysis, orthostatic challenge, 46:89  
 power spectral analysis, panic disorder, 46:89  
 yohimbine, blood pressure, 48:119  
 yohimbine, fluvoxamine, 48:119  
 yohimbine, panic disorder, 48:119  
**Hippocampus**  
 affective disorder, cortisol, 47:163  
 affective disorder, dexamethasone suppression test, 47:163  
 affective disorder, magnetic resonance imaging, 47:163



**Hippocampus continued**

- Alzheimer's disease, neurofibrillary tangles, 49:41
- Alzheimer's disease, post-mortem, 49:41
- Alzheimer's disease, schizophrenia, 49:41
- Alzheimer's disease, senile plaques, 49:41
- cortisol, affective disorder, 47:163
- cortisol, dexamethasone suppression test, 47:163
- cortisol, magnetic resonance imaging, 47:163
- dexamethasone suppression test, affective disorder, 47:163
- dexamethasone suppression test, cortisol, 47:163
- dexamethasone suppression test, magnetic resonance imaging, 47:163
- magnetic resonance imaging, affective disorder, 47:163
- magnetic resonance imaging, cortisol, 47:163
- magnetic resonance imaging, dexamethasone suppression test, 47:163
- neurofibrillary tangles, Alzheimer's disease, 49:41
- neurofibrillary tangles, post-mortem, 49:41
- neurofibrillary tangles, schizophrenia, 49:41
- neurofibrillary tangles, senile plaques, 49:41
- post-mortem, Alzheimer's disease, 49:41
- post-mortem, neurofibrillary tangles, 49:41
- post-mortem, schizophrenia, 49:41
- post-mortem, senile plaques, 49:41
- schizophrenia, Alzheimer's disease, 49:41
- schizophrenia, neurofibrillary tangles, 49:41
- schizophrenia, post-mortem, 49:41
- schizophrenia, senile plaques, 49:41
- senile plaques, Alzheimer's disease, 49:41
- senile plaques, neurofibrillary tangles, 49:41
- senile plaques, post-mortem, 49:41
- senile plaques, schizophrenia, 49:41
- Homovanillic acid**
- affective disorder, 5-hydroxyindoleacetic acid, 46:19
- affective disorder, 3-methoxy-4-hydroxyphenylglycol, 46:19
- affective disorder, norepinephrine, 46:19
- affective disorder, orthostatic challenge, 46:19
- affective disorder, phototherapy, 46:19
- age of onset, dopamine, 48:93
- age of onset, positive and negative symptoms, 48:93
- age of onset, schizophrenia, 48:93

**Homovanillic acid continued**

- Alzheimer's disease, cognitive impairment, 49:211
- Alzheimer's disease, dihydroxyphenylacetic acid, 49:211
- Alzheimer's disease, dopamine, 49:211
- Alzheimer's disease, post-mortem study, 49:211
- Alzheimer's disease, psychiatric symptoms, 49:211
- circadian rhythms, dopamine, 47:141
- circadian rhythms, haloperidol, 47:141
- circadian rhythms, normal subjects, 47:141
- clozapine, dopamine, 46:139, 46:151
- clozapine, 3-methoxy-4-hydroxyphenylglycol, 46:139
- clozapine, norepinephrine, 46:139, 46:151
- clozapine, schizophrenia, 46:139, 46:151
- clozapine, therapeutic response, 46:139, response, 46:151
- cognitive impairment, Alzheimer's disease, 49:211
- cognitive impairment, dihydroxyphenylacetic acid, 49:211
- cognitive impairment, dopamine, 49:211
- cognitive impairment, psychiatric symptoms, 49:211
- dihydroxyphenylacetic acid, Alzheimer's disease, 49:211
- dihydroxyphenylacetic acid, cognitive impairment, 49:211
- dihydroxyphenylacetic acid, dopamine, 49:211
- dihydroxyphenylacetic acid, post-mortem study, 49:211
- dihydroxyphenylacetic acid, psychiatric symptoms, 49:211
- dissociative phenomena, eating disorder, 49:1
- dissociative phenomena, endorphins, 49:1
- dissociative phenomena, 5-hydroxyindoleacetic acid, 49:1
- dissociative phenomena, 3-methoxy-4-hydroxyphenylglycol, 49:1
- dopamine, age of onset, 48:93
- dopamine, Alzheimer's disease, 49:211
- dopamine, circadian rhythms, 47:141
- dopamine, clozapine, 46:139, 46:151
- dopamine, cognitive impairment, 49:211
- dopamine, dihydroxyphenylacetic acid, 49:211
- dopamine, haloperidol, 47:141
- dopamine, 3-methoxy-4-hydroxyphenylglycol, 46:139
- dopamine, norepinephrine, 46:139, 46:151

**Homovanillic acid continued**

- dopamine, normal subjects, 47:141
- dopamine, positive and negative symptoms, 48:93
- dopamine, post-mortem study, 49:211
- dopamine, psychiatric symptoms, 49:211
- dopamine, schizophrenia, 46:139, 46:151, 48:93
- dopamine, therapeutic response, 46:139, 46:151
- eating disorder, cerebrospinal fluid, 49:1
- eating disorder, dissociative phenomena, 49:1
- eating disorder, endorphins, 49:1
- eating disorder, 5-hydroxyindoleacetic acid, 49:1
- eating disorder, 3-methoxy-4-hydroxyphenylglycol, 49:1
- endorphins, cerebrospinal fluid, 49:1
- endorphins, dissociative phenomena, 49:1
- endorphins, eating disorder, 49:1
- endorphins, 5-hydroxyindoleacetic acid, 49:1
- endorphins, 3-methoxy-4-hydroxyphenylglycol, 49:1
- haloperidol, circadian rhythms, 47:141
- haloperidol, dopamine, 47:141
- haloperidol, normal subjects, 47:141
- 5-hydroxyindoleacetic acid, affective disorder, 46:19
- 5-hydroxyindoleacetic acid, cerebrospinal fluid, 46:19, 49:1
- 5-hydroxyindoleacetic acid, dissociative phenomena, 49:1
- 5-hydroxyindoleacetic acid, eating disorder, 49:1
- 5-hydroxyindoleacetic acid, endorphins, 49:1
- 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19, 49:1
- 5-hydroxyindoleacetic acid, norepinephrine, 46:19
- 5-hydroxyindoleacetic acid, orthostatic challenge, 46:19
- 5-hydroxyindoleacetic acid, phototherapy, 46:19
- 5-hydroxyindoleacetic acid, seasonal depression, 46:19
- 3-methoxy-4-hydroxyphenylglycol, affective disorder, 46:19
- 3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 46:19, 49:1
- 3-methoxy-4-hydroxyphenylglycol, clozapine, 46:139
- 3-methoxy-4-hydroxyphenylglycol, dissociative phenomena, 49:1

**Homovanillic acid continued**

- 3-methoxy-4-hydroxyphenylglycol, dopamine, 46:139
- 3-methoxy-4-hydroxyphenylglycol, eating disorder, 49:1
- 3-methoxy-4-hydroxyphenylglycol, endorphins, 49:1
- 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, 46:19, 49:1
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:139, 46:19
- 3-methoxy-4-hydroxyphenylglycol, orthostatic challenge, 46:19
- 3-methoxy-4-hydroxyphenylglycol, phototherapy, 46:19
- 3-methoxy-4-hydroxyphenylglycol, schizophrenia, 46:139
- 3-methoxy-4-hydroxyphenylglycol, seasonal depression, 46:19
- 3-methoxy-4-hydroxyphenylglycol, therapeutic response, 46:139
- norepinephrine, affective disorder, 46:19
- norepinephrine, cerebrospinal fluid, 46:19
- norepinephrine, clozapine, 46:139, 46:151
- norepinephrine, dopamine, 46:139, 46:151
- norepinephrine, 5-hydroxyindoleacetic acid, 46:19
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:19, 46:139
- norepinephrine, orthostatic challenge, 46:19
- norepinephrine, phototherapy, 46:19
- norepinephrine, schizophrenia, 46:139, 46:151
- norepinephrine, seasonal depression, 46:19
- norepinephrine, therapeutic response, 46:139, 46:151
- normal subjects, circadian rhythms, 47:141
- normal subjects, dopamine, 47:141
- normal subjects, haloperidol, 47:141
- orthostatic challenge, affective disorder, 46:19
- orthostatic challenge, 5-hydroxyindoleacetic acid, 46:19
- orthostatic challenge, 3-methoxy-4-hydroxyphenylglycol, 46:19
- orthostatic challenge, norepinephrine, 46:19
- orthostatic challenge, phototherapy, 46:19
- orthostatic challenge, seasonal depression, 46:19
- phototherapy, affective disorder, 46:19
- phototherapy, 5-hydroxyindoleacetic acid, 46:19
- phototherapy, 3-methoxy-4-hydroxyphenylglycol, 46:19

**Homovanillic acid continued**

phototherapy, norepinephrine, 46:19  
 phototherapy, orthostatic challenge, 46:19  
 phototherapy, seasonal depression, 46:19  
 positive and negative symptoms, age of onset, 48:93  
 positive and negative symptoms, dopamine, 48:93  
 positive and negative symptoms, schizophrenia, 48:93  
 post-mortem study, Alzheimer's disease, 49:211  
 post-mortem study, dihydroxyphenylacetic acid, 49:211  
 post-mortem study, dopamine, 49:211  
 psychiatric symptoms, Alzheimer's disease, 49:211  
 psychiatric symptoms, cognitive impairment, 49:211  
 psychiatric symptoms, dihydroxyphenylacetic acid, 49:211  
 psychiatric symptoms, dopamine, 49:211  
 schizophrenia, age of onset, 48:93  
 schizophrenia, clozapine, 46:139, 46:151  
 schizophrenia, dopamine, 46:139, 46:151, 48:93  
 schizophrenia, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 schizophrenia, norepinephrine, 46:139, 46:151  
 schizophrenia, positive and negative symptoms, 48:93  
 schizophrenia, therapeutic response, 46:139, 46:151  
 seasonal depression, 5-hydroxyindoleacetic acid, 46:19  
 seasonal depression, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 seasonal depression, norepinephrine, 46:19  
 seasonal depression, orthostatic challenge, 46:19  
 seasonal depression, phototherapy, 46:19  
 therapeutic response, clozapine, 46:139, 46:151  
 therapeutic response, dopamine, 46:139, 46:151  
 therapeutic response, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 therapeutic response, norepinephrine, 46:139, 46:151  
 therapeutic response, schizophrenia, 46:139, 46:151

**Human immunodeficiency virus**

auditory evoked potential P3, cortical atrophy, 47:175  
 auditory evoked potential P3, magnetic resonance imaging, 47:175  
 auditory evoked potential P3, neuropsychology, 47:175  
 auditory evoked potential P3, substance abuse, 47:175  
 cortical atrophy, auditory evoked potential P3, 47:175  
 cortical atrophy, event related potentials, 47:175  
 cortical atrophy, magnetic resonance imaging, 47:175  
 cortical atrophy, neuropsychology, 47:175  
 cortical atrophy, substance abuse, 47:175  
 event related potentials, auditory P3, 47:175  
 event related potentials, cortical atrophy, 47:175  
 event related potentials, magnetic resonance imaging, 47:175  
 event related potentials, neuropsychology, 47:175  
 event related potentials, substance abuse, 47:175  
 magnetic resonance imaging, auditory evoked potential P3, 47:175  
 magnetic resonance imaging, cortical atrophy, 47:175  
 magnetic resonance imaging, event related potentials, 47:175  
 magnetic resonance imaging, neuropsychology, 47:175  
 magnetic resonance imaging, substance abuse, 47:175  
 neuropsychology, auditory evoked potential P3, 47:175  
 neuropsychology, cortical atrophy, 47:175  
 neuropsychology, event related potentials, 47:175  
 neuropsychology, magnetic resonance imaging, 47:175  
 neuropsychology, substance abuse, 47:175  
 substance abuse, auditory evoked potential P3, 47:175  
 substance abuse, cortical atrophy, 47:175  
 substance abuse, event related potentials, 47:175  
 substance abuse, magnetic resonance imaging, 47:175  
 substance abuse, neuropsychology, 47:175



**Human leukocyte antigen**

affective disorder, family history, 48:201

affective disorder, genetics, 48:201

affective disorder, immune function, 48:201

affective disorder, lymphocytes, 48:201

affective disorder, schizophrenia, 48:201

family history, affective disorder, 48:201

family history, immune function, 48:201

family history, lymphocytes, 48:201

family history, schizophrenia, 48:201

genetics, affective disorder, 48:201

genetics, immune function, 48:201

genetics, lymphocytes, 48:201

genetics, schizophrenia, 48:201

immune function, affective disorder, 48:201

immune function, family history, 48:201

immune function, genetics, 48:201

immune function, lymphocytes, 48:201

immune function, schizophrenia, 48:201

lymphocytes, affective disorder, 48:201

lymphocytes, family history, 48:201

lymphocytes, genetics, 48:201

lymphocytes, immune function, 48:201

lymphocytes, schizophrenia, 48:201

schizophrenia, affective disorder, 48:201

schizophrenia, family history, 48:201

schizophrenia, genetics, 48:201

schizophrenia, immune function, 48:201

schizophrenia, lymphocytes, 48:201

**5-Hydroxyindoleacetic acid**

affective disorder, homovanillic acid, 46:19

affective disorder, 3-methoxy-4-hydroxyphenylglycol, 46:19

affective disorder, norepinephrine, 46:19

affective disorder, orthostatic challenge, 46:19

affective disorder, phototherapy, 46:19

affective disorder, seasonal depression, 46:19

cerebrospinal fluid, endorphins, 49:1

cerebrospinal fluid, homovanillic acid, 46:19, 49:1

cerebrospinal fluid, 3-methoxy-4-hydroxyphenylglycol, 46:19, 49:1

cerebrospinal fluid, norepinephrine, 46:19

cerebrospinal fluid, orthostatic challenge, 46:19

dissociative phenomena, eating disorder, 49:1

dissociative phenomena, endorphins, 49:1

dissociative phenomena, homovanillic acid, 49:1

dissociative phenomena, 3-methoxy-4-hydroxyphenylglycol, 49:1

**5-Hydroxyindoleacetic acid continued**

eating disorder, cerebrospinal fluid, 49:1

eating disorder, dissociative phenomena, 49:1

eating disorder, endorphins, 49:1

eating disorder, homovanillic acid, 49:1

eating disorder, 3-methoxy-4-hydroxyphenylglycol, 49:1

endorphins, cerebrospinal fluid, 49:1

endorphins, dissociative phenomena, 49:1

endorphins, eating disorder, 49:1

endorphins, homovanillic acid, 49:1

endorphins, 3-methoxy-4-hydroxyphenylglycol, 49:1

homovanillic acid, affective disorder, 46:19

homovanillic acid, cerebrospinal fluid, 46:19, 49:1

homovanillic acid, dissociative phenomena, 49:1

homovanillic acid, eating disorder, 49:1

homovanillic acid, endorphins, 49:1

homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19, 49:1

homovanillic acid, norepinephrine, 46:19

homovanillic acid, orthostatic challenge, 46:19

homovanillic acid, phototherapy, 46:19

homovanillic acid, seasonal depression, 46:19

3-methoxy-4-hydroxyphenylglycol, affective disorder, 46:19

3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 46:19, 49:1

3-methoxy-4-hydroxyphenylglycol, dissociative phenomena, 49:1

3-methoxy-4-hydroxyphenylglycol, eating disorder, 49:1

3-methoxy-4-hydroxyphenylglycol, endorphins, 49:1

3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:19, 49:1

3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:19

3-methoxy-4-hydroxyphenylglycol, orthostatic challenge, 46:19

3-methoxy-4-hydroxyphenylglycol, phototherapy, 46:19

3-methoxy-4-hydroxyphenylglycol, seasonal depression, 46:19

norepinephrine, affective disorder, 46:19

norepinephrine, cerebrospinal fluid, 46:19

norepinephrine, homovanillic acid, 46:19

norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:19

**5-Hydroxyindoleacetic acid** continued

norepinephrine, orthostatic challenge, 46:19  
 norepinephrine, phototherapy, 46:19  
 norepinephrine, seasonal depression, 46:19  
 orthostatic challenge, affective disorder, 46:19  
 orthostatic challenge, cerebrospinal fluid, 46:19  
 orthostatic challenge, homovanillic acid, 46:19  
 orthostatic challenge, 3-methoxy-4-hydroxy-phenylglycol, 46:19  
 orthostatic challenge, norepinephrine, 46:19  
 orthostatic challenge, phototherapy, 46:19  
 orthostatic challenge, seasonal depression, 46:19  
 phototherapy, affective disorder, 46:19  
 phototherapy, homovanillic acid, 46:19  
 phototherapy, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 phototherapy, norepinephrine, 46:19  
 phototherapy, orthostatic challenge, 46:19  
 phototherapy, seasonal depression, 46:19  
 seasonal depression, homovanillic acid, 46:19  
 seasonal depression, 3-methoxy-4-hydroxy-phenylglycol, 46:19  
 seasonal depression, norepinephrine, 46:19  
 seasonal depression, orthostatic challenge, 46:19  
 seasonal depression, phototherapy, 46:19

**Imipramine**

calmodulin affinity chromatography, endogenous serotonin uptake inhibitors, 47:121  
 calmodulin affinity chromatography, paroxetine, 47:121  
 calmodulin affinity chromatography, serotonin, 47:121  
 endogenous serotonin uptake inhibitors, calmodulin affinity chromatography, 47:121  
 endogenous serotonin uptake inhibitors, paroxetine, 47:121  
 endogenous serotonin uptake inhibitors, serotonin, 47:121  
 paroxetine, calmodulin affinity chromatography, 47:121  
 paroxetine, endogenous serotonin uptake inhibitors, 47:121  
 paroxetine, serotonin, 47:121  
 serotonin, calmodulin affinity chromatography, 47:121

**Imipramine** continued

serotonin, endogenous serotonin uptake inhibitors, 47:121  
 serotonin, paroxetine, 47:121  
**Immune function**  
 affective disorder, amino acids, 49:151  
 affective disorder, cortisol, 49:11  
 affective disorder, dexamethasone suppression test, 49:11  
 affective disorder, family history, 48:201  
 affective disorder, gender differences, 49:151  
 affective disorder, genetics, 48:201  
 affective disorder, haptoglobin, 47:229, 49:11, 49:151  
 affective disorder, human leukocyte antigen, 48:201  
 affective disorder, interleukin, 49:11, 49:151  
 affective disorder, lymphocytes, 48:201  
 affective disorder, schizophrenia, 48:201  
 affective disorder, serotonin, 49:151  
 affective disorder, sleep, 47:229  
 affective disorder, somatic symptoms, 47:229  
 affective disorder, transferrin, 49:11, 49:151  
 affective disorder, tryptophan, 49:151  
 affective disorder, weight and anorexia, 47:229  
 amino acids, affective disorder, 49:151  
 amino acids, haptoglobin, 49:151  
 amino acids, interleukin, 49:151  
 amino acids, serotonin, 49:151  
 amino acids, transferrin, 49:151  
 amino acids, tryptophan, 49:151  
 CD5 positive B lymphocytes, gender differences, 48:69  
 CD5 positive B lymphocytes, lymphocytes, 48:69  
 CD5 positive B lymphocytes, race differences, 48:69  
 CD5 positive B lymphocytes, schizophrenia, 48:69  
 cortisol, affective disorder, 49:11  
 cortisol, dexamethasone suppression test, 49:11  
 cortisol, haptoglobin, 49:11  
 cortisol, interleukins, 49:11  
 cortisol, transferrin, 49:11  
 dexamethasone suppression test, affective disorder, 49:11  
 dexamethasone suppression test, cortisol, 49:11  
 dexamethasone suppression test, haptoglobin, 49:11

**Immune function continued**

dexamethasone suppression test, interleukins, 49:11  
 dexamethasone suppression test, transferrin, 49:11  
 family history, affective disorder, 48:201  
 family history, human leukocyte antigen, 48:201  
 family history, lymphocytes, 48:201  
 family history, schizophrenia, 48:201  
 gender differences, affective disorder, 49:151  
 gender differences, CD5 positive B lymphocytes, 48:69  
 gender differences, lymphocytes, 48:69  
 gender differences, race differences, 48:69  
 gender differences, schizophrenia, 48:69  
 genetics, affective disorder, 48:201  
 genetics, family history, 48:201  
 genetics, human leukocyte antigen, 48:201  
 genetics, lymphocytes, 48:201  
 genetics, schizophrenia, 48:201  
 haptoglobin, affective disorder, 47:229, 49:11, 49:151  
 haptoglobin, amino acids, 49:151  
 haptoglobin, cortisol, 49:11  
 haptoglobin, dexamethasone suppression test, 49:11  
 haptoglobin, interleukin, 49:11, 49:151  
 haptoglobin, serotonin, 49:151  
 haptoglobin, sleep, 47:229  
 haptoglobin, somatic symptoms, 47:229  
 haptoglobin, transferrin, 49:11, 49:151  
 haptoglobin, tryptophan, 49:151  
 haptoglobin, weight and anorexia, 47:229  
 human leukocyte antigen, affective disorder, 48:201  
 human leukocyte antigen, family history, 48:201  
 human leukocyte antigen, genetics, 48:201  
 human leukocyte antigen, lymphocytes, 48:201  
 human leukocyte antigen, schizophrenia, 48:201  
 interleukins, affective disorder, 49:11, 49:151  
 interleukins, amino acids, 49:151  
 interleukins, cortisol, 49:11  
 interleukins, haptoglobin, 49:11, 49:151  
 interleukins, serotonin, 49:151  
 interleukins, transferrin, 49:11, 49:151  
 interleukins, tryptophan, 49:151  
 lymphocytes, affective disorder, 48:201  
 lymphocytes, CD5 positive B lymphocytes, 48:69

**Immune function continued**

lymphocytes, family history, 48:201  
 lymphocytes, gender differences, 48:69  
 lymphocytes, genetics, 48:201  
 lymphocytes, human leukocyte antigen, 48:201  
 lymphocytes, race differences, 48:69  
 lymphocytes, schizophrenia, 48:69, 48:201  
 race differences, CD5 positive B lymphocytes, 48:69  
 race differences, gender differences, 48:69  
 race differences, lymphocytes, 48:69  
 race differences, schizophrenia, 48:69  
 schizophrenia, affective disorder, 48:201  
 schizophrenia, CD5 positive B lymphocytes, 48:69  
 schizophrenia, family history, 48:201  
 schizophrenia, gender differences, 48:69  
 schizophrenia, genetics, 48:201  
 schizophrenia, human leukocyte antigen, 48:201  
 schizophrenia, lymphocytes, 48:69, 48:201  
 schizophrenia, race differences, 48:69  
 serotonin, affective disorder, 49:151  
 serotonin, amino acids, 49:151  
 serotonin, haptoglobin, 49:151  
 serotonin, interleukin, 49:151  
 serotonin, transferrin, 49:151  
 serotonin, tryptophan, 49:151  
 sleep, affective disorder, 47:229  
 sleep, haptoglobin, 47:229  
 sleep, somatic symptoms, 47:229  
 sleep, weight and anorexia, 47:229  
 somatic symptoms, affective disorder, 47:229  
 somatic symptoms, haptoglobin, 47:229  
 somatic symptoms, sleep, 47:229  
 somatic symptoms, weight and anorexia, 47:229  
 transferrin, affective disorder, 49:11, 49:151  
 transferrin, amino acids, 49:151  
 transferrin, cortisol, 49:11  
 transferrin, dexamethasone suppression test, 49:11  
 transferrin, haptoglobin, 49:11, 49:151  
 transferrin, interleukins, 49:11, 49:151  
 transferrin, serotonin, 49:151  
 transferrin, tryptophan, 49:151  
 tryptophan, affective disorder, 49:151  
 tryptophan, amino acids, 49:151  
 tryptophan, haptoglobin, 49:151  
 tryptophan, interleukins, 49:151  
 tryptophan, serotonin, 49:151



**Immune function continued**

- tryptophan, transferrin, 49:151
- weight and anorexia, affective disorder, 47:229
- weight and anorexia, haptoglobin, 47:229
- weight and anorexia, sleep, 47:229
- weight and anorexia, somatic symptoms, 47:229

**Impulse control disorder**

- alcohol dependence, depression, 47:57
- alcohol dependence, glutamyltransferase, 47:57
- alcohol dependence, serotonin, 47:57
- alcohol dependence, withdrawal, 47:57
- depression, alcohol dependence, 47:57
- depression, glutamyltransferase, 47:57
- depression, serotonin, 47:57
- glutamyltransferase, alcohol dependence, 47:57
- glutamyltransferase, depression, 47:57
- glutamyltransferase, serotonin, 47:57
- platelets, serotonin, 47:57
- serotonin, alcohol dependence, 47:57
- serotonin, depression, 47:57
- serotonin, glutamyltransferase, 47:57
- serotonin, platelets, 47:57
- withdrawal, alcohol dependence, 47:57

**Joint hypermobility syndrome**

- affective disorder, mitral valve prolapse, 46:59
- affective disorder, simple phobia, 46:59
- anxiety disorder, panic, 46:59
- mitral valve prolapse, affective disorder, 46:59
- mitral valve prolapse, simple phobia, 46:59
- panic disorder, 46:59
- simple phobia, affective disorder, 46:59
- simple phobia, mitral valve prolapse, 46:59

**Lactate**

- blood pressure, menstrual cycle, 46:79
- blood pressure, panic attacks, 46:79
- blood pressure, premenstrual syndrome, 46:79
- menstrual cycle, blood pressure, 46:79
- menstrual cycle, panic attacks, 46:79
- panic attacks, blood pressure, 46:79
- panic attacks, menstrual cycle, 46:79
- panic attacks, premenstrual syndrome, 46:79
- premenstrual syndrome, blood pressure, 46:79
- premenstrual syndrome, panic attacks, 46:79

**Language**

- affective disorder, laterality, 47:99
- affective disorder, motor performance, 47:99
- affective disorder, phototherapy, 47:99
- laterality, affective disorder, 47:99
- laterality, motor performance, 47:99
- laterality, phototherapy, 47:99
- laterality, seasonal depression, 47:99
- motor performance, affective disorder, 47:99
- motor performance, laterality, 47:99
- motor performance, phototherapy, 47:99
- motor performance, seasonal depression, 47:99
- phototherapy, affective disorder, 47:99
- phototherapy, laterality, 47:99
- phototherapy, motor performance, 47:99
- phototherapy, seasonal depression, 47:99
- seasonal depression, laterality, 47:99
- seasonal depression, motor performance, 47:99
- seasonal depression, phototherapy, 47:99

**Light therapy.** See Phototherapy**Lipids**

- Alzheimer's disease, erythrocyte membrane, 46:203
- erythrocyte membrane, Alzheimer's disease, 46:203

**Lorazepam**

- alcohol intake, anxiety disorder, 48:135
- alcohol intake, computed tomography, 48:135
- alcohol intake, ventricle-brain ratio, 48:135
- anxiety disorder, alcohol intake, 48:135
- anxiety disorder, computed tomography, 48:135
- anxiety disorder, ventricle-brain ratio, 48:135
- computed tomography, alcohol intake, 48:135
- computed tomography, anxiety disorder, 48:135
- computed tomography, ventricle-brain ratio, 48:135
- diazepam, alcohol intake, 48:135
- diazepam, anxiety disorder, 48:135
- ventricle-brain ratio, alcohol intake, 48:135
- ventricle-brain ratio, anxiety disorder, 48:135
- ventricle-brain ratio, benzodiazepines, 48:135
- ventricle-brain ratio, computed tomography, 48:135

**Luteinizing hormone**

- estradiol, follicle stimulating hormone, 48:153
- estradiol, growth hormone, 48:153
- estradiol, normal volunteers, 48:153
- estradiol, prolactin, 48:153
- estradiol, sleep deprivation, 48:153

**Luteinizing hormone** continued

estradiol, thyroid stimulating hormone, 48:153  
 estradiol, thyroxine, 48:153  
 estradiol, triiodothyronine, 48:153  
 follicle stimulating hormone, estradiol, 48:153  
 follicle stimulating hormone, growth hormone, 48:153  
 follicle stimulating hormone, normal volunteers, 48:153  
 follicle stimulating hormone, prolactin, 48:153  
 follicle stimulating hormone, sleep deprivation, 48:153  
 follicle stimulating hormone, thyroid stimulating hormone, 48:153  
 follicle stimulating hormone, thyroxine, 48:153  
 follicle stimulating hormone, triiodothyronine, 48:153  
 growth hormone, estradiol, 48:153  
 growth hormone, follicle stimulating hormone, 48:153  
 growth hormone, normal volunteers, 48:153  
 growth hormone, prolactin, 48:153  
 growth hormone, sleep deprivation, 48:153  
 growth hormone, thyroid stimulating hormone, 48:153  
 growth hormone, thyroxine, 48:153  
 growth hormone, triiodothyronine, 48:153  
 normal volunteers, estradiol, 48:153  
 normal volunteers, follicle stimulating hormone, 48:153  
 normal volunteers, growth hormone, 48:153  
 normal volunteers, prolactin, 48:153  
 normal volunteers, sleep deprivation, 48:153  
 normal volunteers, thyroid stimulating hormone, 48:153  
 normal volunteers, thyroxine, 48:153  
 normal volunteers, triiodothyronine, 48:153  
 prolactin, estradiol, 48:153  
 prolactin, follicle stimulating hormone, 48:153  
 prolactin, growth hormone, 48:153  
 prolactin, normal volunteers, 48:153  
 prolactin, sleep deprivation, 48:153  
 prolactin, thyroid stimulating hormone, 48:153  
 prolactin, thyroxine, 48:153  
 prolactin, triiodothyronine, 48:153  
 sleep deprivation, estradiol, 48:153

**Luteinizing hormone** continued

sleep deprivation, follicle stimulating hormone, 48:153  
 sleep deprivation, growth hormone, 48:153  
 sleep deprivation, normal volunteers, 48:153  
 sleep deprivation, prolactin, 48:153  
 sleep deprivation, thyroid stimulating hormone, 48:153  
 sleep deprivation, thyroxine, 48:153  
 sleep deprivation, triiodothyronine, 48:153  
 thyroid stimulating hormone, estradiol, 48:153  
 thyroid stimulating hormone, follicle stimulating hormone, 48:153  
 thyroid stimulating hormone, growth hormone, 48:153  
 thyroid stimulating hormone, normal volunteers, 48:153  
 thyroid stimulating hormone, prolactin, 48:153  
 thyroid stimulating hormone, sleep deprivation, 48:153  
 thyroid stimulating hormone, thyroxine, 48:153  
 thyroid stimulating hormone, triiodothyronine, 48:153  
 thyroxine, estradiol, 48:153  
 thyroxine, follicle stimulating hormone, 48:153  
 thyroxine, growth hormone, 48:153  
 thyroxine, normal volunteers, 48:153  
 thyroxine, prolactin, 48:153  
 thyroxine, sleep deprivation, 48:153  
 thyroxine, thyroid stimulating hormone, 48:153  
 thyroxine, triiodothyronine, 48:153  
 triiodothyronine, estradiol, 48:153  
 triiodothyronine, follicle stimulating hormone, 48:153  
 triiodothyronine, growth hormone, 48:153  
 triiodothyronine, normal volunteers, 48:153  
 triiodothyronine, prolactin, 48:153  
 triiodothyronine, sleep deprivation, 48:153  
 triiodothyronine, thyroid stimulating hormone, 48:153  
 triiodothyronine, thyroxine, 48:153

**Lymphocytes**

affective disorder, family history, 48:201  
 affective disorder, genetics, 48:201  
 affective disorder, human leukocyte antigen, 48:201  
 affective disorder, immune function, 48:201

**Lymphocytes continued**

affective disorder, schizophrenia, 48:201  
 CD5 positive B lymphocytes, gender differences, 48:69  
 CD5 positive B lymphocytes, immune function, 48:69  
 CD5 positive B lymphocytes, race differences, 48:69  
 CD5 positive B lymphocytes, schizophrenia, 48:69  
 family history, affective disorder, 48:201  
 family history, human leukocyte antigen, 48:201  
 family history, immune function, 48:201  
 family history, schizophrenia, 48:201  
 gender differences, CD5 positive B lymphocytes, 48:69  
 gender differences, immune function, 48:69  
 gender differences, race differences, 48:69  
 gender differences, schizophrenia, 48:69  
 genetics, affective disorder, 48:201  
 genetics, human leukocyte antigen, 48:201  
 genetics, immune function, 48:201  
 genetics, schizophrenia, 48:201  
 human leukocyte antigen, affective disorder, 48:201  
 human leukocyte antigen, family history, 48:201  
 human leukocyte antigen, genetics, 48:201  
 human leukocyte antigen, immune function, 48:201  
 human leukocyte antigen, schizophrenia, 48:201  
 immune function, affective disorder, 48:201  
 immune function, CD5 positive B lymphocytes, 48:69  
 immune function, family history, 48:201  
 immune function, gender differences, 48:69  
 immune function, genetics, 48:201  
 immune function, human leukocyte antigen, 48:201  
 immune function, race differences, 48:69  
 immune function, schizophrenia, 48:69, 48:201  
 race differences, CD5 positive B lymphocytes, 48:69  
 race differences, gender differences, 48:69  
 race differences, immune function, 48:69  
 race differences, schizophrenia, 48:69  
 schizophrenia, affective disorder, 48:201  
 schizophrenia, CD5 positive B lymphocytes, 48:69

**Lymphocytes continued**

schizophrenia, family history, 48:201  
 schizophrenia, gender differences, 48:69  
 schizophrenia, genetics, 48:201  
 schizophrenia, human leukocyte antigen, 48:201  
 schizophrenia, immune function, 48:69, 48:201  
 schizophrenia, race differences, 48:69  
**Magnetic resonance imaging**  
 affective disorder, cortisol, 47:163  
 affective disorder, dexamethasone suppression test, 47:163  
 affective disorder, hippocampus, 47:163  
 auditory evoked potential P3 wave, cortical atrophy, 47:175  
 auditory evoked potential P3 wave, human immunodeficiency virus, 47:175  
 auditory evoked potential P3 wave, neuropsychology, 47:175  
 auditory evoked potential P3 wave, substance abuse, 47:175  
 cortical atrophy, auditory evoked potential P3 wave, 47:175  
 cortical atrophy, event related potentials, 47:175  
 cortical atrophy, human immunodeficiency virus, 47:175  
 cortical atrophy, neuropsychology, 47:175  
 cortical atrophy, substance abuse, 47:175  
 cortisol, affective disorder, 47:163  
 cortisol, dexamethasone suppression test, 47:163  
 cortisol, hippocampus, 47:163  
 dexamethasone suppression test, affective disorder, 47:163  
 dexamethasone suppression test, cortisol, 47:163  
 dexamethasone suppression test, hippocampus, 47:163  
 event related potentials, auditory P3 wave, 47:175  
 event related potentials, cortical atrophy, 47:175  
 event related potentials, human immunodeficiency virus, 47:175  
 event related potentials, neuropsychology, 47:175  
 event related potentials, substance abuse, 47:175  
 hippocampus, affective disorder, 47:163  
 hippocampus, cortisol, 47:163



**Magnetic resonance imaging** continued  
hippocampus, dexamethasone suppression test, 47:163

human immunodeficiency virus, auditory evoked potential P3, 47:175

human immunodeficiency virus, cortical atrophy, 47:175

human immunodeficiency virus, event related potentials, 47:175

human immunodeficiency virus, neuropsychology, 47:175

human immunodeficiency virus, substance abuse, 47:175

neuropsychology, auditory evoked potential P3 wave, 47:175

neuropsychology, cortical atrophy, 47:175

neuropsychology, event related potentials, 47:175

neuropsychology, human immunodeficiency virus, 47:175

neuropsychology, substance abuse, 47:175

substance abuse, auditory evoked potential P3, 47:175

substance abuse, cortical atrophy, 47:175

substance abuse, event related potentials, 47:175

substance abuse, human immunodeficiency virus, 47:175

substance abuse, neuropsychology, 47:175

## **Memory**

affective disorder, antidepressant medication, 46:295

affective disorder, attention, 46:295

affective disorder, treatment duration, 46:295

affective disorder, visual pattern integration, 46:295

alcohol dependence, frontal lobe, 46:175

alcohol dependence, neuropsychology, 46:175

alcohol dependence, schizophrenia, 46:175

alcohol dependence, Wisconsin Card Sorting Test, 46:175

antidepressant medication, affective disorder, 46:295

antidepressant medication, attention, 46:295

antidepressant medication, treatment duration, 46:295

antidepressant medication, visual pattern integration, 46:295

attention, affective disorder, 46:295

attention, antidepressant medication, 46:295

attention, treatment duration, 46:295

attention, visual pattern integration, 46:295

## **Memory** continued

frontal lobe, alcohol dependence, 46:175

frontal lobe, neuropsychology, 46:175

frontal lobe, schizophrenia, 46:175

frontal lobe, Wisconsin Card Sorting Test, 46:175

neuropsychology, alcohol dependence, 46:175

neuropsychology, frontal lobe, 46:175

neuropsychology, schizophrenia, 46:175

neuropsychology, Wisconsin Card Sorting Test, 46:175

schizophrenia, alcohol dependence, 46:175

schizophrenia, frontal lobe, 46:175

schizophrenia, neuropsychology, 46:175

schizophrenia, Wisconsin Card Sorting Test, 46:175

treatment duration, affective disorder, 46:295

treatment duration, antidepressant medication, 46:295

treatment duration, attention, 46:295

treatment duration, visual pattern integration, 46:295

visual pattern integration, affective disorder, 46:295

visual pattern integration, antidepressant medication, 46:295

visual pattern integration, attention, 46:295

visual pattern integration, treatment duration, 46:295

Wisconsin Card Sorting Test, alcohol dependence, 46:175

Wisconsin Card Sorting Test, frontal lobe, 46:175

Wisconsin Card Sorting Test, neuropsychology, 46:175

Wisconsin Card Sorting Test, schizophrenia, 46:175

## **3-Methoxy-4-hydroxyphenylglycol**

affective disorder, homovanillic acid, 46:19

affective disorder, 5-hydroxyindoleacetic acid, 46:19

affective disorder, norepinephrine, 46:19

affective disorder, orthostatic challenge, 46:19

anxiety disorder, cortisol, 48:119

anxiety disorder, fluvoxamine, 48:119

anxiety disorder, norepinephrine, 48:119

anxiety disorder, panic, 48:119

anxiety disorder, serotonin, 48:119

anxiety disorder, yohimbine, 48:119

clozapine, dopamine, 46:139

clozapine, homovanillic acid, 46:139

**3-Methoxy-4-hydroxyphenylglycol continued**

clozapine, norepinephrine, 46:139  
 clozapine, schizophrenia, 46:139  
 clozapine, therapeutic response, 46:139  
 cortisol, anxiety disorder, 48:119  
 cortisol, fluvoxamine, 48:119  
 cortisol, norepinephrine, 48:119  
 cortisol, panic disorder, 48:119  
 cortisol, serotonin, 48:119  
 cortisol, yohimbine, 48:119  
 dissociative phenomena, eating disorder, 49:1  
 dissociative phenomena, endorphins, 49:1  
 dissociative phenomena, homovanillic acid, 49:1  
 dissociative phenomena, 5-hydroxyindoleacetic acid, 49:1  
 dopamine, clozapine, 46:139  
 dopamine, homovanillic acid, 46:139  
 dopamine, norepinephrine, 46:139  
 dopamine, schizophrenia, 46:139  
 dopamine, therapeutic response, 46:139  
 eating disorder, dissociative phenomena, 49:1  
 eating disorder, endorphins, 49:1  
 eating disorder, homovanillic acid, 49:1  
 eating disorder, 5-hydroxyindoleacetic acid, 49:1  
 endorphins, cerebrospinal fluid, 49:1  
 endorphins, dissociative phenomena, 49:1  
 endorphins, eating disorder, 49:1  
 endorphins, homovanillic acid, 49:1  
 endorphins, 5-hydroxyindoleacetic acid, 49:1  
 fluvoxamine, anxiety disorder, 48:119  
 fluvoxamine, cortisol, 48:119  
 fluvoxamine, norepinephrine, 48:119  
 fluvoxamine, panic disorder, 48:119  
 fluvoxamine, reuptake inhibitor, 48:119  
 fluvoxamine, serotonin, 48:119  
 fluvoxamine, yohimbine, 48:119  
 homovanillic acid, affective disorder, 46:19  
 homovanillic acid, cerebrospinal fluid, 46:19, 49:1  
 homovanillic acid, clozapine, 46:139  
 homovanillic acid, dissociative phenomena, 49:1  
 homovanillic acid, dopamine, 46:139  
 homovanillic acid, eating disorder, 49:1  
 homovanillic acid, endorphins, 49:1  
 homovanillic acid, 5-hydroxyindoleacetic acid, 46:19, 49:1  
 homovanillic acid, norepinephrine, 46:19, 46:139  
 homovanillic acid, orthostatic challenge, 46:19

**3-Methoxy-4-hydroxyphenylglycol continued**

homovanillic acid, phototherapy, 46:19  
 homovanillic acid, schizophrenia, 46:139  
 homovanillic acid, seasonal depression, 46:19  
 homovanillic acid, therapeutic response, 46:139  
 5-hydroxyindoleacetic acid, affective disorder, 46:19  
 5-hydroxyindoleacetic acid, cerebrospinal fluid, 46:19, 49:1  
 5-hydroxyindoleacetic acid, dissociative phenomena, 49:1  
 5-hydroxyindoleacetic acid, eating disorder, 49:1  
 5-hydroxyindoleacetic acid, endorphins, 49:1  
 5-hydroxyindoleacetic acid, homovanillic acid, 46:19, 49:1  
 5-hydroxyindoleacetic acid, norepinephrine, 46:19  
 5-hydroxyindoleacetic acid, orthostatic challenge, 46:19  
 5-hydroxyindoleacetic acid, phototherapy, 46:19  
 5-hydroxyindoleacetic acid, seasonal depression, 46:19  
 norepinephrine, affective disorder, 46:19  
 norepinephrine, anxiety disorder, 48:119  
 norepinephrine, cerebrospinal fluid, 46:19  
 norepinephrine, clozapine, 46:139  
 norepinephrine, cortisol, 48:119  
 norepinephrine, dopamine, 46:139  
 norepinephrine, fluvoxamine, 48:119  
 norepinephrine, homovanillic acid, 46:19, 46:139  
 norepinephrine, 5-hydroxyindoleacetic acid, 46:19  
 norepinephrine, orthostatic challenge, 46:19  
 norepinephrine, panic disorder, 48:119  
 norepinephrine, phototherapy, 46:19  
 norepinephrine, schizophrenia, 46:139  
 norepinephrine, seasonal depression, 46:19  
 norepinephrine, serotonin, 48:119  
 norepinephrine, yohimbine, 48:119  
 orthostatic challenge, affective disorder, 46:19  
 orthostatic challenge, homovanillic acid, 46:19  
 orthostatic challenge, 5-hydroxyindoleacetic acid, 46:19  
 orthostatic challenge, norepinephrine, 46:19  
 orthostatic challenge, seasonal depression, 46:19

**3-Methoxy-4-hydroxyphenylglycol continued**

panic disorder, cortisol, 48:119  
 panic disorder, fluvoxamine, 48:119  
 panic disorder, norepinephrine, 48:119  
 panic disorder, serotonin, 48:119  
 panic disorder, yohimbine, 48:119  
 phototherapy, affective disorder, 46:19  
 phototherapy, homovanillic acid, 46:19  
 phototherapy, 5-hydroxyindoleacetic acid, 46:19  
 phototherapy, norepinephrine, 46:19  
 phototherapy, orthostatic challenge, 46:19  
 phototherapy, seasonal depression, 46:19  
 reuptake inhibitor, serotonin, 48:119  
 schizophrenia, clozapine, 46:139  
 schizophrenia, dopamine, 46:139  
 schizophrenia, homovanillic acid, 46:139  
 schizophrenia, norepinephrine, 46:139  
 schizophrenia, therapeutic response, 46:139  
 seasonal depression, homovanillic acid, 46:19  
 seasonal depression, 5-hydroxyindoleacetic acid, 46:19  
 seasonal depression, norepinephrine, 46:19  
 seasonal depression, orthostatic challenge, 46:19  
 seasonal depression, phototherapy, 46:19  
 serotonin, anxiety disorder, 48:119  
 serotonin, cortisol, 48:119  
 serotonin, fluvoxamine, 48:119  
 serotonin, norepinephrine, 48:119  
 serotonin, panic disorder, 48:119  
 serotonin, reuptake inhibitor, 48:119  
 serotonin, yohimbine, 48:119  
 therapeutic response, clozapine, 46:139  
 therapeutic response, dopamine, 46:139  
 therapeutic response, homovanillic acid, 46:139  
 therapeutic response, norepinephrine, 46:139  
 therapeutic response, schizophrenia, 46:139  
 yohimbine, anxiety disorder, 48:119  
 yohimbine, cortisol, 48:119  
 yohimbine, fluvoxamine, 48:119  
 yohimbine, norepinephrine, 48:119  
 yohimbine, panic disorder, 48:119  
 yohimbine, serotonin, 48:119

**Migraine**

bulimia nervosa, 46:201  
 eating disorders, 46:201

**Motor performance**

affective disorder, language, 47:99  
 affective disorder, laterality, 47:99  
 affective disorder, phototherapy, 47:99

**Motor performance continued**

alcohol dependence, cocaine, 47:69  
 alcohol dependence, substance abuse, 47:69  
 alcohol dependence, tremor and body sway, 47:69  
 cocaine, alcohol dependence, 47:69  
 cocaine, tremor and body sway, 47:69  
 language, affective disorder, 47:99  
 language, laterality, 47:99  
 language, phototherapy, 47:99  
 language, seasonal depression, 47:99  
 laterality, affective disorder, 47:99  
 laterality, language, 47:99  
 laterality, phototherapy, 47:99  
 laterality, seasonal depression, 47:99  
 phototherapy, affective disorder, 47:99  
 phototherapy, language, 47:99  
 phototherapy, laterality, 47:99  
 phototherapy, seasonal depression, 47:99  
 seasonal depression, language, 47:99  
 seasonal depression, laterality, 47:99  
 seasonal depression, phototherapy, 47:99  
 substance abuse, alcohol dependence, 47:69  
 substance abuse, cocaine, 47:69  
 substance abuse, tremor and body sway, 47:69  
 tremor and body sway, alcohol dependence, 47:69  
 tremor and body sway, cocaine, 47:69  
 tremor and body sway, substance abuse, 47:69

**N-acetyl-beta-glucosaminidase**

affective disorder, bipolar subtype, 47:129  
 affective disorder, depressive symptoms, 47:129  
 affective disorder, serotonin, 47:129  
 bipolar subtype, depressive symptoms, 47:129  
 bipolar subtype, serotonin, 47:129  
 depressive symptoms, affective disorder, 47:129  
 depressive symptoms, bipolar subtype, 47:129  
 depressive symptoms, serotonin, 47:129  
 serotonin, affective disorder, 47:129  
 serotonin, bipolar subtype, 47:129  
 serotonin, depressive symptoms, 47:129

**Neuroleptics**

amino acids, circadian rhythm, 47:187  
 amino acids, dopamine, 47:187  
 amino acids, neutral serum amino acids, 47:187



**Neuroleptics continued**

amino acids, phenylalanine, 47:187  
 amino acids, schizophrenia, 47:187  
 amino acids, therapeutic response, 47:187  
 animal models, domperidone, 47:37  
 animal models, dysphoria, 47:37  
 animal models, haloperidol, 47:37  
 animal models, locomotor activity, 47:37  
 animal models, neuroleptic-induced defecation in rats, 47:37  
 circadian rhythm, amino acids, 47:187  
 circadian rhythm, dopamine, 47:187  
 circadian rhythm, neutral serum amino acids, 47:187  
 circadian rhythm, phenylalanine, 47:187  
 circadian rhythm, schizophrenia, 47:187  
 circadian rhythm, therapeutic response, 47:187  
 domperidone, animal models, 47:37  
 domperidone, dysphoria, 47:37  
 domperidone, haloperidol, 47:37  
 domperidone, locomotor activity, 47:37  
 domperidone, neuroleptic-induced defecation in rats, 47:37  
 dopamine, amino acids, 47:187  
 dopamine, circadian rhythm, 47:187  
 dopamine, neutral serum amino acids, 47:187  
 dopamine, phenylalanine, 47:187  
 dopamine, schizophrenia, 47:187  
 dopamine, therapeutic response, 47:187  
 dysphoria, animal models, 47:37  
 dysphoria, domperidone, 47:37  
 dysphoria, haloperidol, 47:37  
 dysphoria, locomotor activity, 47:37  
 dysphoria, neuroleptic-induced defecation in rats, 47:37  
 haloperidol, animal models, 47:37  
 haloperidol, domperidone, 47:37  
 haloperidol, dysphoria, 47:37  
 haloperidol, locomotor activity, 47:37  
 haloperidol, neuroleptic-induced defecation in rats, 47:37  
 locomotor activity, animal models, 47:37  
 locomotor activity, domperidone, 47:37  
 locomotor activity, dysphoria, 47:37  
 locomotor activity, haloperidol, 47:37  
 locomotor activity, neuroleptic-induced defecation in rats, 47:37  
 neuroleptic-induced defecation in rats, animal models, 47:37  
 neuroleptic-induced defecation in rats, domperidone, 47:37

**Neuroleptics continued**

neuroleptic-induced defecation in rats, dysphoria, 47:37  
 neuroleptic-induced defecation in rats, haloperidol, 47:37  
 neuroleptic-induced defecation in rats, locomotor activity, 47:37  
 neutral serum amino acids, circadian rhythm, 47:187  
 neutral serum amino acids, dopamine, 47:187  
 neutral serum amino acids, phenylalanine, 47:187  
 neutral serum amino acids, schizophrenia, 47:187  
 neutral serum amino acids, therapeutic response, 47:187  
 phenylalanine, amino acids, 47:187  
 phenylalanine, circadian rhythm, 47:187  
 phenylalanine, dopamine, 47:187  
 phenylalanine, neutral serum amino acids, 47:187  
 phenylalanine, schizophrenia, 47:187  
 phenylalanine, therapeutic response, 47:187  
 schizophrenia, amino acids, 47:187  
 schizophrenia, circadian rhythm, 47:187  
 schizophrenia, dopamine, 47:187  
 schizophrenia, neutral serum amino acids, 47:187  
 schizophrenia, phenylalanine, 47:187  
 schizophrenia, serotonin S2 receptor in platelets, 48:57  
 schizophrenia, therapeutic response, 47:187  
 serotonin S2 receptor in platelets, schizophrenia, 48:57  
 therapeutic response, amino acids, 47:187  
 therapeutic response, circadian rhythm, 47:187  
 therapeutic response, dopamine, 47:187  
 therapeutic response, neutral serum amino acids, 47:187  
 therapeutic response, phenylalanine, 47:187  
 therapeutic response, schizophrenia, 47:187  
**Neuropsychology**  
 alcohol dependence, frontal lobe, 46:175  
 alcohol dependence, memory, 46:175  
 alcohol dependence, schizophrenia, 46:175  
 alcohol dependence, Wisconsin Card Sorting Test, 46:175  
 antisocial disorder, borderline disorder, 48:257  
 antisocial disorder, impulsivity, 48:257  
 antisocial disorder, neurological soft signs, 48:257

**Neuropsychology continued**

antisocial disorder, personality disorder, 48:257

auditory evoked potential P3, cortical atrophy, 47:175

auditory evoked potential P3, human immunodeficiency virus, 47:175

auditory evoked potential P3, magnetic resonance imaging, 47:175

auditory evoked potential P3, substance abuse, 47:175

borderline disorder, antisocial disorder, 48:257

borderline disorder, impulsivity, 48:257

borderline disorder, neurological soft signs, 48:257

cortical atrophy, auditory evoked potential P3, 47:175

cortical atrophy, event related potentials, 47:175

cortical atrophy, human immunodeficiency virus, 47:175

cortical atrophy, magnetic resonance imaging, 47:175

cortical atrophy, substance abuse, 47:175

event related potentials, cortical atrophy, 47:175

event related potentials, human immunodeficiency virus, 47:175

event related potentials, magnetic resonance imaging, 47:175

event related potentials, substance abuse, 47:175

eye movements, frontal lobe, 48:191

eye movements, obsessive-compulsive disorder, 48:191

eye movements, saccadic, 48:191

eye movements, smooth pursuit, 48:191

eye movements, Wisconsin Card Sorting Test, 48:191

frontal lobe, alcohol dependence, 46:175

frontal lobe, eye movements, 48:191

frontal lobe, memory, 46:175

frontal lobe, obsessive-compulsive disorder, 48:191

frontal lobe, schizophrenia, 46:175

frontal lobe, Wisconsin Card Sorting Test, 46:175, 48:191

human immunodeficiency virus, auditory evoked potential P3, 47:175

human immunodeficiency virus, cortical atrophy, 47:175

**Neuropsychology continued**

human immunodeficiency virus, event related potentials, 47:175

human immunodeficiency virus, magnetic resonance imaging, 47:175

human immunodeficiency virus, substance abuse, 47:175

impulsivity, antisocial disorder, 48:257

impulsivity, borderline disorder, 48:257

impulsivity, neurological soft signs, 48:257

impulsivity, personality disorder, 48:257

magnetic resonance imaging, auditory evoked potential P3, 47:175

magnetic resonance imaging, cortical atrophy, 47:175

magnetic resonance imaging, event related potentials, 47:175

magnetic resonance imaging, human immunodeficiency virus, 47:175

magnetic resonance imaging, substance abuse, 47:175

memory, alcohol dependence, 46:175

memory, frontal lobe, 46:175

memory, schizophrenia, 46:175

memory, Wisconsin Card Sorting Test, 46:175

neurological soft signs, antisocial disorder, 48:257

neurological soft signs, borderline disorder, 48:257

neurological soft signs, impulsivity, 48:257

neurological soft signs, personality disorder, 48:257

obsessive-compulsive disorder, eye movements, 48:191

obsessive-compulsive disorder, frontal lobe, 48:191

obsessive-compulsive disorder, Wisconsin Card Sorting Test, 48:191

personality disorder, antisocial, 48:257

personality disorder, borderline, 48:257

personality disorder, impulsivity, 48:257

personality disorder, neurological soft signs, 48:257

saccadic eye movements, 48:191

saccadic eye movements, frontal lobe, 48:191

saccadic eye movements, obsessive-compulsive disorder, 48:191

saccadic eye movements, Wisconsin Card Sorting Test, 48:191

schizophrenia, alcohol dependence, 46:175

schizophrenia, frontal lobe, 46:175

**Neuropsychology continued**

- schizophrenia, memory, 46:175
- schizophrenia, Wisconsin Card Sorting Test, 46:175
- smooth pursuit eye movements, 48:191
- smooth pursuit eye movements, frontal lobe, 48:191
- smooth pursuit eye movements, obsessive-compulsive disorder, 48:191
- smooth pursuit eye movements, Wisconsin Card Sorting Test, 48:191
- substance abuse, auditory evoked potential P3, 47:175
- substance abuse, cortical atrophy, 47:175
- substance abuse, event related potentials, 47:175
- substance abuse, human immunodeficiency virus, 47:175
- substance abuse, magnetic resonance imaging, 47:175
- Wisconsin Card Sorting Test, alcohol dependence, 46:175
- Wisconsin Card Sorting Test, eye movements, 48:191
- Wisconsin Card Sorting Test, frontal lobe, 46:175, 48:191
- Wisconsin Card Sorting Test, memory, 46:175
- Wisconsin Card Sorting Test, obsessive-compulsive disorder, 48:191
- Wisconsin Card Sorting Test, saccadic eye movements, 48:191
- Wisconsin Card Sorting Test, schizophrenia, 46:175
- Wisconsin Card Sorting Test, smooth pursuit eye movements, 48:191

**Nimodipine**

- affective disorder, bipolar subtype, 49:257
- affective disorder, calcium channel blockers, 49:257
- affective disorder, rapid cycling, 49:257
- affective disorder, therapeutic response, 49:257
- bipolar subtype, affective disorder, 49:257
- bipolar subtype, calcium channel blockers, 49:257
- bipolar subtype, rapid cycling, 49:257
- bipolar subtype, therapeutic response, 49:257
- calcium channel blockers, affective disorder, 49:257
- calcium channel blockers, bipolar subtype, 49:257

**Nimodipine continued**

- calcium channel blockers, therapeutic response, 49:257
- rapid cycling, affective disorder, 49:257
- rapid cycling, bipolar subtype, 49:257
- rapid cycling, calcium channel blockers, 49:257
- therapeutic response, affective disorder, 49:257
- therapeutic response, bipolar subtype, 49:257
- therapeutic response, calcium channel blockers, 49:257
- therapeutic response, rapid cycling, 49:257
- Obsessive-compulsive disorder**
- anxiety disorder, attention, 49:183
- anxiety disorder, auditory N200, 49:167
- anxiety disorder, event related potentials, 49:167
- anxiety disorder, laterality, 49:167
- anxiety disorder, neurological soft signs, 49:167
- anxiety disorder, P3 component, 49:167
- anxiety disorder, Posner task, 49:183
- anxiety disorder, reaction time, 49:183
- anxiety disorder, spatial-linguistic conflict task, 49:183
- attention, anxiety disorder, 49:183
- attention, Posner task, 49:183
- attention, reaction time, 49:183
- attention, spatial-linguistic conflict task, 49:183
- auditory N200, anxiety disorder, 49:167
- auditory N200, event related potentials, 49:167
- auditory N200, laterality, 49:167
- auditory N200, neurological soft signs, 49:167
- auditory N200, P3 component, 49:167
- behavior therapy, exposure, 49:63
- behavior therapy, fluvoxamine, 49:63
- event related potentials, anxiety disorder, 49:167
- event related potentials, auditory N200, 49:167
- event related potentials, laterality, 49:167
- event related potentials, neurological soft signs, 49:167
- event related potentials, P3 component, 49:167
- exposure, behavior therapy, 49:63
- exposure, fluvoxamine, 49:63
- eye movements, frontal lobe, 48:191



- Obsessive-compulsive disorder** continued  
 eye movements, neuropsychology, 48:191  
 eye movements, saccadic, 48:191  
 eye movements, smooth pursuit, 48:191  
 eye movements, Wisconsin Card Sorting Test, 48:191  
 fluvoxamine, behavior therapy, 49:63  
 fluvoxamine, exposure, 49:63  
 frontal lobe, eye movements, 48:191  
 frontal lobe, neuropsychology, 48:191  
 frontal lobe, saccadic eye movements, 48:191  
 frontal lobe, smooth pursuit eye movements, 48:191  
 frontal lobe, Wisconsin Card Sorting Test, 48:191  
 laterality, anxiety disorder, 49:167  
 laterality, auditory N200, 49:167  
 laterality, event related potentials, 49:167  
 laterality, neurological soft signs, 49:167  
 laterality, P3 component, 49:167  
 neurological soft signs, anxiety disorder, 49:167  
 neurological soft signs, auditory N200, 49:167  
 neurological soft signs, event related potentials, 49:167  
 neurological soft signs, laterality, 49:167  
 neurological soft signs, P3 component, 49:167  
 neuropsychology, eye movements, 48:191  
 neuropsychology, frontal lobe, 48:191  
 neuropsychology, saccadic, 48:191  
 neuropsychology, smooth pursuit eye movements, 48:191  
 neuropsychology, Wisconsin Card Sorting Test, 48:191  
 P3 component, anxiety disorder, 49:167  
 P3 component, auditory N200, 49:167  
 P3 component, event related potentials, 49:167  
 P3 component, laterality, 49:167  
 P3 component, neurological soft signs, 49:167  
 Posner task, anxiety disorder, 49:183  
 Posner task, attention, 49:183  
 Posner task, reaction time, 49:183  
 Posner task, spatial-linguistic conflict task, 49:183  
 reaction time, anxiety disorder, 49:183  
 reaction time, attention, 49:183  
 reaction time, Posner task, 49:183  
 reaction time, spatial-linguistic conflict task, 49:183
- Obsessive-compulsive disorder** continued  
 saccadic eye movements, 48:191  
 saccadic eye movements, frontal lobe, 48:191  
 saccadic eye movements, neuropsychology, 48:191  
 saccadic eye movements, Wisconsin Card Sorting Test, 48:191  
 smooth pursuit eye movements, 48:191  
 smooth pursuit eye movements, frontal lobe, 48:191  
 smooth pursuit eye movements, neuropsychology, 48:191  
 smooth pursuit eye movements, Wisconsin Card Sorting Test, 48:191  
 spatial-linguistic conflict task, anxiety disorder, 49:183  
 spatial-linguistic conflict task, attention, 49:183  
 spatial-linguistic conflict task, Posner task, 49:183  
 spatial-linguistic conflict task, reaction time, 49:183  
 Wisconsin Card Sorting Test, eye movements, 48:191  
 Wisconsin Card Sorting Test, frontal lobe, 48:191  
 Wisconsin Card Sorting Test, neuropsychology, 48:191  
 Wisconsin Card Sorting Test, saccadic eye movements, 48:191  
 Wisconsin Card Sorting Test, smooth pursuit eye movements, 48:191
- Opioids**  
 growth hormone, kappa agonist, 47:267  
 growth hormone, motor tics, 47:267  
 growth hormone, prolactin, 47:267  
 growth hormone, spiradoline, 47:267  
 growth hormone, Tourette's syndrome, 47:267  
 kappa agonist, growth hormone, 47:267  
 kappa agonist, motor tics, 47:267  
 kappa agonist, prolactin, 47:267  
 kappa agonist, spiradoline, 47:267  
 kappa agonist, Tourette's syndrome, 47:267  
 motor tics, kappa agonist, 47:267  
 motor tics, spiradoline, 47:267  
 motor tics, Tourette's syndrome, 47:267  
 prolactin, growth hormone, 47:267  
 prolactin, kappa agonist, 47:267  
 prolactin, spiradoline, 47:267  
 prolactin, Tourette's syndrome, 47:267  
 spiradoline, growth hormone, 47:267

**Opioids continued**

spiradoline, motor tics, 47:267  
 spiradoline, prolactin, 47:267  
 spiradoline, Tourette's syndrome, 47:267  
 Tourette's syndrome, growth hormone, 47:267  
 Tourette's syndrome, kappa agonist, 47:267  
 Tourette's syndrome, motor tics, 47:267  
 Tourette's syndrome, prolactin, 47:267  
 Tourette's syndrome, spiradoline, 47:267

**Oxytocin**

arginine vasopressin, electrodermal response, 48:107  
 arginine vasopressin, electromyography, 48:107  
 arginine vasopressin, heart rate response, 48:107  
 arginine vasopressin, personal combat imagery, 48:107  
 arginine vasopressin, posttraumatic stress syndrome, 48:107  
 electrodermal response, arginine vasopressin, 48:107  
 electrodermal response, electromyography, 48:107  
 electrodermal response, heart rate response, 48:107  
 electrodermal response, personal combat imagery, 48:107  
 electrodermal response, posttraumatic stress syndrome, 48:107  
 electromyography, arginine vasopressin, 48:107  
 electromyography, electrodermal response, 48:107  
 electromyography, heart rate response, 48:107  
 electromyography, personal combat imagery, 48:107  
 electromyography, posttraumatic stress syndrome, 48:107  
 heart rate response, arginine vasopressin, 48:107  
 heart rate response, electrodermal response, 48:107  
 heart rate response, electromyography, 48:107  
 heart rate response, personal combat imagery, 48:107  
 heart rate response, posttraumatic stress syndrome, 48:107  
 personal combat imagery, arginine vasopressin, 48:107  
 personal combat imagery, electrodermal response, 48:107  
 personal combat imagery, electromyography, 48:107

**Oxytocin continued**

personal combat imagery, heart rate response, 48:107  
 personal combat imagery, posttraumatic stress syndrome, 48:107  
 posttraumatic stress syndrome, arginine vasopressin, 48:107  
 posttraumatic stress syndrome, electrodermal response, 48:107  
 posttraumatic stress syndrome, electromyography, 48:107  
 posttraumatic stress syndrome, heart rate response, 48:107  
 posttraumatic stress syndrome, personal combat imagery, 48:107  
 posttraumatic stress syndrome, Vietnam veterans, 48:107

**Panic attacks**

blood pressure, lactate infusion, 46:79  
 blood pressure, menstrual cycle, 46:79  
 blood pressure, premenstrual syndrome, 46:79  
 lactate infusion, blood pressure, 46:79  
 lactate infusion, menstrual cycle, 46:79  
 lactate infusion, premenstrual syndrome, 46:79  
 menstrual cycle, blood pressure, 46:79  
 menstrual cycle, lactate infusion, 46:79  
 premenstrual syndrome, blood pressure, 46:79  
 premenstrual syndrome, lactate infusion, 46:79

**Panic disorder**

agoraphobia, alcohol dependence, 46:285  
 agoraphobia, anxiety disorder, 46:285  
 agoraphobia, comorbidity, 46:285  
 agoraphobia, substance abuse, 46:285  
 alcohol dependence, agoraphobia, 46:285  
 alcohol dependence, anxiety disorder, 46:285  
 alcohol dependence, comorbidity, 46:285  
 alcohol dependence, substance abuse, 46:285  
 anxiety disorder, agoraphobia, 46:285  
 anxiety disorder, alcohol dependence, 46:285  
 anxiety disorder, autonomic nervous system, 46:89  
 anxiety disorder, carbon dioxide, 47:1, 47:295  
 anxiety disorder, clomipramine, 47:295  
 anxiety disorder, comorbidity, 46:285  
 anxiety disorder, cortisol, 48:119  
 anxiety disorder, diazepam response, 47:151  
 anxiety disorder, eye movements, 47:151

**Panic disorder continued**

anxiety disorder, fluvoxamine, 48:119  
 anxiety disorder,  $\text{HCO}_3$ , 47:1  
 anxiety disorder, heart rate, 46:89  
 anxiety disorder, hyperventilation, 47:1  
 anxiety disorder, joint hypermobility syndrome, 46:59  
 anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 anxiety disorder, norepinephrine, 48:119  
 anxiety disorder, orthostatic challenge, 46:89  
 anxiety disorder,  $p\text{CO}_2$ , 47:1  
 anxiety disorder, personality, 47:151  
 anxiety disorder,  $p\text{H}$ , 47:1  
 anxiety disorder,  $p\text{O}_2$ , 47:1  
 anxiety disorder, power spectral analysis of heart rate, 46:89  
 anxiety disorder, respiratory alkalosis, 47:1  
 anxiety disorder, saccadic eye movement velocity, 47:151  
 anxiety disorder, serotonin, 48:119  
 anxiety disorder, substance abuse, 46:285  
 anxiety disorder, Tridimensional Personality Questionnaire, 47:151  
 anxiety disorder, ventilatory response, 47:295  
 anxiety disorder, yohimbine, 48:119  
 autonomic nervous system, anxiety disorder, 46:89  
 autonomic nervous system, heart rate, 46:89  
 autonomic nervous system, orthostatic challenge, 46:89  
 autonomic nervous system, power spectral analysis of heart rate, 46:89  
 carbon dioxide, anxiety disorder, 47:295  
 carbon dioxide, clomipramine, 47:295  
 carbon dioxide, ventilatory response, 47:295  
 carbon dioxide, anxiety disorder, 47:1  
 carbon dioxide,  $\text{HCO}_3$ , 47:1  
 carbon dioxide, hyperventilation, 47:1  
 carbon dioxide,  $p\text{CO}_2$ , 47:1  
 carbon dioxide,  $p\text{H}$ , 47:1  
 carbon dioxide,  $p\text{O}_2$ , 47:1  
 carbon dioxide, respiratory alkalosis, 47:1  
 clomipramine, anxiety disorder, 47:295  
 comorbidity, agoraphobia, 46:285  
 comorbidity, alcohol dependence, 46:285  
 comorbidity, anxiety disorder, 46:285  
 comorbidity, substance abuse, 46:285  
 cortisol, anxiety disorder, 48:119  
 cortisol, fluvoxamine, 48:119  
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 48:119

**Panic disorder continued**

cortisol, norepinephrine, 48:119  
 cortisol, serotonin, 48:119  
 cortisol, yohimbine, 48:119  
 diazepam response, anxiety disorder, 47:151  
 diazepam response, eye movements, 47:151  
 diazepam response, personality, 47:151  
 diazepam response, saccadic eye movement velocity, 47:151  
 diazepam response, Tridimensional Personality Questionnaire, 47:151  
 eye movements, anxiety disorder, 47:151  
 eye movements, diazepam response, 47:151  
 eye movements, personality, 47:151  
 eye movements, saccadic eye movement velocity, 47:151  
 eye movements, Tridimensional Personality Questionnaire, 47:151  
 fluvoxamine, anxiety disorder, 48:119  
 fluvoxamine, cortisol, 48:119  
 fluvoxamine, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 fluvoxamine, norepinephrine, 48:119  
 fluvoxamine, reuptake inhibitor, 48:119  
 fluvoxamine, serotonin, 48:119  
 fluvoxamine, yohimbine, 48:119  
 $\text{HCO}_3$ , anxiety disorder, 47:1  
 $\text{HCO}_3$ , carbon dioxide, 47:1  
 $\text{HCO}_3$ , hyperventilation, 47:1  
 $\text{HCO}_3$ ,  $p\text{CO}_2$ , 47:1  
 $\text{HCO}_3$ ,  $p\text{H}$ , 47:1  
 $\text{HCO}_3$ ,  $p\text{O}_2$ , 47:1  
 $\text{HCO}_3$ , respiratory alkalosis, 47:1  
 heart rate, anxiety disorder, 46:89  
 heart rate, autonomic nervous system, 46:89  
 heart rate, orthostatic challenge, 46:89  
 heart rate, power spectral analysis of heart rate, 46:89  
 hyperventilation, anxiety disorder, 47:1  
 hyperventilation, carbon dioxide, 47:1  
 hyperventilation,  $\text{HCO}_3$ , 47:1  
 hyperventilation,  $p\text{CO}_2$ , 47:1  
 hyperventilation,  $p\text{H}$ , 47:1  
 hyperventilation,  $p\text{O}_2$ , 47:1  
 hyperventilation, respiratory alkalosis, 47:1  
 joint hypermobility syndrome, anxiety disorder, 46:59  
 3-methoxy-4-hydroxyphenylglycol, anxiety disorder, 48:119  
 3-methoxy-4-hydroxyphenylglycol, cortisol, 48:119



**Panic disorder continued**

3-methoxy-4-hydroxyphenylglycol, fluvoxamine, 48:119

3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119

3-methoxy-4-hydroxyphenylglycol, serotonin, 48:119

3-methoxy-4-hydroxyphenylglycol, yohimbine, 48:119

norepinephrine, anxiety disorder, 48:119

norepinephrine, cortisol, 48:119

norepinephrine, fluvoxamine, 48:119

norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119

norepinephrine, serotonin, 48:119

norepinephrine, yohimbine, 48:119

orthostatic challenge, anxiety disorder, 46:89

orthostatic challenge, autonomic nervous system, 46:89

orthostatic challenge, heart rate, 46:89

orthostatic challenge, power spectral analysis of heart rate, 46:89

$p\text{CO}_2$ , anxiety disorder, 47:1

$p\text{CO}_2$ ,  $\text{HCO}_3$ , 47:1

$p\text{CO}_2$ , hyperventilation, 47:1

$p\text{CO}_2$ ,  $\text{pH}$ , 47:1

$p\text{CO}_2$ ,  $\text{pO}_2$ , 47:1

$p\text{CO}_2$ , respiratory alkalosis, 47:1

personality, anxiety disorder, 47:151

personality, diazepam response, 47:151

personality, eye movements, 47:151

personality, saccadic eye movement velocity, 47:151

personality, Tridimensional Personality Questionnaire, 47:151

$\text{pH}$ , anxiety disorder, 47:1

$\text{pH}$ , carbon dioxide, 47:1

$\text{pH}$ ,  $\text{HCO}_3$ , 47:1

$\text{pH}$ , hyperventilation, 47:1

$\text{pH}$ ,  $p\text{CO}_2$ , 47:1

$\text{pH}$ ,  $p\text{CO}_2$ , 47:1

$\text{pH}$ , respiratory alkalosis, 47:1

$p\text{CO}_2$ , anxiety disorder, 47:1

$p\text{CO}_2$ , carbon dioxide, 47:1

$p\text{CO}_2$ ,  $\text{HCO}_3$ , 47:1

$p\text{CO}_2$ , hyperventilation, 47:1

$\text{pO}_2$ ,  $p\text{CO}_2$ , 47:1

$\text{pO}_2$ ,  $\text{pH}$ , 47:1

$\text{pO}_2$ , respiratory alkalosis, 47:1

power spectral analysis of heart rate, anxiety disorder, 46:89

**Panic disorder continued**

power spectral analysis of heart rate, autonomic nervous system, 46:89

power spectral analysis of heart rate, orthostatic challenge, 46:89

respiratory alkalosis, anxiety disorder, 47:1

respiratory alkalosis, carbon dioxide, 47:1

respiratory alkalosis,  $\text{HCO}_3$ , 47:1

respiratory alkalosis, hyperventilation, 47:1

respiratory alkalosis,  $p\text{CO}_2$ , 47:1

respiratory alkalosis,  $\text{pH}$ , 47:1

respiratory alkalosis,  $\text{pO}_2$ , 47:1

reuptake inhibitor, serotonin, 48:119

saccadic eye movement velocity, anxiety disorder, 47:151

saccadic eye movement velocity, diazepam response, 47:151

saccadic eye movement velocity, personality, 47:151

saccadic eye movement velocity, Tridimensional Personality Questionnaire, 47:151

serotonin, anxiety disorder, 48:119

serotonin, cortisol, 48:119

serotonin, fluvoxamine, 48:119

serotonin, 3-methoxy-4-hydroxyphenylglycol, 48:119

serotonin, norepinephrine, 48:119

serotonin, reuptake inhibitor, 48:119

serotonin, yohimbine, 48:119

substance abuse, agoraphobia, 46:285

substance abuse, alcohol dependence, 46:285

substance abuse, anxiety disorder, 46:285

substance abuse, comorbidity, 46:285

Tridimensional Personality Questionnaire, anxiety disorder, 47:151

Tridimensional Personality Questionnaire, diazepam response, 47:151

Tridimensional Personality Questionnaire, eye movements, 47:151

Tridimensional Personality Questionnaire, saccadic eye movement velocity, 47:151

ventilatory response, anxiety disorder, 47:295

ventilatory response, carbon dioxide, 47:295

ventilatory response, clomipramine, 47:295

yohimbine, anxiety disorder, 48:119

yohimbine, cortisol, 48:119

yohimbine, fluvoxamine, 48:119

yohimbine, 3-methoxy-4-hydroxyphenylglycol, 48:119

yohimbine, norepinephrine, 48:119

yohimbine, serotonin, 48:119

**Paroxetine**

- calmodulin affinity chromatography, endogenous serotonin uptake inhibitors, 47:121
- calmodulin affinity chromatography, imipramine, 47:121
- calmodulin affinity chromatography, serotonin, 47:121
- endogenous serotonin uptake inhibitors, calmodulin affinity chromatography, 47:121
- endogenous serotonin uptake inhibitors, imipramine, 47:121
- endogenous serotonin uptake inhibitors, serotonin, 47:121
- imipramine, calmodulin affinity chromatography, 47:121
- imipramine, endogenous serotonin uptake inhibitors, 47:121
- imipramine, serotonin, 47:121
- serotonin, calmodulin affinity chromatography, 47:121
- serotonin, endogenous serotonin uptake inhibitors, 47:121
- serotonin, imipramine, 47:121

**Personality**

- affective disorder, divorce, 46:165
- affective disorder, dream masochism, 46:165
- affective disorder, gender differences, 46:165
- affective disorder, sex role identification, 46:165
- affective disorder, sleep, 46:165
- aggression, genetics, 48:229
- aggression, impulsivity, 48:229
- aggression, twin studies, 48:229
- anxiety disorders, diazepam response, 47:151
- anxiety disorders, eye movements, 47:151
- anxiety disorders, panic disorder, 47:151
- anxiety disorders, saccadic eye movement velocity, 47:151
- anxiety disorders, Tridimensional Personality Questionnaire, 47:151
- diazepam response, anxiety disorders, 47:151
- diazepam response, eye movements, 47:151
- diazepam response, panic disorder, 47:151
- diazepam response, saccadic eye movement velocity, 47:151
- diazepam response, Tridimensional Personality Questionnaire, 47:151
- divorce, affective disorder, 46:165
- divorce, dream masochism, 46:165
- divorce, gender differences, 46:165
- divorce, sex role identification, 46:165

**Personality continued**

- divorce, sleep, 46:165
- dream masochism, affective disorder, 46:165
- dream masochism, divorce, 46:165
- dream masochism, gender differences, 46:165
- dream masochism, sex role identification, 46:165
- dream masochism, sleep, 46:165
- eye movements, anxiety disorders, 47:151
- eye movements, diazepam response, 47:151
- eye movements, panic disorder, 47:151
- eye movements, saccadic eye movement velocity, 47:151
- eye movements, Tridimensional Personality Questionnaire, 47:151
- gender differences, affective disorder, 46:165
- gender differences, divorce, 46:165
- gender differences, dream masochism, 46:165
- gender differences, sex role identification, 46:165
- gender differences, sleep, 46:165
- genetics, aggression, 48:229
- genetics, impulsivity, 48:229
- genetics, physical anhedonia, 46:47
- genetics, psychosis proneness scales, 46:47
- genetics, schizotypy, 46:47
- genetics, twin studies, 48:229
- impulsivity, aggression, 48:229
- impulsivity, genetics, 48:229
- impulsivity, twin studies, 48:229
- panic disorder, anxiety disorders, 47:151
- panic disorder, diazepam response, 47:151
- panic disorder, eye movements, 47:151
- panic disorder, saccadic eye movement velocity, 47:151
- panic disorder, Tridimensional Personality Questionnaire, 47:151
- physical anhedonia, genetics, 46:47
- physical anhedonia, psychosis proneness scales, 46:47
- physical anhedonia, schizotypy, 46:47
- psychosis proneness scales, genetics, 46:47
- psychosis proneness scales, physical anhedonia, 46:47
- psychosis proneness scales, schizotypy, 46:47
- saccadic eye movement velocity, anxiety disorders, 47:151
- saccadic eye movement velocity, diazepam response, 47:151
- saccadic eye movement velocity, eye movements, 47:151

**Personality continued**

- saccadic eye movement velocity, panic disorder, 47:151
- saccadic eye movement velocity, Tridimensional Personality Questionnaire, 47:151
- schizotypy, genetics, 46:47
- schizotypy, physical anhedonia, 46:47
- schizotypy, psychosis proneness scales, 46:47
- sex role identification, affective disorder, 46:165
- sex role identification, divorce, 46:165
- sex role identification, dream masochism, 46:165
- sex role identification, gender differences, 46:165
- sex role identification, sleep, 46:165
- sleep, affective disorder, 46:165
- sleep, divorce, 46:165
- sleep, dream masochism, 46:165
- sleep, gender differences, 46:165
- sleep, sex role identification, 46:165
- Tridimensional Personality Questionnaire, anxiety disorders, 47:151
- Tridimensional Personality Questionnaire, diazepam response, 47:151
- Tridimensional Personality Questionnaire, eye movements, 47:151
- Tridimensional Personality Questionnaire, panic disorder, 47:151
- Tridimensional Personality Questionnaire, saccadic eye movement velocity, 47:151
- twin studies, aggression, 48:229
- twin studies, genetics, 48:229
- twin studies, impulsivity, 48:229

**Personality disorders**

- affective disorder, family history, 48:243
- affective disorder, schizophrenia, 48:243
- antisocial disorder, borderline disorder, 48:257
- antisocial disorder, family history, 48:267
- antisocial disorder, genetics, 48:267
- antisocial disorder, impulsivity, 48:257
- antisocial disorder, neurological soft signs, 48:257
- antisocial disorder, neuropsychology, 48:257
- antisocial disorder, sadistic disorder, 48:267
- antisocial disorder, veterans, 48:267
- borderline disorder, antisocial disorder, 48:257
- borderline disorder, impulsivity, 48:257
- borderline disorder, neurological soft signs, 48:257

**Personality disorders continued**

- borderline disorder, neuropsychology, 48:257
- family history, affective disorder, 48:243
- family history, antisocial disorder, 48:267
- family history, sadistic disorder, 48:267
- family history, schizophrenia, 48:243
- family history, veterans, 48:267
- genetics, antisocial disorder, 48:267
- genetics, sadistic disorder, 48:267
- genetics, veterans, 48:267
- impulsivity, antisocial disorder, 48:257
- impulsivity, borderline disorder, 48:257
- impulsivity, neurological soft signs, 48:257
- impulsivity, neuropsychology, 48:257
- laterality, neurological soft signs, 48:257
- laterality, Wisconsin Card Sorting Test, 48:257
- neurological soft signs, antisocial disorder, 48:257
- neurological soft signs, borderline disorder, 48:257
- neurological soft signs, impulsivity, 48:257
- neurological soft signs, laterality, 48:257
- neurological soft signs, neuropsychology, 48:257
- neurological soft signs, Wisconsin Card Sorting Test, 48:257
- neuropsychology, antisocial disorder, 48:257
- neuropsychology, borderline disorder, 48:257
- neuropsychology, impulsivity, 48:257
- neuropsychology, neurological soft signs, 48:257
- sadistic disorder, antisocial disorder, 48:267
- sadistic disorder, family history, 48:267
- sadistic disorder, genetics, 48:267
- sadistic disorder, veterans, 48:267
- schizophrenia, affective disorder, 48:243
- schizophrenia, family history, 48:243
- veterans, antisocial disorder, 48:267
- veterans, family history, 48:267
- veterans, sadistic disorder, 48:267
- Wisconsin Card Sorting Test, laterality, 48:257
- Wisconsin Card Sorting Test, neurological soft signs, 48:257

**Phenylalanine**

- amino acids, circadian rhythm, 47:187
- amino acids, dopamine, 47:187
- amino acids, neuroleptics, 47:187
- amino acids, neutral serum amino acids, 47:187
- amino acids, schizophrenia, 47:187



**Phenylalanine continued**

amino acids, therapeutic response, 47:187  
 circadian rhythm, amino acids, 47:187  
 circadian rhythm, dopamine, 47:187  
 circadian rhythm, neuroleptics, 47:187  
 circadian rhythm, neutral serum amino acids, 47:187  
 circadian rhythm, schizophrenia, 47:187  
 circadian rhythm, therapeutic response, 47:187  
 dopamine, amino acids, 47:187  
 dopamine, circadian rhythm, 47:187  
 dopamine, neuroleptics, 47:187  
 dopamine, neutral serum amino acids, 47:187  
 dopamine, schizophrenia, 47:187  
 dopamine, therapeutic response, 47:187  
 neuroleptics, amino acids, 47:187  
 neuroleptics, circadian rhythm, 47:187  
 neuroleptics, dopamine, 47:187  
 neuroleptics, neutral serum amino acids, 47:187  
 neuroleptics, schizophrenia, 47:187  
 neuroleptics, therapeutic response, 47:187  
 neutral serum amino acids, circadian rhythm, 47:187  
 neutral serum amino acids, dopamine, 47:187  
 neutral serum amino acids, neuroleptics, 47:187  
 neutral serum amino acids, schizophrenia, 47:187  
 neutral serum amino acids, therapeutic response, 47:187  
 schizophrenia, amino acids, 47:187  
 schizophrenia, circadian rhythm, 47:187  
 schizophrenia, dopamine, 47:187  
 schizophrenia, neuroleptics, 47:187  
 schizophrenia, neutral serum amino acids, 47:187  
 schizophrenia, therapeutic response, 47:187  
 therapeutic response, amino acids, 47:187  
 therapeutic response, circadian rhythm, 47:187  
 therapeutic response, dopamine, 47:187  
 therapeutic response, neuroleptics, 47:187  
 therapeutic response, neutral serum amino acids, 47:187  
 therapeutic response, schizophrenia, 47:187

**Phosphatidylethanolamine**  
 erythrocytes, membrane phospholipids, 49:89  
 erythrocytes, schizophrenia, 49:89  
 erythrocytes, sphingomyelin, 49:89  
 membrane phospholipids, erythrocytes, 49:89

**Phosphatidylethanolamine continued**

membrane phospholipids, schizophrenia, 49:89  
 membrane phospholipids, sphingomyelin, 49:89  
 schizophrenia, erythrocytes, 49:89  
 schizophrenia, membrane phospholipids, 49:89  
 schizophrenia, sphingomyelin, 49:89  
 sphingomyelin, erythrocytes, 49:89  
 sphingomyelin, membrane phospholipids, 49:89  
 sphingomyelin, schizophrenia, 49:89

**Phototherapy**  
 affective disorder, carbohydrate craving, 46:107  
 affective disorder, circadian rhythms, 46:107  
 affective disorder, circannual rhythm, 46:29, 47:79  
 affective disorder, diet, 46:107  
 affective disorder, eating sweets, 46:107  
 affective disorder, electrooculography, 49:99  
 affective disorder, eye blink rate, 47:79  
 affective disorder, gender differences, 47:79  
 affective disorder, homovanillic acid, 46:19  
 affective disorder, 5-hydroxyindoleacetic acid, 46:19  
 affective disorder, language, 47:99  
 affective disorder, laterality, 47:99  
 affective disorder, light visor treatment, 46:29  
 affective disorder, 3-methoxy-4-hydroxy-phenylglycol, 46:19  
 affective disorder, motor performance, 47:99  
 affective disorder, norepinephrine, 46:19  
 affective disorder, orthostatic challenge, 46:19  
 aging, depressed mood in elderly women, 47:87  
 aging, sleep, 47:87  
 carbohydrate craving, affective disorder, 46:107  
 carbohydrate craving, circadian rhythms, 46:107  
 carbohydrate craving, seasonal affective disorder, 46:107  
 cerebrospinal fluid, homovanillic acid, 46:19  
 cerebrospinal fluid, 5-hydroxyindoleacetic acid, 46:19  
 cerebrospinal fluid, 3-methoxy-4-hydroxy-phenylglycol, 46:19  
 cerebrospinal fluid, norepinephrine, 46:19  
 circadian rhythms, affective disorder, 46:107  
 circadian rhythms, carbohydrate craving, 46:107  
 circadian rhythms, diet, 46:107

**Phototherapy continued**

circadian rhythms, eating sweets, 46:107  
 circadian rhythms, seasonal affective disorder, 46:107  
 circannual rhythms, affective disorder, 46:29, 47:79  
 circannual rhythms, eye blink rate, 47:79  
 circannual rhythms, gender differences, 47:79  
 circannual rhythms, light visor treatment, 46:29  
 circannual rhythms, seasonal affective disorder, 46:29, 47:79  
 depressed mood in elderly women, aging, 47:87  
 depressed mood in elderly women, sleep, 47:87  
 diet, affective disorder, 46:107  
 diet, circadian rhythms, 46:107  
 diet, eating sweets, 46:107  
 diet, seasonal affective disorder, 46:107  
 eating sweets, affective disorder, 46:107  
 eating sweets, carbohydrate craving, 46:107  
 eating sweets, circadian rhythms, 46:107  
 eating sweets, seasonal affective disorder, 46:107  
 electrooculography, affective disorder, 49:99  
 electrooculography, seasonal affective disorder, 49:99  
 eye blink rate, affective disorder, 47:79  
 eye blink rate, circannual rhythms, 47:79  
 eye blink rate, gender differences, 47:79  
 eye blink rate, seasonal affective disorder, 47:79  
 gender differences, affective disorder, 47:79  
 gender differences, circannual rhythms, 47:79  
 gender differences, eye blink rate, 47:79  
 gender differences, seasonal affective disorder, 47:79  
 homovanillic acid, affective disorder, 46:19  
 homovanillic acid, cerebrospinal fluid, 46:19  
 homovanillic acid, 5-hydroxyindoleacetic acid, 46:19  
 homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 homovanillic acid, norepinephrine, 46:19  
 homovanillic acid, orthostatic challenge, 46:19  
 homovanillic acid, seasonal affective disorder, 46:19  
 5-hydroxyindoleacetic acid, affective disorder, 46:19  
 5-hydroxyindoleacetic acid, cerebrospinal fluid, 46:19

**Phototherapy continued**

5-hydroxyindoleacetic acid, homovanillic acid, 46:19  
 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 5-hydroxyindoleacetic acid, norepinephrine, 46:19  
 5-hydroxyindoleacetic acid, orthostatic challenge, 46:19  
 5-hydroxyindoleacetic acid, seasonal affective disorder, 46:19  
 language, affective disorder, 47:99  
 language, laterality, 47:99  
 language, motor performance, 47:99  
 language, seasonal affective disorder, 47:99  
 laterality, affective disorder, 47:99  
 laterality, language, 47:99  
 laterality, motor performance, 47:99  
 laterality, seasonal affective disorder, 47:99  
 light visor treatment, affective disorder, 46:29  
 light visor treatment, circannual rhythm, 46:29  
 light visor treatment, seasonal affective disorder, 46:29  
 3-methoxy-4-hydroxyphenylglycol, affective disorder, 46:19  
 3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 46:19  
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:19  
 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, 46:19  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:19  
 3-methoxy-4-hydroxyphenylglycol, orthostatic challenge, 46:19  
 3-methoxy-4-hydroxyphenylglycol, seasonal affective disorder, 46:19  
 motor performance, affective disorder, 47:99  
 motor performance, language, 47:99  
 motor performance, laterality, 47:99  
 motor performance, seasonal affective disorder, 47:99  
 norepinephrine, affective disorder, 46:19  
 norepinephrine, cerebrospinal fluid, 46:19  
 norepinephrine, homovanillic acid, 46:19  
 norepinephrine, 5-hydroxyindoleacetic acid, 46:19  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:19  
 norepinephrine, orthostatic challenge, 46:19

**Phototherapy continued**

- norepinephrine, seasonal affective disorder, 46:19
- orthostatic challenge, affective disorder, 46:19
- orthostatic challenge, homovanillic acid, 46:19
- orthostatic challenge, 5-hydroxyindoleacetic acid, 46:19
- orthostatic challenge, 3-methoxy-4-hydroxyphenylglycol, 46:19
- orthostatic challenge, norepinephrine, 46:19
- orthostatic challenge, seasonal affective disorder, 46:19
- seasonal affective disorder, carbohydrate craving, 46:107
- seasonal affective disorder, circadian rhythms, 46:107
- seasonal affective disorder, circannual rhythms, 46:29, 47:79
- seasonal affective disorder, diet, 46:107
- seasonal affective disorder, eating sweets, 46:107
- seasonal affective disorder, electrooculography, 49:99
- seasonal affective disorder, eye blink rate, 47:79
- seasonal affective disorder, gender differences, 47:79
- seasonal affective disorder, homovanillic acid, 46:19
- seasonal affective disorder, 5-hydroxyindoleacetic acid, 46:19
- seasonal affective disorder, language, 47:99
- seasonal affective disorder, laterality, 47:99
- seasonal affective disorder, light visor treatment, 46:29
- seasonal affective disorder, 3-methoxy-4-hydroxyphenylglycol, 46:19
- seasonal affective disorder, motor performance, 47:99
- seasonal affective disorder, norepinephrine, 46:19
- seasonal affective disorder, orthostatic challenge, 46:19
- sleep, aging, 47:87
- sleep, depressed mood in elderly women, 47:87

**Positron emission tomography**

- aging, dopamine D<sub>2</sub> receptor density, 49:219
- aging, gender differences, 49:219
- aging, illness duration, 49:219

**Positron emission tomography continued**

- aging, methylspiperone, 49:219
- aging, schizophrenia, 49:219
- aging, striatum, 49:219
- dopamine D<sub>2</sub> receptor density, aging, 49:219
- dopamine D<sub>2</sub> receptor density, gender differences, 49:219
- dopamine D<sub>2</sub> receptor density, illness duration, 49:219
- dopamine D<sub>2</sub> receptor density, methylspiperone, 49:219
- dopamine D<sub>2</sub> receptor density, schizophrenia, 49:219
- dopamine D<sub>2</sub> receptor density, striatum, 49:219
- gender differences, aging, 49:219
- gender differences, dopamine D<sub>2</sub> receptor density, 49:219
- gender differences, illness duration, 49:219
- gender differences, methylspiperone, 49:219
- gender differences, schizophrenia, 49:219
- gender differences, striatum, 49:219
- illness duration, aging, 49:219
- illness duration, dopamine D<sub>2</sub> receptor density, 49:219
- illness duration, gender differences, 49:219
- illness duration, methylspiperone, 49:219
- illness duration, schizophrenia, 49:219
- illness duration, striatum, 49:219
- methylspiperone, aging, 49:219
- methylspiperone, dopamine D<sub>2</sub> receptor density, 49:219
- methylspiperone, gender differences, 49:219
- methylspiperone, illness duration, 49:219
- methylspiperone, schizophrenia, 49:219
- methylspiperone, striatum, 49:219
- schizophrenia, aging, 49:219
- schizophrenia, dopamine D<sub>2</sub> receptor density, 49:219
- schizophrenia, gender differences, 49:219
- schizophrenia, illness duration, 49:219
- schizophrenia, methylspiperone, 49:219
- schizophrenia, striatum, 49:219
- striatum, aging, 49:219
- striatum, dopamine D<sub>2</sub> receptor density, 49:219
- striatum, gender differences, 49:219
- striatum, illness duration, 49:219
- striatum, methylspiperone, 49:219
- striatum, schizophrenia, 49:219

**Posttraumatic stress disorder**

- arginine vasopressin, electrodermal response, 48:107



**Posttraumatic stress disorder continued**

arginine vasopressin, electromyography, 48:107  
 arginine vasopressin, heart rate response, 48:107  
 arginine vasopressin, oxytocin, 48:107  
 arginine vasopressin, personal combat imagery, 48:107  
 arginine vasopressin, Vietnam veterans, 48:107  
 electrodermal response, arginine vasopressin, 48:107  
 electrodermal response, electromyography, 48:107  
 electrodermal response, heart rate response, 48:107  
 electrodermal response, oxytocin, 48:107  
 electrodermal response, personal combat imagery, 48:107  
 electrodermal response, Vietnam veterans, 48:107  
 electromyography, arginine vasopressin, 48:107  
 electromyography, electrodermal response, 48:107  
 electromyography, heart rate response, 48:107  
 electromyography, oxytocin, 48:107  
 electromyography, personal combat imagery, 48:107  
 electromyography, Vietnam veterans, 48:107  
 heart rate response, arginine vasopressin, 48:107  
 heart rate response, electrodermal response, 48:107  
 heart rate response, electromyography, 48:107  
 heart rate response, oxytocin, 48:107  
 heart rate response, personal combat imagery, 48:107  
 heart rate response, Vietnam veterans, 48:107  
 oxytocin, arginine vasopressin, 48:107  
 oxytocin, electrodermal response, 48:107  
 oxytocin, electromyography, 48:107  
 oxytocin, heart rate response, 48:107  
 oxytocin, personal combat imagery, 48:107  
 oxytocin, Vietnam veterans, 48:107  
 personal combat imagery, arginine vasopressin, 48:107  
 personal combat imagery, electrodermal response, 48:107  
 personal combat imagery, electromyography, 48:107  
 personal combat imagery, heart rate response, 48:107

**Posttraumatic stress disorder continued**

personal combat imagery, oxytocin, 48:107  
 personal combat imagery, Vietnam veterans, 48:107  
 Vietnam veterans, arginine vasopressin, 48:107  
 Vietnam veterans, electrodermal response, 48:107  
 Vietnam veterans, electromyography, 48:107  
 Vietnam veterans, heart rate response, 48:107  
 Vietnam veterans, oxytocin, 48:107  
 Vietnam veterans, personal combat imagery, 48:107

**Premenstrual syndrome**

blood pressure, lactate infusion, 46:79  
 blood pressure, menstrual cycle, 46:79  
 blood pressure, panic attacks, 46:79  
 lactate infusion, blood pressure, 46:79  
 lactate infusion, menstrual cycle, 46:79  
 lactate infusion, panic attacks, 46:79  
 menstrual cycle, blood pressure, 46:79  
 menstrual cycle, lactate infusion, 46:79  
 menstrual cycle, panic attacks, 46:79  
 panic attacks, blood pressure, 46:79  
 panic attacks, lactate infusion, 46:79  
 panic attacks, menstrual cycle, 46:79

**Prolactin**

affective disorder, antidepressant medication, 46:213  
 affective disorder, cortisol, 46:213  
 affective disorder, sleep deprivation, 46:213  
 affective disorder, thyroid stimulating hormone, 46:213  
 affective disorder, triiodothyronine, 46:213  
 antidepressant medication, affective disorder, 46:213  
 antidepressant medication, cortisol, 46:213  
 antidepressant medication, sleep deprivation, 46:213  
 antidepressant medication, thyroid stimulating hormone, 46:213  
 antidepressant medication, triiodothyronine, 46:213  
 circadian rhythm, schizophrenia, 47:187  
 circadian rhythm, tyrosine, 47:187  
 cortisol, affective disorder, 46:213  
 cortisol, antidepressant medication, 46:213  
 cortisol, sleep deprivation, 46:213  
 cortisol, thyroid stimulating hormone, 46:213  
 cortisol, triiodothyronine, 46:213  
 estradiol, follicle stimulating hormone, 48:153

**Prolactin continued**

estradiol, growth hormone, 48:153  
 estradiol, luteinizing hormone, 48:153  
 estradiol, normal volunteers, 48:153  
 estradiol, sleep deprivation, 48:153  
 estradiol, thyroid stimulating hormone, 48:153  
 estradiol, thyroxine, 48:153  
 estradiol, triiodothyronine, 48:153  
 follicle stimulating hormone, estradiol, 48:153  
 follicle stimulating hormone, growth hormone, 48:153  
 follicle stimulating hormone, luteinizing hormone, 48:153  
 follicle stimulating hormone, normal volunteers, 48:153  
 follicle stimulating hormone, sleep deprivation, 48:153  
 follicle stimulating hormone, thyroid stimulating hormone, 48:153  
 follicle stimulating hormone, thyroxine, 48:153  
 follicle stimulating hormone, triiodothyronine, 48:153  
 growth hormone, estradiol, 48:153  
 growth hormone, follicle stimulating hormone, 48:153  
 growth hormone, kappa agonist, 47:267  
 growth hormone, luteinizing hormone, 48:153  
 growth hormone, motor tics, 47:267  
 growth hormone, normal volunteers, 48:153  
 growth hormone, opioids, 47:267  
 growth hormone, sleep deprivation, 48:153  
 growth hormone, spiradoline, 47:267  
 growth hormone, thyroid stimulating hormone, 48:153  
 growth hormone, thyroxine, 48:153  
 growth hormone, Tourette's syndrome, 47:267  
 growth hormone, triiodothyronine, 48:153  
 kappa agonist, growth hormone, 47:267  
 kappa agonist, motor tics, 47:267  
 kappa agonist, opioids, 47:267  
 kappa agonist, spiradoline, 47:267  
 kappa agonist, Tourette's syndrome, 47:267  
 luteinizing hormone, estradiol, 48:153  
 luteinizing hormone, follicle stimulating hormone, 48:153  
 luteinizing hormone, growth hormone, 48:153

**Prolactin continued**

luteinizing hormone, normal volunteers, 48:153  
 luteinizing hormone, sleep deprivation, 48:153  
 luteinizing hormone, thyroid stimulating hormone, 48:153  
 luteinizing hormone, thyroxine, 48:153  
 luteinizing hormone, triiodothyronine, 48:153  
 motor tics, growth hormone, 47:267  
 motor tics, kappa agonist, 47:267  
 motor tics, opioids, 47:267  
 motor tics, spiradoline, 47:267  
 motor tics, Tourette's syndrome, 47:267  
 normal volunteers, estradiol, 48:153  
 normal volunteers, follicle stimulating hormone, 48:153  
 normal volunteers, growth hormone, 48:153  
 normal volunteers, luteinizing hormone, 48:153  
 normal volunteers, sleep deprivation, 48:153  
 normal volunteers, thyroid stimulating hormone, 48:153  
 normal volunteers, thyroxine, 48:153  
 normal volunteers, triiodothyronine, 48:153  
 opioids, growth hormone, 47:267  
 opioids, kappa agonist, 47:267  
 opioids, motor tics, 47:267  
 opioids, spiradoline, 47:267  
 opioids, Tourette's syndrome, 47:267  
 schizophrenia, circadian rhythm, 47:187  
 schizophrenia, tyrosine, 47:187  
 sleep deprivation, affective disorder, 46:213  
 sleep deprivation, antidepressant medication, 46:213  
 sleep deprivation, cortisol, 46:213  
 sleep deprivation, estradiol, 48:153  
 sleep deprivation, follicle stimulating hormone, 48:153  
 sleep deprivation, growth hormone, 48:153  
 sleep deprivation, luteinizing hormone, 48:153  
 sleep deprivation, normal volunteers, 48:153  
 sleep deprivation, thyroid stimulating hormone, 46:213, 48:153  
 sleep deprivation, thyroxine, 48:153  
 sleep deprivation, triiodothyronine, 46:213, 48:153  
 spiradoline, growth hormone, 47:267  
 spiradoline, motor tics, 47:267  
 spiradoline, opioids, 47:267  
 spiradoline, Tourette's syndrome, 47:267

**Prolactin continued**

thyroid stimulating hormone, affective disorder, 46:213  
 thyroid stimulating hormone, antidepressant medication, 46:213  
 thyroid stimulating hormone, cortisol, 46:213  
 thyroid stimulating hormone, estradiol, 48:153  
 thyroid stimulating hormone, follicle stimulating hormone, 48:153  
 thyroid stimulating hormone, growth hormone, 48:153  
 thyroid stimulating hormone, luteinizing hormone, 48:153  
 thyroid stimulating hormone, normal volunteers, 48:153  
 thyroid stimulating hormone, sleep deprivation, 46:213, 48:153  
 thyroid stimulating hormone, thyroxine, 48:153  
 thyroid stimulating hormone, triiodothyronine, 46:213, 48:153  
 thyroxine, estradiol, 48:153  
 thyroxine, follicle stimulating hormone, 48:153  
 thyroxine, growth hormone, 48:153  
 thyroxine, luteinizing hormone, 48:153  
 thyroxine, normal volunteers, 48:153  
 thyroxine, sleep deprivation, 48:153  
 thyroxine, thyroid stimulating hormone, 48:153  
 thyroxine, triiodothyronine, 48:153  
 Tourette's syndrome, growth hormone, 47:267  
 Tourette's syndrome, kappa agonist, 47:267  
 Tourette's syndrome, motor tics, 47:267  
 Tourette's syndrome, opioids, 47:267  
 Tourette's syndrome, spiradoline, 47:267  
 triiodothyronine, affective disorder, 46:213  
 triiodothyronine, antidepressant medication, 46:213  
 triiodothyronine, cortisol, 46:213  
 triiodothyronine, estradiol, 48:153  
 triiodothyronine, follicle stimulating hormone, 48:153  
 triiodothyronine, growth hormone, 48:153  
 triiodothyronine, luteinizing hormone, 48:153  
 triiodothyronine, normal volunteers, 48:153  
 triiodothyronine, sleep deprivation, 46:213, 48:153  
 triiodothyronine, thyroid stimulating hormone, 46:213, 48:153

**Prolactin continued**

triiodothyronine, thyroxine, 48:153  
 tyrosine, circadian rhythms, 47:187  
 tyrosine, schizophrenia, 47:187  
**Reaction time**  
 alcohol dependence, attention, 46:202  
 alcohol dependence, cocaine, 46:202  
 alcohol dependence, substance abuse, 46:202  
 alcohol dependence, visual and auditory suppression tasks, 46:202  
 alcohol dependence, withdrawal, 46:202  
 anxiety disorder, attention, 49:183  
 anxiety disorder, obsessive-compulsive disorder, 49:183  
 anxiety disorder, Posner task, 49:183  
 anxiety disorder, spatial-linguistic conflict task, 49:183  
 attention, alcohol dependence, 46:202  
 attention, anxiety disorder, 49:183  
 attention, cocaine, 46:202  
 attention, obsessive-compulsive disorder, 49:183  
 attention, Posner task, 49:183  
 attention, spatial-linguistic conflict task, 49:183  
 attention, substance abuse, 46:202  
 attention, visual and auditory suppression tasks, 46:202  
 cocaine, alcohol dependence, 46:202  
 cocaine, attention, 46:202  
 cocaine, visual and auditory suppression tasks, 46:202  
 cocaine, withdrawal, 46:202  
 obsessive-compulsive disorder, anxiety disorder, 49:183  
 obsessive-compulsive disorder, attention, 49:183  
 obsessive-compulsive disorder, Posner task, 49:183  
 obsessive-compulsive disorder, spatial-linguistic conflict task, 49:183  
 Posner task, anxiety disorder, 49:183  
 Posner task, attention, 49:183  
 Posner task, obsessive-compulsive disorder, 49:183  
 Posner task, spatial-linguistic conflict task, 49:183  
 spatial-linguistic conflict task, anxiety disorder, 49:183  
 spatial-linguistic conflict task, attention, 49:183



**Reaction time continued**

- spatial-linguistic conflict task, obsessive-compulsive disorder, 49:183
- spatial-linguistic conflict task, Posner task, 49:183
- substance abuse, alcohol dependence, 46:202
- substance abuse, attention, 46:202
- substance abuse, cocaine, 46:202
- substance abuse, visual and auditory suppression tasks, 46:202
- substance abuse, withdrawal, 46:202
- visual and auditory suppression tasks, alcohol dependence, 46:202
- visual and auditory suppression tasks, attention, 46:202
- visual and auditory suppression tasks, cocaine, 46:202
- visual and auditory suppression tasks, substance abuse, 46:202
- withdrawal, alcohol dependence, 46:202
- withdrawal, cocaine, 46:202
- withdrawal, substance abuse, 46:202

**Schizophrenia**

- admixture analysis, epidemiology, 49:199
- admixture analysis, hebephrenic subtype, 49:199
- admixture analysis, paranoid subtype, 49:199
- affective disorder, family history, 48:201
- affective disorder, family history of personality disorder, 48:243
- affective disorder, genetics, 48:243, 48:201
- affective disorder, human leukocyte antigen, 48:201
- affective disorder, immune function, 48:201
- affective disorder, lymphocytes, 48:201
- age of onset, dopamine, 48:93
- age of onset, homovanillic acid, 48:93
- age of onset, positive and negative symptoms, 48:93
- aging, dopamine D<sub>2</sub> receptor density, 49:219
- aging, gender differences, 49:219
- aging, illness duration, 49:219
- aging, methylspiperone, 49:219
- aging, positron emission tomography, 49:219
- aging, striatum, 49:219
- alcohol dependence, frontal lobe, 46:175
- alcohol dependence, memory, 46:175
- alcohol dependence, neuropsychology, 46:175
- alcohol dependence, Wisconsin Card Sorting Test, 46:175
- alogia, dyadic interaction, 48:181
- alogia, speech, 48:181

**Schizophrenia continued**

- alogia, vocal acoustic scale, 48:181
- Alzheimer's disease, hippocampus, 49:41
- Alzheimer's disease, neurofibrillary tangles, 49:41
- Alzheimer's disease, post-mortem, 49:41
- Alzheimer's disease, senile plaques, 49:41
- amino acids, circadian rhythm, 47:187
- amino acids, dopamine, 47:187
- amino acids, neuroleptics, 47:187
- asymmetry, auditory acuity, 46:127
- attention, continuous performance test, 47:205
- attention, paranoid subtype, 48:17
- attention, positive and negative symptoms, 47:205
- attention, span of apprehension, 47:205
- attention, Stroop task, 48:17
- attention, thought disorder, 47:205
- attention, undifferentiated subtype, 48:17
- audiograms, hallucinations, 46:127
- audiograms, laterality, 46:127
- audiograms, positive and negative symptoms, 46:127
- auditory acuity, asymmetry, 46:127
- auditory P50 component, cocaine, 47:243
- auditory P50 component, paranoid subtype, 47:243
- auditory P50 component, substance abuse, 47:243
- auditory sensory gating, P50 component, 49:29
- auditory sensory gating, sleep, 49:29
- Brief Psychiatric Rating Scale, deficit syndrome diagnosis, 47:47
- CD5 positive B lymphocytes, gender differences, 48:69
- CD5 positive B lymphocytes, immune function, 48:69
- CD5 positive B lymphocytes, lymphocytes, 48:69
- CD5 positive B lymphocytes, race differences, 48:69
- circadian rhythms, amino acids, 47:187
- circadian rhythms, dopamine, 47:187
- circadian rhythms, neuroleptics, 47:187
- circadian rhythms, neutral serum amino acids, 47:187
- circadian rhythms, phenylalanine, 47:187
- circadian rhythms, prolactin, 47:187
- circadian rhythms, therapeutic response, 47:187

**Schizophrenia continued**

circadian rhythms, tyrosine, 47:187  
 clonidine, diagnostic systems, 48:79  
 clonidine, growth hormone, 48:79  
 clozapine, dopamine, 46:139, 46:151  
 clozapine, homovanillic acid, 46:139  
 clozapine, homovanillic acid, 46:151  
 clozapine, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 clozapine, norepinephrine, 46:139, 46:151  
 clozapine, therapeutic response, 46:139, 46:151  
 cocaine, auditory P50 component, 47:243  
 cocaine, event related potentials, 47:243  
 cocaine, paranoid subtype, 47:243  
 cocaine, substance abuse, 47:243  
 continuous performance test, attention, 47:205  
 continuous performance test, positive and negative symptoms, 47:205  
 continuous performance test, span of apprehension, 47:205  
 continuous performance test, thought disorder, 47:205  
 D<sub>2</sub> receptor density, aging, 49:219  
 D<sub>2</sub> receptor density, gender differences, 49:219  
 D<sub>2</sub> receptor density, illness duration, 49:219  
 D<sub>2</sub> receptor density, methylspiperone, 49:219  
 D<sub>2</sub> receptor density, positron emission tomography, 49:219  
 D<sub>2</sub> receptor density, striatum, 49:219  
 D<sub>3</sub> receptor gene linkage, Icelandic pedigrees, 46:69  
 deficit syndrome, demographic features, 47:47  
 deficit syndrome diagnosis, Brief Psychiatric Rating Scale, 47:47  
 deficit syndrome, epidemiology, 47:47  
 deficit syndrome, negative symptoms, 47:47  
 demographic features, deficit syndrome, 47:47  
 demographic features, negative symptoms, 47:47  
 diagnostic systems, clonidine, 48:79  
 diagnostic systems, growth hormone, 48:79  
 discordant monozygotic twins, genetics, 48:27  
 discordant monozygotic twins, microsatellite repeats, 48:27  
 discordant monozygotic twins, polymorphic markers, 48:27  
 dopamine, age of onset, 48:93

**Schizophrenia continued**

dopamine, aging, 49:219  
 dopamine, amino acids, 47:187  
 dopamine, circadian rhythms, 47:187  
 dopamine, clozapine, 46:139, 46:151  
 dopamine, D<sub>2</sub> receptor density, 49:219  
 dopamine, D<sub>3</sub> receptor gene linkage, 46:69  
 dopamine, gender differences, 49:219  
 dopamine, genetics, 46:69  
 dopamine, homovanillic acid, 46:139, 46:151, 48:93  
 dopamine, Icelandic pedigrees, 46:69  
 dopamine, illness duration, 49:219  
 dopamine, linkage of D<sub>3</sub> receptor gene, 46:69  
 dopamine, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 dopamine, methylspiperone, 49:219  
 dopamine, neuroleptics, 47:187  
 dopamine, neutral serum amino acids, 47:187  
 dopamine, norepinephrine, 46:139, 46:151  
 dopamine, phenylalanine, 47:187  
 dopamine, positive and negative symptoms, 48:93  
 dopamine, positron emission tomography, 49:219  
 dopamine, striatum, 49:219  
 dopamine, therapeutic response, 46:139, 46:151, 47:187  
 dyadic interaction, alogia, 48:181  
 dyadic interaction, speech, 48:181  
 dyadic interaction, vocal acoustic scale, 48:181  
 epidemiology, admixture analysis, 49:199  
 epidemiology, deficit syndrome, 47:47  
 epidemiology, hebephrenic subtype, 49:199  
 epidemiology, negative symptoms, 47:47  
 epidemiology, paranoid subtype, 49:199  
 erythrocytes, membrane phospholipids, 49:89  
 erythrocytes, phosphatidylethanolamine, 49:89  
 erythrocytes, sphingomyelin, 49:89  
 event related potential, auditory sensory gating, 49:29  
 event related potential, P50 component, 49:29  
 event related potential, sleep, 49:29  
 event related potentials, auditory P50 component, 47:243  
 event related potentials, cocaine, 47:243  
 event related potentials, paranoid subtype, 47:243  
 event related potentials, substance abuse, 47:243

**Schizophrenia** continued

family history, affective disorder, 48:201  
 family history, immune function, 48:201  
 family history, lymphocytes, 48:201  
 family history of personality disorder, affective disorder, 48:243  
 frontal lobe, alcohol dependence, 46:175  
 frontal lobe, memory, 46:175  
 frontal lobe, neurodegeneration, 48:145  
 frontal lobe, neuropsychology, 46:175  
 frontal lobe, post-mortem study, 48:145  
 frontal lobe, ubiquitin, 48:145  
 frontal lobe, Wisconsin Card Sorting Test, 46:175  
 gender differences, aging, 49:219  
 gender differences, CD5 positive B lymphocytes, 48:69  
 gender differences, D<sub>2</sub> receptor density, 49:219  
 gender differences, dopamine, 49:219  
 gender differences, illness duration, 49:219  
 gender differences, immune function, 48:69  
 gender differences, lymphocytes, 48:69  
 gender differences, methylspiperone, 49:219  
 gender differences, positron emission tomography, 49:219  
 gender differences, race differences, 48:69  
 gender differences, striatum, 49:219  
 genetics, affective disorder, 48:201, 48:243  
 genetics, D<sub>3</sub> receptor gene linkage, 46:69  
 genetics, discordant monozygotic twins, 48:27  
 genetics, dopamine, 46:69  
 genetics, family history of personality disorder, 48:243  
 genetics, human leukocyte antigen, 48:201  
 genetics, immune function, 48:201  
 genetics, linkage of D<sub>3</sub> receptor gene, 46:69  
 genetics, lymphocytes, 48:201  
 genetics, microsatellite repeats, 48:27  
 genetics, polymorphic markers, 48:27  
 genetics, twin studies, 48:27  
 growth hormone, clonidine, 48:79  
 growth hormone, diagnostic systems, 48:79  
 hallucinations, audiograms, 46:127  
 hallucinations, laterality, 46:127  
 hallucinations, positive and negative symptoms, 46:127  
 hebephrenic subtype, admixture analysis, 49:199  
 hebephrenic subtype, epidemiology, 49:199

**Schizophrenia** continued

hebephrenic subtype, paranoid subtype, 49:199  
 hippocampus, Alzheimer's disease, 49:41  
 hippocampus, neurofibrillary tangles, 49:41  
 hippocampus, post-mortem, 49:41  
 hippocampus, senile plaques, 49:41  
 homovanillic acid, age of onset, 48:93  
 homovanillic acid, clozapine, 46:139, 46:151  
 homovanillic acid, dopamine, 46:139, 46:151, 48:93  
 homovanillic acid, 3-methoxy-4-hydroxy-phenylglycol, 46:139  
 homovanillic acid, norepinephrine, 46:139, 46:151  
 homovanillic acid, positive and negative symptoms, 48:93  
 homovanillic acid, therapeutic response, 46:139, 46:151  
 human leukocyte antigen, affective disorder, 48:201  
 human leukocyte antigen, family history, 48:201  
 human leukocyte antigen, genetics, 48:201  
 human leukocyte antigen, immune function, 48:201  
 human leukocyte antigen, lymphocytes, 48:201  
 illness duration, aging, 49:219  
 illness duration, D<sub>2</sub> receptor density, 49:219  
 illness duration, dopamine, 49:219  
 illness duration, gender differences, 49:219  
 illness duration, methylspiperone, 49:219  
 illness duration, positron emission tomography, 49:219  
 illness duration, striatum, 49:219  
 immune function, affective disorder, 48:201  
 immune function, CD5 positive B lymphocytes, 48:69  
 immune function, family history, 48:201  
 immune function, gender differences, 48:69  
 immune function, genetics, 48:201  
 immune function, human leukocyte antigen, 48:201  
 immune function, lymphocytes, 48:69, 48:201  
 immune function, race differences, 48:69  
 infectious disease, negative symptoms, 47:297  
 laterality, audiograms, 46:127  
 laterality, hallucinations, 46:127  
 laterality, positive and negative symptoms, 46:127  
 linkage of D<sub>3</sub> receptor gene, Icelandic pedigrees, 46:69



**Schizophrenia continued**

lymphocytes, affective disorder, 48:201  
 lymphocytes, CD5 positive B lymphocytes, 48:69  
 lymphocytes, family history, 48:201  
 lymphocytes, gender differences, 48:69  
 lymphocytes, genetics, 48:201  
 lymphocytes, human leukocyte antigen, 48:201  
 lymphocytes, immune function, 48:69, 48:201  
 lymphocytes, race differences, 48:69  
 membrane phospholipids, erythrocytes, 49:89  
 membrane phospholipids, phosphatidylethanolamine, 49:89  
 membrane phospholipids, sphingomyelin, 49:89  
 memory, alcohol dependence, 46:175  
 memory, frontal lobe, 46:175  
 memory, neuropsychology, 46:175  
 memory, Wisconsin Card Sorting Test, 46:175  
 3-methoxy-4-hydroxyphenylglycol, clozapine, 46:139  
 3-methoxy-4-hydroxyphenylglycol, dopamine, 46:139  
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:139  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:139  
 3-methoxy-4-hydroxyphenylglycol, therapeutic response, 46:139  
 methylspiperone, aging, 49:219  
 methylspiperone, D<sub>2</sub> receptor density, 49:219  
 methylspiperone, dopamine, 49:219  
 methylspiperone, gender differences, 49:219  
 methylspiperone, illness duration, 49:219  
 methylspiperone, positron emission tomography, 49:219  
 methylspiperone, striatum, 49:219  
 microsatellite repeats, discordant monozygotic twins, 48:27  
 microsatellite repeats, genetics, 48:27  
 microsatellite repeats, polymorphic markers, 48:27  
 microsatellite repeats, twin studies, 48:27  
 negative symptoms, deficit syndrome, 47:47  
 negative symptoms, demographic features, 47:47  
 negative symptoms, epidemiology, 47:47  
 negative symptoms, infectious disease, 47:297  
 neurodegeneration, frontal lobe, 48:145  
 neurodegeneration, post-mortem study, 48:145

**Schizophrenia continued**

neurodegeneration, ubiquitin, 48:145  
 neurofibrillary tangles, Alzheimer's disease, 49:41  
 neurofibrillary tangles, hippocampus, 49:41  
 neurofibrillary tangles, senile plaques, 49:41  
 neuroleptics, amino acids, 47:187  
 neuroleptics, circadian rhythms, 47:187  
 neuroleptics, dopamine, 47:187  
 neuroleptics, neutral serum amino acids, 47:187  
 neuroleptics, phenylalanine, 47:187  
 neuroleptics, S<sub>2</sub> receptor in platelets, 48:57  
 neuroleptics, serotonin, 48:57  
 neuroleptics, therapeutic response, 47:187  
 neuropsychology, alcohol dependence, 46:175  
 neuropsychology, frontal lobe, 46:175  
 neuropsychology, memory, 46:175  
 neuropsychology, Wisconsin Card Sorting Test, 46:175  
 neutral serum amino acids, circadian rhythms, 47:187  
 neutral serum amino acids, dopamine, 47:187  
 neutral serum amino acids, neuroleptics, 47:187  
 neutral serum amino acids, phenylalanine, 47:187  
 neutral serum amino acids, therapeutic response, 47:187  
 norepinephrine, clozapine, 46:139, 46:151  
 norepinephrine, dopamine, 46:139, 46:151  
 norepinephrine, homovanillic acid, 46:139, 46:151  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:139  
 norepinephrine, therapeutic response, 46:139, 46:151  
 P50 component, auditory sensory gating, 49:29  
 P50 component, sleep, 49:29  
 paranoid subtype, admixture analysis, 49:199  
 paranoid subtype, attention, 48:17  
 paranoid subtype, auditory P50 component, 47:243  
 paranoid subtype, cocaine, 47:243  
 paranoid subtype, epidemiology, 49:199  
 paranoid subtype, event related potentials, 47:243  
 paranoid subtype, hebephrenic subtype, 49:199  
 paranoid subtype, Stroop task, 48:17  
 paranoid subtype, substance abuse, 47:243

**Schizophrenia continued**

paranoid subtype, undifferentiated subtype, 48:17

phenylalanine, amino acids, 47:187

phenylalanine, circadian rhythms, 47:187

phenylalanine, dopamine, 47:187

phenylalanine, neuroleptics, 47:187

phenylalanine, neutral serum amino acids, 47:187

phenylalanine, therapeutic response, 47:187

phosphatidylethanolamine, erythrocytes, 49:89

phosphatidylethanolamine, membrane phospholipids, 49:89

phosphatidylethanolamine, sphingomyelin, 49:89

polymorphic markers, discordant monozygotic twins, 48:27

polymorphic markers, genetics, 48:27

polymorphic markers, microsatellite repeats, 48:27

polymorphic markers, twin studies, 48:27

positive and negative symptoms, age of onset, 48:93

positive and negative symptoms, attention, 47:205

positive and negative symptoms, audiograms, 46:127

positive and negative symptoms, continuous performance test, 47:205

positive and negative symptoms, dopamine, 48:93

positive and negative symptoms, hallucinations, 46:127

positive and negative symptoms, homovanillic acid, 48:93

positive and negative symptoms, laterality, 46:127

positive and negative symptoms, span of apprehension, 47:205

positive and negative symptoms, thought disorder, 47:205

positron emission tomography, aging, 49:219

positron emission tomography, D<sub>2</sub> receptor density, 49:219

positron emission tomography, dopamine, 49:219

positron emission tomography, gender differences, 49:219

positron emission tomography, illness duration, 49:219

positron emission tomography, methylspiperone, 49:219

**Schizophrenia continued**

positron emission tomography, striatum, 49:219

post-mortem study, Alzheimer's disease, 49:41

post-mortem study, frontal lobe, 48:145

post-mortem study, hippocampus, 49:41

post-mortem study, neurodegeneration, 48:145

post mortem study, neurofibrillary tangles, 49:41

post-mortem study, senile plaques, 49:41

post-mortem study, ubiquitin, 48:145

prolactin, circadian rhythm, 47:187

prolactin, tyrosine, 47:187

race differences, CD5 positive B lymphocytes, 48:69

race differences, gender differences, 48:69

race differences, immune function, 48:69

race differences, lymphocytes, 48:69

S<sub>2</sub> receptor binding in platelets, suicide, 47:111

S<sub>2</sub> receptor in platelets, neuroleptics, 48:57

senile plaques, Alzheimer's disease, 49:41

senile plaques, hippocampus, 49:41

senile plaques, neurofibrillary tangles, 49:41

serotonin, neuroleptics, 48:57

serotonin, S<sub>2</sub> receptor binding in platelets, 47:111, 48:57

serotonin, suicide, 47:111

sleep, auditory sensory gating, 49:29

sleep, event related potential, 49:29

sleep, P50 component, 49:29

span of apprehension, attention, 47:205

span of apprehension, continuous performance test, 47:205

span of apprehension, positive and negative symptoms, 47:205

span of apprehension, thought disorder, 47:205

speech, alogia, 48:181

speech, dyadic interaction, 48:181

speech, vocal acoustic scale, 48:181

sphingomyelin, erythrocytes, 49:89

sphingomyelin, membrane phospholipids, 49:89

sphingomyelin, phosphatidylethanolamine, 49:89

striatum, aging, 49:219

striatum, D<sub>2</sub> receptor density, 49:219

striatum, dopamine, 49:219

striatum, gender differences, 49:219

striatum, illness duration, 49:219

**Schizophrenia continued**

- striatum, methylspiperone, 49:219
- striatum, positron emission tomography, 49:219
- Stroop task, attention, 48:17
- Stroop task, paranoid subtype, 48:17
- Stroop task, undifferentiated subtype, 48:17
- substance abuse, auditory P50 component, 47:243
- substance abuse, cocaine, 47:243
- substance abuse, event related potentials, 47:243
- substance abuse, paranoid subtype, 47:243
- suicide, S<sub>2</sub> receptor binding in platelets, 47:111
- suicide, serotonin, 47:111
- therapeutic response, amino acids, 47:187
- therapeutic response, circadian rhythms, 47:187
- therapeutic response, clozapine, 46:139, 46:151
- therapeutic response, dopamine, 46:139, 46:151, 47:187
- therapeutic response, homovanillic acid, 46:139, 46:151
- therapeutic response, 3-methoxy-4-hydroxy-phenylglycol, 46:139
- therapeutic response, neuroleptics, 47:187
- therapeutic response, neutral serum amino acids, 47:187
- therapeutic response, norepinephrine, 46:139, 46:151
- therapeutic response, phenylalanine, 47:187
- thought disorder, attention, 47:205
- thought disorder, continuous performance test, 47:205
- thought disorder, positive and negative symptoms, 47:205
- thought disorder, span of apprehension, 47:205
- twin studies, discordant monozygotic twins, 48:27
- twin studies, microsatellite repeats, 48:27
- twin studies, polymorphic markers, 48:27
- tyrosine, circadian rhythms, 47:187
- tyrosine, prolactin, 47:187
- ubiquitin, frontal lobe, 48:145
- ubiquitin, neurodegeneration, 48:145
- ubiquitin, post-mortem study, 48:145
- undifferentiated subtype, attention, 48:17
- undifferentiated subtype, paranoid subtype, 48:17

**Schizophrenia continued**

- undifferentiated subtype, Stroop task, 48:17
- vocal acoustic scale, alogia, 48:181
- vocal acoustic scale, dyadic interaction, 48:181
- vocal acoustic scale, speech, 48:181
- Wisconsin Card Sorting Test, alcohol dependence, 46:175
- Wisconsin Card Sorting Test, frontal lobe, 46:175
- Wisconsin Card Sorting Test, memory, 46:175
- Wisconsin Card Sorting Test, neuropsychology, 46:175

**Schizotypy**

- genetics, personality disorder, 46:47
- genetics, physical anhedonia, 46:47
- genetics, psychosis proneness scales, 46:47
- personality disorder, genetics, 46:47
- personality disorder, physical anhedonia, 46:47
- personality disorder, psychosis proneness scales, 46:47
- physical anhedonia, genetics, 46:47
- physical anhedonia, personality disorder, 46:47
- physical anhedonia, psychosis proneness scales, 46:47
- psychosis proneness scales, genetics, 46:47
- psychosis proneness scales, personality disorder, 46:47
- psychosis proneness scales, physical anhedonia, 46:47

**Seasonal affective disorder.** See Affective disorder, seasonal depression

**Serotonin**

- affective disorder, amino acids, 49:151
- affective disorder, bipolar subtype, 47:129
- affective disorder, depressive symptoms, 47:129
- affective disorder, haptoglobin, 49:151
- affective disorder, immune function, 49:151
- affective disorder, interleukin, 49:151
- affective disorder, N-acetyl-beta-glucosaminidase, 47:129
- affective disorder, transferrin, 49:151
- affective disorder, tryptophan, 49:151
- alcohol dependence, depression, 47:57
- alcohol dependence, glutamyltransferase, 47:57
- alcohol dependence, impulse control disorder, 47:57
- alcohol dependence, withdrawal, 47:57



**Serotonin continued**

amino acids, affective disorder, 49:151  
 amino acids, haptoglobin, 49:151  
 amino acids, immune function, 49:151  
 amino acids, interleukin, 49:151  
 amino acids, transferrin, 49:151  
 amino acids, tryptophan, 49:151  
 anxiety disorder, cortisol, 48:119  
 anxiety disorder, fluvoxamine, 48:119  
 anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 anxiety disorder, norepinephrine, 48:119  
 anxiety disorder, panic disorder, 48:119  
 anxiety disorder, yohimbine, 48:119  
 bipolar subtype, affective disorder, 47:129  
 bipolar subtype, depressive symptoms, 47:129  
 bipolar subtype, *N*-acetyl-beta-glucosaminidase, 47:129  
 bulimia, novelty seeking, 48:9  
 bulimia, Tridimensional Personality Questionnaire, 48:9  
 bulimia, whole blood levels, 48:9  
 calmodulin affinity chromatography, endogenous uptake inhibitors, 47:121  
 calmodulin affinity chromatography, imipramine, 47:121  
 calmodulin affinity chromatography, paroxetine, 47:121  
 cortisol, anxiety disorder, 48:119  
 cortisol, fluvoxamine, 48:119  
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 cortisol, norepinephrine, 48:119  
 cortisol, panic disorder, 48:119  
 cortisol, yohimbine, 48:119  
 depression, alcohol dependence, 47:57  
 depression, glutamyltransferase, 47:57  
 depression, impulse control disorder, 47:57  
 depression, withdrawal, 47:57  
 depressive symptoms, bipolar subtype, 47:129  
 depressive symptoms, *N*-acetyl-beta-glucosaminidase, 47:129  
 eating disorder, bulimia, 48:9  
 eating disorder, novelty seeking, 48:9  
 eating disorder, Tridimensional Personality Questionnaire, 48:9  
 endogenous uptake inhibitors, calmodulin affinity chromatography, 47:121  
 endogenous uptake inhibitors, imipramine, 47:121

**Serotonin continued**

endogenous uptake inhibitors, paroxetine, 47:121  
 fluvoxamine, anxiety disorder, 48:119  
 fluvoxamine, cortisol, 48:119  
 fluvoxamine, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 fluvoxamine, norepinephrine, 48:119  
 fluvoxamine, panic disorder, 48:119  
 fluvoxamine, yohimbine, 48:119  
 glutamyltransferase, alcohol dependence, 47:57  
 glutamyltransferase, depression, 47:57  
 glutamyltransferase, impulse control disorder, 47:57  
 glutamyltransferase, withdrawal, 47:57  
 haptoglobin, affective disorder, 49:151  
 haptoglobin, amino acids, 49:151  
 haptoglobin, immune function, 49:151  
 haptoglobin, interleukin, 49:151  
 haptoglobin, transferrin, 49:151  
 haptoglobin, tryptophan, 49:151  
 imipramine, calmodulin affinity chromatography, 47:121  
 imipramine, endogenous serotonin uptake inhibitors, 47:121  
 imipramine, paroxetine, 47:121  
 immune function, affective disorder, 49:151  
 immune function, amino acids, 49:151  
 immune function, haptoglobin, 49:151  
 immune function, interleukin, 49:151  
 immune function, transferrin, 49:151  
 immune function, tryptophan, 49:151  
 impulse control disorder, alcohol dependence, 47:57  
 impulse control disorder, depression, 47:57  
 impulse control disorder, glutamyltransferase, 47:57  
 impulse control disorder, withdrawal, 47:57  
 interleukin, affective disorder, 49:151  
 interleukin, amino acids, 49:151  
 interleukin, haptoglobin, 49:151  
 interleukin, immune function, 49:151  
 interleukin, transferrin, 49:151  
 interleukin, tryptophan, 49:151  
 3-methoxy-4-hydroxyphenylglycol, anxiety disorder, 48:119  
 3-methoxy-4-hydroxyphenylglycol, cortisol, 48:119  
 3-methoxy-4-hydroxyphenylglycol, fluvoxamine, 48:119  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119

**Serotonin continued**

3-methoxy-4-hydroxyphenylglycol, panic disorder, 48:119  
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 48:119  
*N*-acetyl-beta-glucosaminidase, affective disorder, 47:129  
*N*-acetyl-beta-glucosaminidase, bipolar subtype, 47:129  
*N*-acetyl-beta-glucosaminidase, depressive symptoms, 47:129  
 neuroleptics, S<sub>2</sub> receptor in platelets, 48:57  
 neuroleptics, schizophrenia, 48:57  
 norepinephrine, anxiety disorder, 48:119  
 norepinephrine, cortisol, 48:119  
 norepinephrine, fluvoxamine, 48:119  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 norepinephrine, panic disorder, 48:119  
 norepinephrine, yohimbine, 48:119  
 novelty seeking, bulimia, 48:9  
 novelty seeking, eating disorder, 48:9  
 novelty seeking, Tridimensional Personality Questionnaire, 48:9  
 panic disorder, cortisol, 48:119  
 panic disorder, fluvoxamine, 48:119  
 panic disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 panic disorder, norepinephrine, 48:119  
 panic disorder, yohimbine, 48:119  
 paroxetine, calmodulin affinity chromatography, 47:121  
 paroxetine, endogenous serotonin uptake inhibitors, 47:121  
 paroxetine, imipramine, 47:121  
 platelets, alcohol dependence, 47:57  
 platelets, depression, 47:57  
 platelets, impulse control disorder, 47:57  
 reuptake inhibitor, anxiety disorder, 48:119  
 reuptake inhibitor, cortisol, 48:119  
 reuptake inhibitor, fluvoxamine, 48:119  
 reuptake inhibitor, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 reuptake inhibitor, norepinephrine, 48:119  
 reuptake inhibitor, panic disorder, 48:119  
 reuptake inhibitor, yohimbine, 48:119  
 S<sub>2</sub> receptor binding in platelets, schizophrenia, 47:111, 48:57  
 S<sub>2</sub> receptor binding in platelets, suicide, 47:111  
 schizophrenia, neuroleptics, 48:57  
 schizophrenia, S<sub>2</sub> receptor binding in platelets, 47:111, 48:57

**Serotonin continued**

schizophrenia, suicide, 47:111  
 suicide, S<sub>2</sub> receptor binding in platelets, 47:111  
 suicide, schizophrenia, 47:111  
 transferrin, affective disorder, 49:151  
 transferrin, amino acids, 49:151  
 transferrin, haptoglobin, 49:151  
 transferrin, immune function, 49:151  
 transferrin, interleukin, 49:151  
 transferrin, tryptophan, 49:151  
 Tridimensional Personality Questionnaire, bulimia, 48:9  
 Tridimensional Personality Questionnaire, eating disorder, 48:9  
 Tridimensional Personality Questionnaire, novelty seeking, 48:9  
 tryptophan, affective disorder, 49:151  
 tryptophan, amino acids, 49:151  
 tryptophan, haptoglobin, 49:151  
 tryptophan, immune function, 49:151  
 tryptophan, interleukin, 49:151  
 tryptophan, transferrin, 49:151  
 whole blood levels, bulimia, 48:9  
 whole blood levels, eating disorder, 48:9  
 whole blood levels, novelty seeking, 48:9  
 whole blood levels, Tridimensional Personality Questionnaire, 48:9  
 withdrawal, alcohol dependence, 47:57  
 withdrawal, depression, 47:57  
 withdrawal, glutamyltransferase, 47:57  
 withdrawal, impulse control disorder, 47:57  
 yohimbine, anxiety disorder, 48:119  
 yohimbine, cortisol, 48:119  
 yohimbine, fluvoxamine, 48:119  
 yohimbine, 3-methoxy-4-hydroxyphenylglycol, 48:119  
 yohimbine, norepinephrine, 48:119  
 yohimbine, panic disorder, 48:119  
**Sleep**  
 affective disorder, circadian rhythms, 47:215, 49:139  
 affective disorder, daytime affect, 49:139  
 affective disorder, depressed mood, 49:109  
 affective disorder, divorce, 46:165  
 affective disorder, dream masochism, 46:165  
 affective disorder, endogenous subtype, 47:215  
 affective disorder, gender differences, 46:165  
 affective disorder, growth hormone, 47:215  
 affective disorder, growth hormone releasing hormone, 47:215

**Sleep continued**

affective disorder, haptoglobin, 47:229  
 affective disorder, immune function, 47:229  
 affective disorder, interpersonal psychotherapy, 49:121  
 affective disorder, naps, 49:109  
 affective disorder, nocturnal penile tumescence, 49:139  
 affective disorder, personality, 46:165  
 affective disorder, rapid eye movement latency, 46:269, 49:121  
 affective disorder, remission, 46:269, 49:121  
 affective disorder, sex role identification, 46:165  
 affective disorder, sexual function, 49:139  
 affective disorder, sleep deprivation, 49:109  
 affective disorder, somatic symptoms, 47:229  
 affective disorder, weight and anorexia, 47:229  
 aging, agitation, 48:277  
 aging, circadian rhythms, 48:277  
 aging, circannual rhythms, 48:277  
 aging, dementia, 48:277  
 aging, depressed mood in elderly women, 47:87  
 aging, phototherapy, 47:87  
 aging, sundowning, 48:277  
 agitation, aging, 48:277  
 agitation, circadian rhythms, 48:277  
 agitation, circannual rhythms, 48:277  
 agitation, dementia, 48:277  
 agitation, sundowning, 48:277  
 anxiety disorder, depressive mood, 49:251  
 anxiety disorder, insomnia, 49:251  
 anxiety disorder, phobia, 49:251  
 anxiety disorder, quality of sleep, 49:251  
 auditory sensory gating, event related potential, 49:29  
 auditory sensory gating, P50 component, 49:29  
 auditory sensory gating, schizophrenia, 49:29  
 circadian rhythms, affective disorder, 47:215, 49:139  
 circadian rhythms, aging, 48:277  
 circadian rhythms, agitation, 48:277  
 circadian rhythms, circannual rhythms, 48:277  
 circadian rhythms, daytime affect, 49:139  
 circadian rhythms, dementia, 48:277  
 circadian rhythms, endogenous subtype, 47:215  
 circadian rhythms, growth hormone, 47:215

**Sleep continued**

circadian rhythms, growth hormone releasing hormone, 47:215  
 circadian rhythms, nocturnal penile tumescence, 49:139  
 circadian rhythms, sexual function, 49:139  
 circadian rhythms, sundowning, 48:277  
 circannual rhythms, aging, 48:277  
 circannual rhythms, agitation, 48:277  
 circannual rhythms, circadian rhythms, 48:277  
 circannual rhythms, dementia, 48:277  
 circannual rhythms, sundowning, 48:277  
 daytime affect, affective disorder, 49:139  
 daytime affect, circadian rhythms, 49:139  
 daytime affect, nocturnal penile tumescence, 49:139  
 daytime affect, sexual function, 49:139  
 dementia, aging, 48:277  
 dementia, agitation, 48:277  
 dementia, circadian rhythms, 48:277  
 dementia, circannual rhythms, 48:277  
 dementia, sundowning, 48:277  
 depressed mood, affective disorder, 49:109  
 depressed mood in elderly women, aging, 47:87  
 depressed mood in elderly women, phototherapy, 47:87  
 depressed mood, naps, 49:109  
 depressed mood, sleep deprivation, 49:109  
 depressive mood, anxiety disorder, 49:251  
 depressive mood, insomnia, 49:251  
 depressive mood, phobia, 49:251  
 depressive mood, quality of sleep, 49:251  
 divorce, affective disorder, 46:165  
 divorce, dream masochism, 46:165  
 divorce, gender differences, 46:165  
 divorce, personality, 46:165  
 divorce, sex role identification, 46:165  
 dream masochism, affective disorder, 46:165  
 dream masochism, divorce, 46:165  
 dream masochism, gender differences, 46:165  
 dream masochism, personality, 46:165  
 dream masochism, sex role identification, 46:165  
 endogenous subtype, circadian rhythms, 47:215  
 endogenous subtype, growth hormone, 47:215  
 endogenous subtype, growth hormone releasing hormone, 47:215  
 event related potential, auditory sensory gating, 49:29



**Sleep continued**

event related potential, P50 component, 49:29

event related potential, schizophrenia, 49:29

gender differences, affective disorder, 46:165

gender differences, divorce, 46:165

gender differences, dream masochism, 46:165

gender differences, personality, 46:165

gender differences, sex role identification, 46:165

growth hormone, affective disorder, 47:215

growth hormone, circadian rhythms, 47:215

growth hormone, endogenous subtype, 47:215

growth hormone, growth hormone releasing hormone, 47:215

growth hormone releasing hormone, affective disorder, 47:215

growth hormone releasing hormone, circadian rhythms, 47:215

growth hormone releasing hormone, endogenous subtype, 47:215

growth hormone releasing hormone, growth hormone, 47:215

haptoglobin, affective disorder, 47:229

haptoglobin, immune function, 47:229

haptoglobin, somatic symptoms, 47:229

haptoglobin, weight and anorexia, 47:229

immune function, affective disorder, 47:229

immune function, haptoglobin, 47:229

immune function, somatic symptoms, 47:229

immune function, weight and anorexia, 47:229

insomnia, anxiety disorder, 49:251

insomnia, depressive mood, 49:251

insomnia, phobia, 49:251

insomnia, quality of sleep, 49:251

interpersonal psychotherapy, affective disorder, 49:121

interpersonal psychotherapy, rapid eye movement latency, 49:121

interpersonal psychotherapy, recovery, 49:121

naps, affective disorder, 49:109

naps, depressed mood, 49:109

naps, sleep deprivation, 49:109

nocturnal penile tumescence, affective disorder, 49:139

nocturnal penile tumescence, circadian rhythms, 49:139

nocturnal penile tumescence, daytime affect, 49:139

nocturnal penile tumescence, sexual function, 49:139

**Sleep continued**

P50 component, auditory sensory gating, 49:29

P50 component, schizophrenia, 49:29

personality, affective disorder, 46:165

personality, divorce, 46:165

personality, dream masochism, 46:165

personality, gender differences, 46:165

personality, sex role identification, 46:165

phobia, anxiety disorder, 49:251

phobia, depressive mood, 49:251

phobia, insomnia, 49:251

phobia, quality of sleep, 49:251

phototherapy, aging, 47:87

phototherapy, depressed mood in elderly women, 47:87

quality of sleep, anxiety disorder, 49:251

quality of sleep, depressive mood, 49:251

quality of sleep, insomnia, 49:251

quality of sleep, phobia, 49:251

rapid eye movement latency, affective disorder, 46:269, 49:121

rapid eye movement latency, interpersonal psychotherapy, 49:121

rapid eye movement latency, remission, 46:269, 49:121

recovery, affective disorder, 49:121

recovery, interpersonal psychotherapy, 49:121

recovery, rapid eye movement latency, 49:121

remission, affective disorder, 46:269

remission, rapid eye movement latency, 46:269

schizophrenia, auditory sensory gating, 49:29

schizophrenia, event related potential, 49:29

schizophrenia, P50 component, 49:29

sex role identification, affective disorder, 46:165

sex role identification, divorce, 46:165

sex role identification, dream masochism, 46:165

sex role identification, gender differences, 46:165

sex role identification, personality, 46:165

sexual function, affective disorder, 49:139

sexual function, circadian rhythms, 49:139

sexual function, daytime affect, 49:139

sexual function, nocturnal penile tumescence, 49:139

sleep deprivation, affective disorder, 49:109

sleep deprivation, depressed mood, 49:109

sleep deprivation, naps, 49:109

somatic symptoms, affective disorder, 47:229

**Sleep continued**

- somatic symptoms, haptoglobin, 47:229
- somatic symptoms, immune function, 47:229
- somatic symptoms, weight and anorexia, 47:229
- sundowning, aging, 48:277
- sundowning, agitation, 48:277
- sundowning, circadian rhythms, 48:277
- sundowning, circannual rhythms, 48:277
- sundowning, dementia, 48:277
- weight and anorexia, affective disorder, 47:229
- weight and anorexia, haptoglobin, 47:229
- weight and anorexia, immune function, 47:229
- weight and anorexia, somatic symptoms, 47:229

**Sleep deprivation**

- affective disorder, antidepressant medication, 46:213
- affective disorder, cortisol, 46:213
- affective disorder, depressed mood, 49:109
- affective disorder, fluoxetine, 46:213
- affective disorder, naps, 49:109
- affective disorder, prolactin, 46:213
- affective disorder, sleep, 49:109
- affective disorder, thyroid stimulating hormone, 46:213
- affective disorder, triiodothyronine, 46:213
- antidepressant medication, affective disorder, 46:213
- antidepressant medication, cortisol, 46:213
- antidepressant medication, prolactin, 46:213
- antidepressant medication, thyroid stimulating hormone, 46:213
- antidepressant medication, triiodothyronine, 46:213
- cortisol, affective disorder, 46:213
- cortisol, antidepressant medication, 46:213
- cortisol, prolactin, 46:213
- cortisol, thyroid stimulating hormone, 46:213
- cortisol, triiodothyronine, 46:213
- depressed mood, affective disorder, 49:109
- depressed mood, naps, 49:109
- depressed mood, sleep, 49:109
- estradiol, follicle stimulating hormone, 48:153
- estradiol, growth hormone, 48:153
- estradiol, luteinizing hormone, 48:153
- estradiol, normal volunteers, 48:153
- estradiol, prolactin, 48:153
- estradiol, thyroid stimulating hormone, 48:153
- estradiol, thyroxine, 48:153

**Sleep deprivation continued**

- estradiol, triiodothyronine, 48:153
- fluoxetine, affective disorder, 46:213
- follicle stimulating hormone, estradiol, 48:153
- follicle stimulating hormone, growth hormone, 48:153
- follicle stimulating hormone, luteinizing hormone, 48:153
- follicle stimulating hormone, normal volunteers, 48:153
- follicle stimulating hormone, prolactin, 48:153
- follicle stimulating hormone, thyroid stimulating hormone, 48:153
- follicle stimulating hormone, thyroxine, 48:153
- follicle stimulating hormone, triiodothyronine, 48:153
- growth hormone, estradiol, 48:153
- growth hormone, follicle stimulating hormone, 48:153
- growth hormone, luteinizing hormone, 48:153
- growth hormone, normal volunteers, 48:153
- growth hormone, prolactin, 48:153
- growth hormone, thyroid stimulating hormone, 48:153
- growth hormone, thyroxine, 48:153
- growth hormone, triiodothyronine, 48:153
- luteinizing hormone, estradiol, 48:153
- luteinizing hormone, follicle stimulating hormone, 48:153
- luteinizing hormone, growth hormone, 48:153
- luteinizing hormone, normal volunteers, 48:153
- luteinizing hormone, prolactin, 48:153
- luteinizing hormone, thyroid stimulating hormone, 48:153
- luteinizing hormone, thyroxine, 48:153
- luteinizing hormone, triiodothyronine, 48:153
- naps, affective disorder, 49:109
- naps, depressed mood, 49:109
- naps, sleep, 49:109
- normal volunteers, estradiol, 48:153
- normal volunteers, follicle stimulating hormone, 48:153
- normal volunteers, growth hormone, 48:153
- normal volunteers, luteinizing hormone, 48:153
- normal volunteers, prolactin, 48:153

**Sleep deprivation continued**

normal volunteers, thyroid stimulating hormone, 48:153  
 normal volunteers, thyroxine, 48:153  
 normal volunteers, triiodothyronine, 48:153  
 prolactin, affective disorder, 46:213  
 prolactin, antidepressant medication, 46:213  
 prolactin, cortisol, 46:213  
 prolactin, estradiol, 48:153  
 prolactin, follicle stimulating hormone, 48:153  
 prolactin, growth hormone, 48:153  
 prolactin, luteinizing hormone, 48:153  
 prolactin, normal volunteers, 48:153  
 prolactin, thyroid stimulating hormone, 46:213, 48:153  
 prolactin, thyroxine, 48:153  
 prolactin, triiodothyronine, 46:213, 48:153  
 sleep, affective disorder, 49:109  
 sleep, depressed mood, 49:109  
 sleep, naps, 49:109  
 thyroid stimulating hormone, affective disorder, 46:213  
 thyroid stimulating hormone, antidepressant medication, 46:213  
 thyroid stimulating hormone, cortisol, 46:213  
 thyroid stimulating hormone, estradiol, 48:153  
 thyroid stimulating hormone, follicle stimulating hormone, 48:153  
 thyroid stimulating hormone, growth hormone, 48:153  
 thyroid stimulating hormone, luteinizing hormone, 48:153  
 thyroid stimulating hormone, normal volunteers, 48:153  
 thyroid stimulating hormone, prolactin, 46:213, 48:153  
 thyroid stimulating hormone, thyroxine, 48:153  
 thyroid stimulating hormone, triiodothyronine, 46:213, 48:153  
 thyroxine, estradiol, 48:153  
 thyroxine, follicle stimulating hormone, 48:153  
 thyroxine, growth hormone, 48:153  
 thyroxine, luteinizing hormone, 48:153  
 thyroxine, normal volunteers, 48:153  
 thyroxine, prolactin, 48:153  
 thyroxine, thyroid stimulating hormone, 48:153  
 thyroxine, triiodothyronine, 48:153  
 triiodothyronine, affective disorder, 46:213  
 triiodothyronine, antidepressant medication, 46:213

**Sleep deprivation continued**

triiodothyronine, cortisol, 46:213  
 triiodothyronine, estradiol, 48:153  
 triiodothyronine, follicle stimulating hormone, 48:153  
 triiodothyronine, growth hormone, 48:153  
 triiodothyronine, luteinizing hormone, 48:153  
 triiodothyronine, normal volunteers, 48:153  
 triiodothyronine, prolactin, 46:213, 48:153  
 triiodothyronine, thyroid stimulating hormone, 46:213, 48:153  
 triiodothyronine, thyroxine, 48:153

**Sleep disorders**

fatigue, visual analogue scale, 46:207  
 visual analogue scale, fatigue, 46:207

**Speech**

alogia, dyadic interaction, 48:181  
 alogia, schizophrenia, 48:181  
 alogia, vocal acoustic scale, 48:181  
 dyadic interaction, alogia, 48:181  
 dyadic interaction, schizophrenia, 48:181  
 dyadic interaction, vocal acoustic scale, 48:181  
 schizophrenia, alogia, 48:181  
 schizophrenia, dyadic interaction, 48:181  
 schizophrenia, vocal acoustic scale, 48:181  
 vocal acoustic scale, alogia, 48:181  
 vocal acoustic scale, dyadic interaction, 48:181  
 vocal acoustic scale, schizophrenia, 48:181

**Sphingomyelin**

erythrocytes, membrane phospholipids, 49:89  
 erythrocytes, phosphatidylethanolamine, 49:89  
 erythrocytes, schizophrenia, 49:89  
 membrane phospholipids, erythrocytes, 49:89  
 membrane phospholipids, phosphatidylethanolamine, 49:89  
 membrane phospholipids, schizophrenia, 49:89  
 phosphatidylethanolamine, erythrocytes, 49:89  
 phosphatidylethanolamine, membrane phospholipids, 49:89  
 phosphatidylethanolamine, schizophrenia, 49:89  
 schizophrenia, erythrocytes, 49:89  
 schizophrenia, membrane phospholipids, 49:89  
 schizophrenia, phosphatidylethanolamine, 49:89

**Spiradoline**

growth hormone, motor tics, 47:267  
 growth hormone, opioids, 47:267  
 growth hormone, prolactin, 47:267



**Spiradoline continued**

growth hormone, Tourette's syndrome, 47:267

motor tics, growth hormone, 47:267

motor tics, prolactin, 47:267

prolactin, growth hormone, 47:267

prolactin, motor tics, 47:267

prolactin, Tourette's syndrome, 47:267

Tourette's syndrome, growth hormone, 47:267

Tourette's syndrome, motor tics, 47:267

Tourette's syndrome, prolactin, 47:267

**Statistics**

bootstrap resampling, kappa coefficient, 49:97

kappa coefficient, bootstrap resampling, 49:97

**Striatum**

aging, dopamine D<sub>2</sub> receptor density, 49:219

aging, positron emission tomography, 49:219

aging, schizophrenia, 49:219

dopamine D<sub>2</sub> receptor density, aging, 49:219

dopamine D<sub>2</sub> receptor density, gender differences, 49:219

dopamine D<sub>2</sub> receptor density, illness duration, 49:219

dopamine D<sub>2</sub> receptor density, methylspiperone, 49:219

dopamine D<sub>2</sub> receptor density, positron emission tomography, 49:219

dopamine D<sub>2</sub> receptor density, schizophrenia, 49:219

gender differences, dopamine D<sub>2</sub> receptor density, 49:219

gender differences, positron emission tomography, 49:219

gender differences, schizophrenia, 49:219

illness duration, dopamine D<sub>2</sub> receptor density, 49:219

methylspiperone, dopamine D<sub>2</sub> receptor density, 49:219

positron emission tomography, dopamine D<sub>2</sub> receptor density, 49:219

schizophrenia, dopamine D<sub>2</sub> receptor density, 49:219

**Suicide**

impulsivity, inpatient sample, 47:281

impulsivity, risk assessment, 47:281

impulsivity, violence, 47:281

risk assessment, impulsivity, 47:281

risk assessment, inpatient sample, 47:281

risk assessment, social support, 47:281

**Suicide continued**

risk assessment, violence, 47:281

schizophrenia, serotonin S<sub>2</sub> receptor binding in platelets, 47:111

serotonin S<sub>2</sub> receptor binding in platelets, 47:111

serotonin, schizophrenia, 47:111

social support, impulsivity, 47:281

social support, risk assessment, 47:281

social support, violence, 47:281

violence, impulsivity, 47:281

violence, inpatient sample, 47:281

violence, risk assessment, 47:281

violence, social support, 47:281

**Thyroid**

affective disorder, cortisol, 47:7, 47:23

affective disorder, dexamethasone suppression test, 47:7, 47:23

affective disorder, dysthymic disorder, 47:7

affective disorder, electrodermal activity, 47:23

affective disorder, hypothalamic-pituitary-adrenal axis, 47:7

affective disorder, thyroid stimulating hormone, 47:7, 47:23

affective disorder, thyroxine, 47:7, 47:23

affective disorder, triiodothyronine, 47:7, 47:23

cortisol, affective disorder, 47:7, 47:23

cortisol, dextracircannual rhythms, triiodothyronine, 49:77

circannual rhythms, Vitamin D, 49:77

cortisol, affective disorder, 46:213, 47:7, 47:23

cortisol, antidepressant medication, 46:213

cortisol, dexamethasone suppression test, 47:7, 47:23

cortisol, dysthymic disorder, 47:7

cortisol, electrodermal activity, 47:23

cortisol, prolactin, 46:213

cortisol, sleep deprivation, 46:213

cortisol, thyroxine, 47:7, 47:23

cortisol, triiodothyronine, 46:213, 47:7, 47:23

depressed mood, circannual rhythms, 49:77

depressed mood, normal women, 49:77

depressed mood, Profile of Mood States, 49:77

depressed mood, thyroxine, 49:77

depressed mood, triiodothyronine, 49:77

depressed mood, Vitamin D, 49:77

dexamethasone suppression test, affective disorder, 47:7, 47:23

**Thyroid continued**

dexamethasone suppression test, cortisol, 47:7, 47:23

dexamethasone suppression test, dysthymic disorder, 47:7

dexamethasone suppression test, electrodermal activity, 47:23

dexamethasone suppression test, thyroxine, 47:7, 47:23

dexamethasone suppression test, triiodothyronine, 47:7, 47:23

dysthymic disorder, affective disorder, 47:7

dysthymic disorder, cortisol, 47:7

dysthymic disorder, dexamethasone suppression test, 47:7

dysthymic disorder, thyroxine, 47:7

dysthymic disorder, triiodothyronine, 47:7

electrodermal activity, affective disorder, 47:23

electrodermal activity, cortisol, 47:23

electrodermal activity, dexamethasone suppression test, 47:23

electrodermal activity, thyroxine, 47:23

electrodermal activity, triiodothyronine, 47:23

estradiol, follicle stimulating hormone, 48:153

estradiol, growth hormone, 48:153

estradiol, luteinizing hormone, 48:153

estradiol, normal volunteers, 48:153

estradiol, prolactin, 48:153

estradiol, sleep deprivation, 48:153

estradiol, thyroxine, 48:153

estradiol, triiodothyronine, 48:153

follicle stimulating hormone, estradiol, 48:153

follicle stimulating hormone, growth hormone, 48:153

follicle stimulating hormone, luteinizing hormone, 48:153

follicle stimulating hormone, normal volunteers, 48:153

follicle stimulating hormone, prolactin, 48:153

follicle stimulating hormone, sleep deprivation, 48:153

follicle stimulating hormone, thyroxine, 48:153

follicle stimulating hormone, triiodothyronine, 48:153

growth hormone, estradiol, 48:153

growth hormone, follicle stimulating hormone, 48:153

**Thyroid continued**

growth hormone, luteinizing hormone, 48:153

growth hormone, normal volunteers, 48:153

growth hormone, prolactin, 48:153

growth hormone, sleep deprivation, 48:153

growth hormone, thyroxine, 48:153

growth hormone, triiodothyronine, 48:153

luteinizing hormone, estradiol, 48:153

luteinizing hormone, follicle stimulating hormone, 48:153

luteinizing hormone, growth hormone, 48:153

luteinizing hormone, normal volunteers, 48:153

luteinizing hormone, prolactin, 48:153

thyroid stimulating hormone, affective disorder, 47:23

thyroid stimulating hormone, affective disorder, 47:7

thyroid stimulating hormone, cortisol, 47:7, 47:23

thyroid stimulating hormone, dexamethasone suppression test, 47:7, 47:23

thyroid stimulating hormone, dysthymic disorder, 47:7

thyroid stimulating hormone, electrodermal activity, 47:23

thyroid stimulating hormone, hypothalamic-pituitary-adrenal axis, 47:7

thyroid stimulating hormone, thyroxine, 47:7, 47:23

thyroid stimulating hormone, triiodothyronine, 47:7, 47:23

thyroxine, affective disorder, 47:7, 47:23

thyroxine, cortisol, 47:7, 47:23

thyroxine, dexamethasone suppression test, 47:7, 47:23

thyroxine, dysthymic disorder, 47:7

thyroxine, electrodermal activity, 47:23

thyroxine, hypothalamic-pituitary-adrenal axis, 47:7

thyroxine, thyroid stimulating hormone, 47:7, 47:23

thyroxine, triiodothyronine, 47:7, 47:23

triiodothyronine, affective disorder, 47:7, 47:23

triiodothyronine, cortisol, 47:7, 47:23

triiodothyronine, dexamethasone suppression test, 47:7, 47:23

triiodothyronine, dysthymic disorder, 47:7

triiodothyronine, electrodermal activity, 47:23

**Thyroid continued**

triiodothyronine, hypothalamic-pituitary-adrenal axis, 47:7

triiodothyronine, thyroid stimulating hormone, 47:7, 47:23

triiodothyronine, thyroxine, 47:7, 47:23

**Thyroid stimulating hormone**

affective disorder, antidepressant medication, 46:213

affective disorder, cortisol, 46:213, 47:7, 47:23

affective disorder, dexamethasone suppression test, 47:7, 47:23

affective disorder, dysthymic disorder, 47:7

affective disorder, electrodermal activity, 47:23

affective disorder, prolactin, 46:213

affective disorder, sleep deprivation, 46:213

affective disorder, thyroxine, 47:7, 47:23

affective disorder, triiodothyronine, 46:213, 47:7, 47:23

antidepressant medication, affective disorder, 46:213

antidepressant medication, cortisol, 46:213

antidepressant medication, prolactin, 46:213

antidepressant medication, sleep deprivation, 46:213

antidepressant medication, triiodothyronine, 46:213

circannual rhythms, depressed mood, 49:77

circannual rhythms, normal women, 49:77

circannual rhythms, Profile of Mood States, 49:77

circannual rhythms, thyroxine, 49:77

luteinizing hormone, thyroxine, 48:153

luteinizing hormone, triiodothyronine, 48:153

normal volunteers, estradiol, 48:153

normal volunteers, follicle stimulating hormone, 48:153

normal volunteers, growth hormone, 48:153

normal volunteers, luteinizing hormone, 48:153

normal volunteers, prolactin, 48:153

normal volunteers, sleep deprivation, 48:153

normal volunteers, thyroxine, 48:153

normal volunteers, triiodothyronine, 48:153

normal women, circannual rhythms, 49:77

normal women, depressed mood, 49:77

normal women, Profile of Mood States, 49:77

normal women, thyroxine, 49:77

normal women, triiodothyronine, 49:77

normal women, Vitamin D, 49:77

**Thyroid stimulating hormone continued**

Profile of Mood States, circannual rhythms, 49:77

Profile of Mood States, depressed mood, 49:77

Profile of Mood States, normal women, 49:77

Profile of Mood States, thyroxine, 49:77

Profile of Mood States, triiodothyronine, 49:77

Profile of Mood States, Vitamin D, 49:77

prolactin, affective disorder, 46:213

prolactin, antidepressant medication, 46:213

prolactin, cortisol, 46:213

prolactin, estradiol, 48:153

prolactin, follicle stimulating hormone, 48:153

prolactin, growth hormone, 48:153

prolactin, luteinizing hormone, 48:153

prolactin, normal volunteers, 48:153

prolactin, sleep deprivation, 46:213, 48:153

prolactin, thyroxine, 48:153

prolactin, triiodothyronine, 46:213, 48:153

sleep deprivation, 48:153

sleep deprivation, affective disorder, 46:213

sleep deprivation, antidepressant medication, 46:213

sleep deprivation, cortisol, 46:213

sleep deprivation, estradiol, 48:153

sleep deprivation, follicle stimulating hormone, 48:153

sleep deprivation, growth hormone, 48:153

sleep deprivation, luteinizing hormone, 48:153

sleep deprivation, normal volunteers, 48:153

sleep deprivation, prolactin, 46:213, 48:153

sleep deprivation, thyroxine, 48:153

sleep deprivation, triiodothyronine, 46:213, 48:153

thyroxine, affective disorder, 47:7, 47:23

thyroxine, circannual rhythms, 49:77

thyroxine, cortisol, 47:7, 47:23

thyroxine, depressed mood, 49:77

thyroxine, dexamethasone suppression test, 47:7, 47:23

thyroxine, dysthymic disorder, 47:7

thyroxine, electrodermal activity, 47:23

thyroxine, estradiol, 48:153

thyroxine, follicle stimulating hormone, 48:153

thyroxine, growth hormone, 48:153

thyroxine, luteinizing hormone, 48:153

thyroxine, normal volunteers, 48:153

thyroxine, normal women, 49:77



**Thyroid stimulating hormone** continued

thyroxine, Profile of Mood States, 49:77

thyroxine, prolactin, 48:153

thyroxine, sleep deprivation, 48:153

thyroxine, triiodothyronine, 47:7, 47:23, 48:153, 49:77

thyroxine, Vitamin D, 49:77

triiodothyronine, affective disorder, 46:213, 47:7, 47:23

triiodothyronine, antidepressant medication, 46:213

triiodothyronine, circannual rhythms, 49:77

triiodothyronine, cortisol, 46:213, 47:7, 47:23

triiodothyronine, depressed mood, 49:77

triiodothyronine, dexamethasone suppression test, 47:7, 47:23

triiodothyronine, dysthymic disorder, 47:7

triiodothyronine, electrodermal activity, 47:23

triiodothyronine, estradiol, 48:153

triiodothyronine, follicle stimulating hormone, 48:153

triiodothyronine, growth hormone, 48:153

triiodothyronine, luteinizing hormone, 48:153

triiodothyronine, normal volunteers, 48:153

triiodothyronine, normal women, 49:77

triiodothyronine, Profile of Mood States, 49:77

triiodothyronine, prolactin, 46:213, 48:153

triiodothyronine, sleep deprivation, 46:213, 48:153

triiodothyronine, thyroxine, 47:7, 47:23, 48:153, 49:77

triiodothyronine, Vitamin D, 49:77

Vitamin D, circannual rhythms, 49:77

Vitamin D, depressed mood, 49:77

Vitamin D, normal women, 49:77

Vitamin D, Profile of Mood States, 49:77

Vitamin D, thyroxine, 49:77

Vitamin D, triiodothyronine, 49:77

**Tourette's syndrome**

growth hormone, kappa agonist, 47:267

growth hormone, motor tics, 47:267

growth hormone, opioids, 47:267

growth hormone, prolactin, 47:267

growth hormone, spiradoline, 47:267

kappa agonist, growth hormone, 47:267

kappa agonist, motor tics, 47:267

kappa agonist, opioids, 47:267

kappa agonist, prolactin, 47:267

kappa agonist, spiradoline, 47:267

motor tics, growth hormone, 47:267

motor tics, kappa agonist, 47:267

motor tics, opioids, 47:267

motor tics, prolactin, 47:267

**Tourette's syndrome** continued

motor tics, spiradoline, 47:267

opioids, growth hormone, 47:267

opioids, kappa agonist, 47:267

opioids, motor tics, 47:267

opioids, prolactin, 47:267

opioids, spiradoline, 47:267

prolactin, growth hormone, 47:267

prolactin, kappa agonist, 47:267

prolactin, motor tics, 47:267

prolactin, opioids, 47:267

prolactin, spiradoline, 47:267

spiradoline, growth hormone, 47:267

spiradoline, motor tics, 47:267

spiradoline, opioids, 47:267

spiradoline, prolactin, 47:267

**Transferrin**

affective disorder, amino acids, 49:151

affective disorder, cortisol, 49:11

affective disorder, dexamethasone suppression test, 49:11

affective disorder, haptoglobin, 49:11, 49:151

affective disorder, immune function, 49:11, 49:151

affective disorder, interleukins, 49:11, 49:151

affective disorder, serotonin, 49:151

affective disorder, tryptophan, 49:151

amino acids, affective disorder, 49:151

amino acids, haptoglobin, 49:151

amino acids, immune function, 49:151

amino acids, interleukins, 49:151

amino acids, serotonin, 49:151

amino acids, tryptophan, 49:151

cortisol, affective disorder, 49:11

cortisol, dexamethasone suppression test, 49:11

cortisol, haptoglobin, 49:11

cortisol, immune function, 49:11

cortisol, interleukins, 49:11

dexamethasone suppression test, affective disorder, 49:11

dexamethasone suppression test, cortisol, 49:11

dexamethasone suppression test, haptoglobin, 49:11

dexamethasone suppression test, immune function, 49:11

dexamethasone suppression test, interleukins, 49:11

haptoglobin, affective disorder, 49:11, 49:151

haptoglobin, amino acids, 49:151

haptoglobin, cortisol, 49:11

haptoglobin, dexamethasone suppression test, 49:11

haptoglobin, immune function, 49:11, 49:151

**Transferrin continued**

haptoglobin, interleukins, 49:11, 49:151  
 haptoglobin, serotonin, 49:151  
 haptoglobin, tryptophan, 49:151  
 immune function, affective disorder, 49:11, 49:151  
 immune function, amino acids, 49:151  
 immune function, cortisol, 49:11  
 immune function, dexamethasone suppression test, 49:11  
 immune function, haptoglobin, 49:11, 49:151  
 immune function, interleukins, 49:11, 49:151  
 immune function, serotonin, 49:151  
 immune function, tryptophan, 49:151  
 interleukins, affective disorder, 49:11, 49:151  
 interleukins, amino acids, 49:151  
 interleukins, cortisol, 49:11  
 interleukins, haptoglobin, 49:11, 49:151  
 interleukins, immune function, 49:11, 49:151  
 interleukins, serotonin, 49:151  
 interleukins, tryptophan, 49:151  
 serotonin, affective disorder, 49:151  
 serotonin, amino acids, 49:151  
 serotonin, haptoglobin, 49:151  
 serotonin, immune function, 49:151  
 serotonin, interleukins, 49:151  
 serotonin, tryptophan, 49:151  
 tryptophan, affective disorder, 49:151  
 tryptophan, amino acids, 49:151  
 tryptophan, haptoglobin, 49:151  
 tryptophan, immune function, 49:151  
 tryptophan, interleukins, 49:151  
 tryptophan, serotonin, 49:151

**Tryptophan**

affective disorder, aging, 49:151  
 affective disorder, amino acids, 49:151  
 affective disorder, haptoglobin, 49:151  
 affective disorder, immune function, 49:151  
 affective disorder, interleukin, 49:151  
 affective disorder, serotonin, 49:151  
 affective disorder, transferrin, 49:151  
 aging, affective disorder, 49:151  
 amino acids, affective disorder, 49:151  
 amino acids, haptoglobin, 49:151  
 amino acids, immune function, 49:151  
 amino acids, interleukin, 49:151  
 amino acids, serotonin, 49:151  
 amino acids, transferrin, 49:151  
 autism, c-Harvey-Ras-1 marker, 46:261  
 autism, dopamine-beta-hydroxylase, 46:261  
 autism, genetics, 46:261  
 autism, restriction fragment length polymorphism, 46:261  
 autism, tyrosine hydroxylase, 46:261

**Tryptophan continued**

c-Harvey-Ras-1 marker, autism, 46:261  
 c-Harvey-Ras-1 marker, dopamine-beta-hydroxylase, 46:261  
 c-Harvey-Ras-1 marker, genetics, 46:261  
 c-Harvey-Ras-1 marker, restriction fragment length polymorphism, 46:261  
 c-Harvey-Ras-1 marker, tyrosine hydroxylase, 46:261  
 dopamine-beta-hydroxylase, autism, 46:261  
 dopamine-beta-hydroxylase, c-Harvey-Ras-1 marker, 46:261  
 dopamine-beta-hydroxylase, genetics, 46:261  
 dopamine-beta-hydroxylase, restriction fragment length polymorphism, 46:261  
 dopamine-beta-hydroxylase, tyrosine hydroxylase, 46:261  
 genetics, autism, 46:261  
 genetics, c-Harvey-Ras-1 marker, 46:261  
 genetics, dopamine-beta-hydroxylase, 46:261  
 genetics, restriction fragment length polymorphism, 46:261  
 genetics, tyrosine hydroxylase, 46:261  
 haptoglobin, affective disorder, 49:151  
 haptoglobin, amino acids, 49:151  
 haptoglobin, immune function, 49:151  
 haptoglobin, interleukin, 49:151  
 haptoglobin, serotonin, 49:151  
 haptoglobin, transferrin, 49:151  
 immune function, affective disorder, 49:151  
 immune function, amino acids, 49:151  
 immune function, haptoglobin, 49:151  
 immune function, interleukin, 49:151  
 immune function, serotonin, 49:151  
 immune function, transferrin, 49:151  
 interleukin, affective disorder, 49:151  
 interleukins, amino acids, 49:151  
 interleukins, haptoglobin, 49:151  
 interleukins, immune function, 49:151  
 interleukins, serotonin, 49:151  
 interleukins, transferrin, 49:151  
 restriction fragment length polymorphism, autism, 46:261  
 restriction fragment length polymorphism, c-Harvey-Ras-1 marker, 46:261  
 restriction fragment length polymorphism, dopamine-beta-hydroxylase, 46:261  
 restriction fragment length polymorphism, genetics, 46:261  
 restriction fragment length polymorphism, tyrosine hydroxylase, 46:261  
 serotonin, affective disorder, 49:151  
 serotonin, amino acids, 49:151

**Tryptophan continued**

serotonin, haptoglobin, 49:151  
 serotonin, immune function, 49:151  
 serotonin, interleukins, 49:151  
 serotonin, transferrin, 49:151  
 transferrin, affective disorder, 49:151  
 transferrin, amino acids, 49:151  
 transferrin, haptoglobin, 49:151  
 transferrin, immune function, 49:151  
 transferrin, interleukins, 49:151  
 transferrin, serotonin, 49:151  
 tyrosine hydroxylase, autism, 46:261  
 tyrosine hydroxylase, c-Harvey-Ras-1 marker, 46:261  
 tyrosine hydroxylase, dopamine-beta-hydroxylase, 46:261  
 tyrosine hydroxylase, genetics, 46:261  
 tyrosine hydroxylase, restriction fragment length polymorphism, 46:261  
**Twin studies.** See Genetics.  
**Tyrosine hydroxylase**  
 autism, c-Harvey-Ras-1 marker, 46:261  
 autism, dopamine-beta-hydroxylase, 46:261  
 autism, genetics, 46:261  
 autism, restriction fragment length polymorphism, 46:261  
 autism, tryptophan hydroxylase, 46:261  
 c-Harvey-Ras-1 marker, autism, 46:261  
 c-Harvey-Ras-1 marker, dopamine-beta-hydroxylase, 46:261  
 c-Harvey-Ras-1 marker, genetics, 46:261  
 c-Harvey-Ras-1 marker, restriction fragment length polymorphism, 46:261  
 c-Harvey-Ras-1 marker, tryptophan hydroxylase, 46:261  
 circadian rhythm, prolactin, 47:187  
 circadian rhythm, schizophrenia, 47:187  
 dopamine-beta-hydroxylase, autism, 46:261  
 dopamine-beta-hydroxylase, c-Harvey-Ras-1 marker, 46:261  
 dopamine-beta-hydroxylase, genetics, 46:261  
 dopamine-beta-hydroxylase, restriction fragment length polymorphism, 46:261  
 dopamine-beta-hydroxylase, tryptophan hydroxylase, 46:261  
 genetics, autism, 46:261  
 genetics, c-Harvey-Ras-1 marker, 46:261  
 genetics, dopamine-beta-hydroxylase, 46:261  
 genetics, restriction fragment length polymorphism, 46:261  
 genetics, tryptophan hydroxylase, 46:261  
 prolactin, circadian rhythm, 47:187  
 prolactin, schizophrenia, 47:187

**Tyrosine hydroxylase continued**

restriction fragment length polymorphism, autism, 46:261  
 restriction fragment length polymorphism, c-Harvey-Ras-1 marker, 46:261  
 restriction fragment length polymorphism, dopamine-beta-hydroxylase, 46:261  
 restriction fragment length polymorphism, genetics, 46:261  
 restriction fragment length polymorphism, tryptophan hydroxylase, 46:261  
 schizophrenia, circadian rhythm, 47:187  
 schizophrenia, prolactin, 47:187  
 tryptophan hydroxylase, autism, 46:261  
 tryptophan hydroxylase, c-Harvey-Ras-1 marker, 46:261  
 tryptophan hydroxylase, dopamine-beta-hydroxylase, 46:261  
 tryptophan hydroxylase, genetics, 46:261  
 tryptophan hydroxylase, restriction fragment length polymorphism, 46:261

**Ubiquitin**

frontal lobe, neurodegeneration, 48:145  
 frontal lobe, post-mortem study, 48:145  
 frontal lobe, schizophrenia, 48:145  
 neurodegeneration, frontal lobe, 48:145  
 neurodegeneration, post-mortem study, 48:145  
 neurodegeneration, schizophrenia, 48:145  
 post-mortem study, frontal lobe, 48:145  
 post-mortem study, neurodegeneration, 48:145  
 post-mortem study, schizophrenia, 48:145  
 schizophrenia, frontal lobe, 48:145  
 schizophrenia, neurodegeneration, 48:145  
 schizophrenia, post-mortem study, 48:145

**Ventricle-brain ratio**

alcohol intake, anxiety disorder, 48:135  
 alcohol intake, benzodiazepines, 48:135  
 alcohol intake, computed tomography, 48:135  
 alcohol intake, diazepam, 48:135  
 alcohol intake, lorazepam, 48:135  
 anxiety disorder, alcohol intake, 48:135  
 anxiety disorder, benzodiazepines, 48:135  
 anxiety disorder, computed tomography, 48:135  
 anxiety disorder, diazepam, 48:135  
 anxiety disorder, lorazepam, 48:135  
 benzodiazepines, alcohol intake, 48:135  
 benzodiazepines, anxiety disorder, 48:135  
 benzodiazepines, computed tomography, 48:135  
 benzodiazepines, diazepam, 48:135  
 benzodiazepines, lorazepam, 48:135  
 computed tomography, alcohol intake, 48:135



**Ventricle-brain ratio** continued

- computed tomography, anxiety disorder, 48:135
- computed tomography, benzodiazepines, 48:135
- computed tomography, diazepam, 48:135
- computed tomography, lorazepam, 48:135
- diazepam, alcohol intake, 48:135
- diazepam, anxiety disorder, 48:135
- diazepam, benzodiazepines, 48:135
- diazepam, computed tomography, 48:135
- diazepam, lorazepam, 48:135
- lorazepam, alcohol intake, 48:135
- lorazepam, anxiety disorder, 48:135
- lorazepam, benzodiazepines, 48:135
- lorazepam, computed tomography, 48:135
- lorazepam, diazepam, 48:135

**Violence**

- impulsivity, inpatient sample, 47:281
- impulsivity, risk assessment, 47:281
- impulsivity, social support, 47:281
- impulsivity, suicide, 47:281
- risk assessment, impulsivity, 47:281
- risk assessment, inpatient sample, 47:281
- risk assessment, social support, 47:281
- risk assessment, suicide, 47:281
- social support, impulsivity, 47:281
- social support, inpatient sample, 47:281
- social support, risk assessment, 47:281
- social support, suicide, 47:281
- suicide, impulsivity, 47:281
- suicide, inpatient sample, 47:281
- suicide, risk assessment, 47:281
- suicide, social support, 47:281

**Wisconsin Card Sorting Test.** See Frontal lobe; Neuropsychology.

**Yohimbine**

- anxiety disorder, cortisol, 48:119
- anxiety disorder, fluvoxamine, 48:119
- anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
- anxiety disorder, norepinephrine, 48:119
- anxiety disorder, panic, 48:119
- anxiety disorder, serotonin, 48:119
- blood pressure, fluvoxamine, 48:119
- blood pressure, heart rate, 48:119
- blood pressure, panic disorder, 48:119
- cortisol, anxiety disorder, 48:119
- cortisol, fluvoxamine, 48:119
- cortisol, 3-methoxy-4-hydroxyphenylglycol, 48:119
- cortisol, norepinephrine, 48:119

**Yohimbine** continued

- cortisol, panic disorder, 48:119
- cortisol, serotonin, 48:119
- fluvoxamine, anxiety disorder, 48:119
- fluvoxamine, blood pressure, 48:119
- fluvoxamine, cortisol, 48:119
- fluvoxamine, heart rate, 48:119
- fluvoxamine, 3-methoxy-4-hydroxyphenylglycol, 48:119
- fluvoxamine, norepinephrine, 48:119
- fluvoxamine, panic disorder, 48:119
- fluvoxamine, serotonin, 48:119
- heart rate, blood pressure, 48:119
- heart rate, fluvoxamine, 48:119
- heart rate, panic disorder, 48:119
- 3-methoxy-4-hydroxyphenylglycol, anxiety disorder, 48:119
- 3-methoxy-4-hydroxyphenylglycol, cortisol, 48:119
- 3-methoxy-4-hydroxyphenylglycol, fluvoxamine, 48:119
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119
- 3-methoxy-4-hydroxyphenylglycol, panic disorder, 48:119
- 3-methoxy-4-hydroxyphenylglycol, serotonin, 48:119
- norepinephrine, anxiety disorder, 48:119
- norepinephrine, cortisol, 48:119
- norepinephrine, fluvoxamine, 48:119
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119
- norepinephrine, panic disorder, 48:119
- norepinephrine, serotonin, 48:119
- panic disorder, blood pressure, 48:119
- panic disorder, fluvoxamine, 48:119
- panic disorder, heart rate, 48:119
- panic disorder, cortisol, 48:119
- panic disorder, fluvoxamine, 48:119
- panic disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
- panic disorder, norepinephrine, 48:119
- panic disorder, reuptake inhibitor, 48:119
- panic disorder, serotonin, 48:119
- serotonin, anxiety disorder, 48:119
- serotonin, cortisol, 48:119
- serotonin, fluvoxamine, 48:119
- serotonin, 3-methoxy-4-hydroxyphenylglycol, 48:119
- serotonin, norepinephrine, 48:119
- serotonin, panic disorder, 48:119
- serotonin, reuptake inhibitor, 48:119

